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THE ROLE OF MICROTUBULE-ASSOCIATED PROTEIN TAU IN NEURONAL 




Tauopathies, including Alzheimer’s disease (AD), are devastating diseases with an 
immense burden on society which is predicted to increase in coming decades. In addition 
to progressive loss of memory and cognitive function, patients with tauopathies have a 6-
10 fold increase in lifetime risk for seizures, and many are diagnosed with epilepsy. The 
presence of epileptiform activity on electroencephalogram (EEG) recordings from patients 
with AD predicts faster cognitive decline compared to patients without abnormal EEG 
readings. Electrophysiological measurements in murine models of AD have identified 
neuronal hyperexcitability. Furthermore, reducing tau phosphorylation or expression 
confers seizure resistance in animal epilepsy models. Although evidence suggests the 
presence of common mechanisms contributing to both tauopathy and epilepsy, more work 
is needed to understand how this interaction works and whether tau can be effectively 
targeted to improve patients’ lives. This study investigated the relationship between 
tauopathy using transgenic mice that expressed no tau protein (tau-/-) or expressed non-
mutant, human tau protein without expressing murine tau (htau). The htau mice develop 
progressive tauopathy with age. Non-transgenic C57BL/6J mice were used as controls. 
Whole-cell patch-clamp electrophysiology was used to define tau’s role in neuronal 
excitability in vivo in dentate gyrus granule cells. Both transgenic mouse strains exhibited 
a lower frequency of evoked action potentials and reduced likelihood of neurotransmitter 
release from perforant pathway inputs as measured by the paired pulse ratio compared to 
control at 1.5 months of age, but these differences were lost with age. The similarities 
between the tau-/- and htau mice suggest that hyperexcitability is related to the amount of 
normally functioning tau rather than the presence of pathological tau, and that the presence 
of normal murine tau may influence the results of other studies involving models of 
tauopathy. Furthermore, tau’s role in epileptogenesis was studied using intrahippocampal 
injection of kainate (i.ie., IHK) to induce status epilepticus, a model that induces temporal 
lobe epileptogenesis, in tau-/-, htau, and C57BL/6J mice. The process of epileptogenesis 
appeared to be modified compared to control in both transgenic strains, but did not appear 
to be prevented. Compared to either tau-/- or C57BL/6J mice, htau mice experienced 
significantly greater mortality after IHK. Modifications in tau expression, wither deletion 
or humanization, partially abrogated synaptic excitability that developed following IHK. 
In conclusion, this study showed that neuronal excitability is affected similarly by either 
deletion or humanization of tau, with the notable exception of survival after IHK. This 
     
 
study provides clearer understanding of tau’s role in acquired epilepsy and suggests novel 
therapeutics targeting tau may be effective for the treatment of epilepsy. 
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CHAPTER 1. INTRODUCTION 
1.1 Microtubule associated protein tau 
The microtubule-associated protein tau (MAPT, tau) is a key microtubule- binding 
protein predominantly found in neurons. Although tau is typically thought of primarily as 
a microtubule stabilizer, it serves additional key functions. Tau is extremely versatile due 
to a combination of multiple isoforms arising from alternative splicing (section 1.1.1) and 
extensive post-translational modification (section 1.1.3). This versatility allows tau to serve 
many functions in addition to stabilizing microtubules, but also allows for significant 
pathologic potential. Tauopathies are a growing list of diseases which are caused by or 
involve tau dysfunction. Although tauopathies are diverse and overall not fully understood, 
disruptions in the normal splicing and post-translational modification have been heavily 
implicated in their pathogenesis (section 1.2.1) 
 Expression and alternative splicing 
Tau is encoded by the gene MAPT on chromosome 17q21 (Neve et al., 1986). Human 
MAPT contains 16 exons which are alternatively spliced to produce 6 isoforms of tau 
protein (Andreadis et al., 1992). Eight of these exons (1, 4, 5, 7, 9, 11, 12, and 13) are 
constitutively translated in the brain, while 3 exons (2, 3, and 10, discussed below) are 
subject to alternative splicing. Three exons (4a, 6, and 8) are translated only in ganglia of 
the peripheral nervous system (Couchie et al., 1992; Goedert et al., 1992). The last two 
exons (0 and 14) are located in the 5’ and 3’ untranslated regions (Figure 1.1A).   
The isoforms of tau arise from the presence or absence of 2 inserts near the amino-





Figure 1.1 Structure of MAPT and microtubule associated protein tau 
(A) MAPT contains 16 exons. In neurons, 8 exons (black boxes) are constitutively 
translated and 5 exons (gray boxes) are not translated. Three exons (white boxes) are 
subject to alternative splicing. (B) Structure of 2N4R tau including demarcations between 
major domains. N1, N2, and R2 (marked in gray) are be absent in shorter isoforms of tau. 
(C) Approximate representation (not to scale) of the “paperclip” conformation adopted by 
soluble tau in solution. Dotted lines denote estimated interactions between residues 
responsible for conformation.  
3 
 
of either 3 or 4 repeat domains in the microtubule binding domain near the carboxy 
terminus. The amino-terminus may exclude both exons 2 and 3 (giving rise to 0N tau), 
include exon 2 but not exon 3 (giving rise to 1N tau), or include exons 2 and 3 (giving rise 
to 2N tau) (Goedert and Jakes, 1990). Exon 3 is not observed in the absence of exon 2 in 
the human brain (Goedert et al., 1989a). The additional isoforms arise from alternative 
splicing of exon 10, which results in either 3 (3R) or 4 (4R) repeat domains near the carboxy 
terminus (Goedert et al., 1989b; Goedert et al., 1988). The resulting isoforms range from 
352-441 residues. Unless otherwise noted, all residue numbers listed in this work will refer 
to 2N4R tau. 
The relative expression of each isoform of tau depends on developmental stage and 
brain region. In the fetal brain, 0N3R tau is the primary isoform (Goedert and Jakes, 1990; 
Goedert et al., 1989a; Goedert et al., 1989b), although 4R tau expression begins late in fetal 
development (Kosik et al., 1989). Because 4R tau has a higher affinity for microtubules 
(discussed more in section 1.1.4), the development of 4R tau may promote axon growth by 
stabilizing the abundant microtubules in the axonal growth cone (Bamburg et al., 1986). In 
the adult brain, 3R and 4R tau are normally present in roughly equal amounts (Hong et al., 
1998). This ratio can become perturbed in some disease, resulting in an excess of one 
isoform or the other depending on the disease (Chambers et al., 1999; Connell et al., 2005; 
Ishizawa et al., 2000). Pathologic changes in the ratio of 3R to 4R tau will be discussed in 
more depth in section 1.2.1. 
Tau expression within the neuron is normally concentrated in the axons (Binder et 
al., 1985). Several mechanisms have been implicated in maintaining tau’s localization. 
Unlike mRNA for MAP2 or tubulin, which localize to the neuron body or dendrites, tau 
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mRNA extends into the proximal axon (Litman et al., 1993), suggesting some degree of 
regional specificity in translation. Furthermore, biotinylated tau injected into the cell body 
of cultured neurons migrates preferentially to the axon (Hirokawa et al., 1996). Tau’s 
localization to the axons is at least partially dependent on its microtubule binding domain. 
Chimeric proteins containing the N-terminal region of MAP2 (normally found in the 
neuron body and dendrites) and microtubule binding domain of tau localize to the axon, 
whereas chimeric proteins containing the N-terminal region of tau and microtubule binding 
domain of MAP2 localize to the neuron body and dendrites (Kanai and Hirokawa, 1995). 
 Tau structure and structural domains 
Physiological tau is a “natively unfolded” protein, meaning it has little stable 
secondary or tertiary structure (Schweers et al., 1994). As a notable exception, dynamic 
interactions between tau’s amino-terminus, carboxy terminus, and repeat domains results 
in adoption of a “paperclip” superstructure in solution (Jeganathan et al., 2006). Tau’s 
naturally disordered nature was first recognized due to the protein’s resistance to 
denaturing methods that render most proteins nonfunctional (Cleveland et al., 1977). This 
general lack of higher order structure renders x-ray crystallography impractical and 
detailed structural information must be gleaned through other methods. Nuclear magnetic 
resonance (NMR) spectroscopy studies have produced single-residue resolution of tau, 
revealing a highly dynamic structure (Mukrasch et al., 2009). Overall tau is basic and 
highly hydrophilic, although these properties vary by region and post-translational 
modification. Tau consists of 3 major structural regions: the projection domain, the proline 
rich domain, and the microtubule binding domain (Figure 1.1B). 
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Tau’s projection domain comprises residues 1-151 in 2N4R tau and contains the 
amino-terminal inserts coded by exons 2 and 3 (if present). The projection domain is acidic 
and extends into the cytoplasm when tau is bound to microtubules (Hirokawa et al., 1988). 
The functions of the projection domain are not fully understood, but include interacting 
with the dynein-activator complex dynactin (Magnani et al., 2007), spacing and 
crosslinking microtubules (Chen et al., 1992; Hirokawa et al., 1988), and forming 
microtubule bundles (Gustke et al., 1994; Kanai et al., 1992). Tau’s projection domain also 
mediates interaction with cellular components other than microtubules. The projection 
domain binds to and mediates interaction with the plasma membrane (Brandt et al., 1995). 
Interactions between microtubules and the plasma membrane are especially important at 
the axonal growth cone, where microtubules concentrate during axon elongation (Bamburg 
et al., 1986). GSK3β, a key disease-related tau kinase, binds in the projection domain (Sun 
et al., 2002). As the least studied domain of tau, the projection domain may play additional 
as yet undiscovered roles. 
The proline-rich domain of tau, so called for its 7 PxxP motifs, comprises residues 
151-244 in 2N4R tau. This domain is relatively rigid, likely due to the reduced flexibility 
of proline compared to other amino acids (Mukrasch et al., 2009). The proline rich domain 
is involved in interactions with cytoskeletal fibers. Although not the primary binding 
microtubule site, this region of tau contributes significantly to microtubule binding (Brandt 
and Lee, 1993; Goode et al., 1997; Gustke et al., 1994). In particular, two short sequences 
in this domain, 215KKVAVVR221 and 225KVAVVRT231, have a critical role in microtubule 
assembly, increasing binding affinity through conformational changes and interactions 
with microtubules (Goode et al., 1997; Mukrasch et al., 2007). The proline rich domain is 
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also capable of binding actin (He et al., 2009) and the projection domain of other tau 
molecules (Rosenberg et al., 2008). In addition to containing many well-described 
phosphorylation sites (discussed more in section 1.1.3.1), the proline rich domain serves as 
a binding site for some key regulators of tau phosphorylation such as the src-family kinases 
including Fyn (Lee et al., 1998; Reynolds et al., 2008). 
Of tau’s 3 major structural domains, the microtubule binding domain has been the 
most extensively studied. It comprises residues 245-441 in 2N4R tau and contains the 
repeat segments that are the primary microtubule binding sites (Butner and Kirschner, 
1991; Gustke et al., 1994; Himmler et al., 1989; Lee et al., 1989). Tau contains up to four 
imperfectly repeated segments, encoded by exons 9-12 (Lee et al., 1989). The number of 
repeat segments depends on the alternative splicing of exon 10, which codes for the second 
of four possible repeat sequences (Andreadis et al., 1992; Goedert et al., 1989b). The 
microtubule binding domain forms transient beta-structure, leading to regions with high 
rigidity (Mukrasch et al., 2009). The major features of the microtubule binding domain are 
the repeat domains, each consisting of 31 or 32 residues (Goedert et al., 1989b). Each repeat 
domain contains a conserved PGGG and KxGS motif. The PGGG motifs form hairpin turns 
that ensure proper conformation for efficient binding (Kadavath et al., 2015b). The KxGS 
motifs, particularly the one in the first repeat, form important interactions with 
microtubules (Biernat et al., 1993; Drewes et al., 1995). In addition to microtubules, this 
region of tau contains binding sites for many other targets including protein phosphatase 
2A (Sontag et al., 1999; Xu et al., 2008), chaperone proteins including Hsc70 and Hsp90 
(Sarkar et al., 2008; Tortosa et al., 2009), α-synuclein (Jensen et al., 1999), presenillin-1 
(Takashima et al., 1998), and apolipoprotein E3 (Strittmatter et al., 1994). 
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 Post-translational modifications 
In addition to six different isoforms, tau is subject to extensive post-translational 
modification that further increases its diversity. These modifications include 
phosphorylation, acetylation, ubiquitination, methylation, and glycosylation. Although 
phosphorylation has long been the center of focus, the importance of other modifications 
has been increasingly recognized recently. Tau post-translational modification impacts its 
function in normal physiology and disease pathology by changing its microtubule binding 
affinity, aggregation potential, and degradation. In some cases, competition between 
modification mechanisms may occur at a residue. For example, some lysine residues can 
be subject to acetylation, ubiquitination, and methylation, and occurrence of one 
modification precludes the others (Morris et al., 2015; Thomas et al., 2012). Several key 
post-translational modifications will be reviewed here. 
1.1.3.1 Phosphorylation 
The longest tau isoform contains 85 potential phosphorylation sites: 44 serine 
residues, 36 threonine residues, and 5 tyrosine residues (Martin et al., 2013b). Out of these 
85 potential sites, 31 are associated with normal physiological function, 28 are disease-
specific, and 16 are found in both healthy and diseased brains (Hanger et al., 1998; Hanger 
et al., 2007; Martin et al., 2013b). Tau’s ability to bind microtubules is heavily influenced 
by phosphorylation at key residues. In general, increasing phosphorylation reduces tau’s 
binding affinity (Lindwall and Cole, 1984). Several specific phosphorylation sites have 
been studied for their associations with pathogenesis, particularly in the development of 
Alzheimer’s disease (AD). Several of these sites serve as the binding epitopes for common 




Table 1.1 Common tau antibodies and associated epitopes 
 
  
Antibody Name Epitope Reference 
AT8 pS202 and pT205 (Goedert et al., 1995b) 
AT100 pT212 and pS214 (Hoffmann et al., 1997) 
AT180 pT231 (Amniai et al., 2011) 
12E8 pS262 (Seubert et al., 1995) 
PHF1 pS396 and pS404 (Otvos et al., 1994) 
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The specific functional outcome has not been identified for every phosphorylation 
site on tau, but the effects of phosphorylation at some key sites has been well-characterized. 
Phosphorylation at several sites, including S214, T231, and S396, promotes detachment of 
tau from microtubules and may be involved in normal physiology and disease (Illenberger 
et al., 1998; Kadavath et al., 2018; Sengupta et al., 1998). In contrast, phosphorylation at 
some sites, particularly S262, is a key step in disease processes (Biernat et al., 1993; 
Drewes et al., 1995; Martin et al., 2013b; Sengupta et al., 1998; Trinczek et al., 1995). A 
number of kinases and phosphatases are involved in maintaining physiological 
phosphorylation of tau and involved in pathogenesis. Some critical regulators of tau 
phosphorylation associated with key disease-related phosphosites will be briefly reviewed 
here. Important disease related phosphorylation sites for each kinase or phosphatase are 
summarized in Table 1.2. 
Glycogen synthase kinase 3 (GSK3) is a key tau kinase originally discovered for 
its role in glycogen metabolism (Embi et al., 1980). Two isoforms of GSK3 (α and β) have 
been described which share 85% homology (Woodgett, 1990). The β isoform is strongly 
associated with hyperphosphorylation of tau. Overexpression of GSK3β induces tau 
hyperphosphorylation (Lucas et al., 2001), but this effect is prevented by administration of 
the GSK3β inhibitor lithium chloride (Engel et al., 2006). GSK3β activity is upregulated 
by administration of amyloid-beta (Aβ), demonstrating GSK3β can contribute to AD 
related tau hyperphosphorylation (Takashima et al., 1996; Terwel et al., 2008). GSK3β is 
a key AD-related tau kinase and phosphorylates tau at numerous disease-related 
phosphosites. Pre-phosphorylation of tau by PKA increases the GSK3β’s ability to  
phosphorylate tau (Liu et al., 2006; Liu et al., 2004b).  
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Table 1.2 Key Tau Kinases/Phosphatases and Associated Phosphorylation Sites 
Kinase/Phosphatase Key Confirmed Phosphorylation Sites References 
GSK3β S199, S202, T205, T231, S262, S404 
(Hanger et al., 2007; Liu et 
al., 2006; Reynolds et al., 
2000; Wang et al., 1998) 
CK1δ S202, T205, S262, S396, S404 
(Hanger et al., 2007; Li et 
al., 2004; Singh et al., 
1995) 
PKA S202, T205, S214, S262 
(Andorfer and Davies, 
2000; Benitez et al., 2021; 
Ko et al., 2019; Liu et al., 
2004b) 
PP2A pS199, pS202, pT205, pS262, pS396, pS404 






Casein kinase (CK) 1 and 2, which each have multiple isoforms, are involved in 
regulation of apoptosis and cell survival through regulation of β-catenin in the wnt-
signaling pathway (Liu et al., 2002a; Marin et al., 2003; Sakanaka, 2002). The delta 
isoform of CK1 is especially important in tau phosphorylation. Phosphorylation by CK1δ 
impairs tau binding to microtubules (Li et al., 2004). CK1/2 are involved in AD beyond 
their role in tau phosphorylation. Different isoforms of CK1/2 are both activated by and 
contribute to production of Aβ (Chauhan et al., 1993; Flajolet et al., 2007; Pigino et al., 
2009), phosphorylate ApoE (Raftery et al., 2005), and can activate or inhibit PP2A 
(Heriche et al., 1997; Pérez and Avila, 1999). 
Protein kinase A (PKA), also called cAMP-dependent protein kinase, contributes to 
numerous signaling cascade pathways involving a broad array of processes. PKA is known 
to phosphorylate many other kinases, contributing to many physiologic and pathologic 
processes (Embogama and Pflum, 2017; Jung et al., 2017). Tau is one of PKA’s many 
substrates (Steiner et al., 1990). Intrahippocampal injection of PKA activators results in tau 
hyperphosphorylation and memory deficits (Sun et al., 2005; Tian et al., 2009). Pre-
phosphorylation of tau by PKA primes tau for phosphorylation by GSK3β and cdk5 (Liu 
et al., 2006; Liu et al., 2004b) 
Although tau can be dephosphorylated by a number of phosphatases, one tau 
phosphatase, PP2A, stands out as the primary tau phosphatase. PP2A is the most prominent 
tau phosphatase, constituting approximately 70% of the total phosphatase activity (Goedert 
et al., 1995a; Liu et al., 2005). Treatment with PP2A dephosphorylates tau sequestered in 
insoluble deposits associated with AD (Drewes et al., 1993; Wang et al., 1995). PP2A 
activity is decreased in brains of people with AD, contributing to the accumulation of 
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hyperphosphorylated tau (Gong et al., 1995; Gong et al., 1993). In addition to directly 
dephosphorylating tau, PP2A also regulates the activity of major tau kinases (Chung and 
Brautigan, 1999; Kins et al., 2003; Liauw and Steinberg, 1996; Louis et al., 2011). 
Dysregulation of PP2A therefore contributes to tau hyperphosphorylation by multiple 
mechanisms.  
1.1.3.2 Acetylation 
Acetylation of lysine residues is an important reversible post-translational 
modification that regulates key cellular functions (Choudhary et al., 2009). Tau contains 
up to 44 lysine residues (Goedert et al., 1989a) and at least 23 of these lysine residues are 
subject to acetylation (Min et al., 2010). Tau is acetylated primarily by the closely related 
acyltransferases p300 and Creb-binding protein (CBP) (Kamah et al., 2014; Min et al., 
2010) and deacetylated primarily by HDAC6 and SIRT1 (Choi et al., 2020; Cook et al., 
2014). Tau also possess intrinsic acetyltransferase activity, using C291 and C322 as 
intermediates to transfer an acetyl group from acetyl CoA to lysine residues within tau or 
other proteins (Cohen et al., 2016; Cohen et al., 2013b). 
The importance of tau acetylation in disease is becoming increasingly recognized. 
Tau acetylation increases relatively early in tauopathies, and acetylated tau resists 
proteasome-mediated degradation (Min et al., 2010). Several specific acetylation sites have 
been identified in association with AD. In particular, acetylation at K174 slows tau turnover 
and worsens tau-mediated deficits in animal models (Min et al., 2015). Acetylation at K274 
and K281 is associated with cytoskeletal destabilization leading to memory impairment, 
reduced synaptic plasticity, and tau mislocalization (Sohn et al., 2016; Tracy et al., 2016). 
Acetylation at K280 impairs interaction with microtubules and increases the rate of tau 
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aggregation (Cohen et al., 2016; Cohen et al., 2011; Haj-Yahya and Lashuel, 2018). While 
acetylation at several sites is associated with promoting disease, acetylation of the KxGS 
motifs, especially K259, is associated with reduced aggregation of tau, likely through 
reduction in phosphorylation at S262 (Cook et al., 2014). Inhibition of HDAC6, which 
deacetylates the KxGS motifs, promotes tau clearance and may represent a novel 
therapeutic strategy (Carlomagno et al., 2017; Choi et al., 2020; Cook et al., 2014). 
1.1.3.3 Ubiquitination 
Ubiquitin is a 76 residue protein that is expressed by nearly all eukaryotic cells 
(Hershko and Ciechanover, 1998). Lysine residues on ubiquitin bind covalently to lysine 
residues on the target protein or other ubiquitin proteins, allowing chains of ubiquitin to 
develop. Ubiquitin binding is mediated through a multi-step process which culminates in 
an E3 ligase catalyzing the binding of ubiquitin to the target protein (Zheng and Shabek, 
2017). Ubiquitin contains 7 lysine residues, and the fate of the target protein depends on 
which ubiquitin lysine binds (Ikeda and Dikic, 2008). Binding via K48 or K63 marks the 
target protein for degradation via the 26S proteasome or lysosome-autophagy systems, 
respectively (Ikeda and Dikic, 2008). Three E3 ligases are capable of ubiquitinating tau. 
The C-terminus of the Hsc70-interacting protein (CHIP) ubiquitinates tau via K48 or K63, 
marking it for degradation by the proteasome or lysosome system (Petrucelli et al., 2004). 
The TNF receptor-associated factor 6 (TRAF6) ubiquitinates tau via K63, marking it for 
lysosomal degradation (Babu et al., 2005). Axotrophin, also called MARCH7, 
ubiquitinates tau’s microtubule binding domain and impairs microtubule binding, but as of 
yet this process is not well understood (Flach et al., 2014). The cysteine protease Otub1 is 
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the only deubiquitinase known to target tau, removing K48-linked ubiquitin units (Wang 
et al., 2017). 
Tau ubiquitination primarily occurs in the microtubule binding domain. Mono- or 
poly-ubiquitination occurs at K254, K257, K311, K317, and K353 in brains from patients 
with AD (Cripps et al., 2006; Morishima-Kawashima et al., 1993). Insoluble tau is 
generally ubiquitinated via K48 linage, indicating a preference for proteasome mediated 
degradation (Cripps et al., 2006). Ubiquitinated tau can be found in mature neurofibrillary 
tangles but not in pre-tangles, suggesting ubiquitination is a compensatory mechanism 
against accumulation of aggregated tau (Bancher et al., 1991; Garcia-Sierra et al., 2012; 
Iwatsubo et al., 1992; Perry et al., 1987). 
1.1.3.4 Methylation 
Protein methylation involves covalently attaching a methyl group to a residue, 
typically lysine or arginine, changing its charge and altering its interactions with other 
residues. Methylation in tau has been observed primarily on lysine residues, although some 
arginine methylation occurs (Morris et al., 2015). Lysine methylation in tau is a recently 
recognized factor contributing to pathogenesis. Tau can be methylated in vitro at up to 23 
different lysine residues (Funk et al., 2014). Tau from paired-helical filaments exhibits 
methylation at up to 7 lysine residues, while soluble tau can be methylated at 11 different 
lysine residues (Funk et al., 2014; Thomas et al., 2012). Lysine methylation occurs most 
often in the proline rich domain and micro tubule binding domains, particularly at K180 
and K267 (Thomas et al., 2012). The mechanisms of tau methylation, including specific 
the methyltransferases and demethylases involved, have not been identified. 
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Lysine methylation in tau modulates its microtubule binding and aggregation 
potential. Within the microtubule binding domain, the lysine residues in the KxGS motifs 
are subject to methylation, which will affect other modifications within these motifs (Funk 
et al., 2014). However, the specific effect of methylation on tau binding is unclear. Tau 
methylation is enriched in neurofibrillary tangles and methylation at K267 is associated 
with increased phosphorylation at S262, which drastically reduces tau’s affinity for 
microtubules (Thomas et al., 2012). However, in vitro methylation of tau has also been 
found to reduce the rate of aggregation (Funk et al., 2014). A likely explanation for the 
apparently discrepant results is the non-specific nature of the in vitro reductive methylation, 
indicating that the specific pattern of methylation is important in determining the effect. 
The specific role of tau methylation will likely become clearer as more research is 
conducted into this relatively newly recognized modification. 
1.1.3.5 Glycosylation 
Glycosylation, the addition of a carbohydrate to the side chains of residues, is the 
most common type of post-translational modification. Two broad types of glycosylation 
reactions have been identified: N-glycosylation, which attaches a carbohydrate chain to the 
side chain of an asparagine residue separated by one residue from a serine or threonine 
(NxS or NxT motifs), and O-glycosylation, which attaches a carbohydrate chain to the side 
chain of a serine or threonine residue (Haukedal and Freude, 2020). Tau can undergo N-
glycosylation at N167, N359, and N410 (Sato et al., 2001). N-glycosylated tau is only 
found in AD brains, suggesting it is a pathology-specific modification (Liu et al., 2002c; 
Wang et al., 1996). N-glycosylation stabilizes tau aggregates and promotes 
hyperphosphorylation via modulation of PKA and PP2A activity (Liu et al., 2002b; Liu et 
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al., 2002c; Wang et al., 1996). Tau can undergo O-glycosylation at T123, S208, S400, and 
either S409, S412, or S413 (Yuzwa et al., 2012; Yuzwa et al., 2011). Unlike N-
glycosylation, O-glycosylation of tau occurs in healthy brains, and O-glycosylated tau 
exhibits a reduced propensity for hyperphosphorylation and aggregation (Liu et al., 2004a; 
Yuzwa et al., 2012). O-glycosylation and phosphorylation apparently compete for residues 
on tau, and occurrence of one modification is frequently associated with a reduction of the 
other (Lefebvre et al., 2003). 
 Physiologic functions of tau 
Physiological function of tau depends on coordination between the major structural 
domains and is significantly influenced by various post-translational modifications, 
especially phosphorylation. Tau’s primary function is stabilization of microtubules. Tau 
binds longitudinally to the microtubule, at the interface between tubulin heterodimers (Al-
Bassam et al., 2002; Kadavath et al., 2015a). Tau’s binding to microtubules is significantly 
reduced by the microtubule-inhibitor vinblastine, suggesting tau and vinblastine bind the 
same site on microtubules (Kadavath et al., 2015a). The primary sites of direct interaction 
with microtubules are the repeat domains within the microtubule binding domain (Gustke 
et al., 1994; Himmler et al., 1989; Lee et al., 1989). NMR analysis of tau bound to 
microtubules has shown tau binds α-tubulin through a series of short sequence motifs 
which correspond largely, but not exclusively, with the repeat domains (Kadavath et al., 
2018; Kadavath et al., 2015a). Interestingly, the specific order of the various binding 
sequences has little overall effect on binding affinity as long as all sequences are present 
(Trinczek et al., 1995). The number of repeat domains contributes to binding affinity, with 
4R tau binding more strongly to tubulin than 3R tau (Butner and Kirschner, 1991; Goedert 
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and Jakes, 1990; Gustke et al., 1994). The increased binding affinity of 4R tau is apparently 
not simply due to the additional microtubule binding sequence, however. Rather, the 
sequence 216KVQIINK223, which falls between the first and second repeat sequences and 
is present only in 4R tau, exhibits a higher binding affinity than any of the repeat sequences 
and contributes significantly to tubulin binding in full-length tau (Goode and Feinstein, 
1994; Panda et al., 1995).  
While the repeat domains are the primary microtubule binding site, the regions 
flanking the repeats improve binding, described as a “jaws” model of binding (Gustke et 
al., 1994; Mandelkow et al., 1996; Mukrasch et al., 2007; Preuss et al., 1997). In this jaws 
model, the binding of the repeat domains is strengthened significantly by the flanking 
regions, resulting in much stronger binding than observed from the repeat domains alone. 
Specifically, the sequences 225KVAVVRT231 and 243LQTA246 in the proline rich domain 
and 370KIETHKTFREN380 in the microtubule binding domain contribute to the jaws model 
of binding (Mukrasch et al., 2007). Synthetic tau peptides composed of 4 repeat domains 
but lacking the flanking regions bind tubulin weakly, indicating these additional 
interactions are crucial to normal tau binding (Gustke et al., 1994). Additional sequences 
contribute to binding by promoting optimal conformation of tau to increase binding 
affinity. To promote binding, conformational changes mediated by the sequence 
215KKVAVVR221 in the proline rich domain and by the PGGG motifs at the end of repeats 
1 and 2 ensure the binding sequences align optimally (Goode et al., 1997; Kadavath et al., 
2015b). 
Although tau’s primary physiological function is stabilizing and promoting assembly 
of microtubules, it is involved in many additional processes. Tau’s projection domain, 
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which has a major direct role in microtubule binding, plays a key role in microtubule 
bundling, forming cross bridges with the projection domains of tau bound to nearby 
microtubules (Hirokawa et al., 1988; Kanai et al., 1992). Tau with a longer projection 
domain, as determined by the number of amino-terminal inserts, is more efficient at 
promoting formation of microtubule bundles (Kanai et al., 1992). Tau’s projection domain 
has not been studied as thoroughly as the microtubule binding domain, so it may have 
additional as yet unidentified functions. 
Tau may contribute axonal transport through modulation of the motor protein 
kinesin. Microtubule-bound tau promotes the detachment of kinesin proteins in vitro (Dixit 
et al., 2008; Vershinin et al., 2007). Taken in the context of tau’s concentration gradient 
the effect of tau on kinesin acts to promote transport toward the synapse. Kinesin more 
easily binds microtubules in the soma, where tau concentration is low, and is more likely 
to disassociate as it approaches the synapse as tau concentration rises along the axon (Dixit 
et al., 2008). However, tau’s role in axonal transport is not straightforward as axon 
transport has been found to be unaffected in retinal nerve axons of mice which lack or 
overexpress tau (Yuan et al., 2008). Although increased expression alone does not affect 
axonal transport, pathological tau has been shown to impair axonal transport (Kanaan et 
al., 2011). Tau’s role in axonal transport in vivo therefore seems to depend on several 
factors beyond normal physiology. 
Although tau is primarily located in the axon, it has some key somatic and dendritic 
functions as well. Small amounts of tau are normally found in the nucleus, where it protects 
DNA and RNA against oxidative and hyperthermic damage and may participate in 
nucleolar organization (Loomis et al., 1990; Sjoberg et al., 2006; Sultan et al., 2011; Violet 
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et al., 2014). Abnormal accumulations of nuclear tau have been identified in brains of 
patients with Huntington’s disease (HD), and mouse models of HD show improvement of 
motor abnormalities when tau is deleted, suggesting a role for nuclear tau in HD 
(Fernandez-Nogales et al., 2014). Dendritic tau has an important role in synaptic function 
and contributes a role in dysfunction associated with Alzheimer’s disease (Frandemiche et 
al., 2014; Ittner et al., 2010; Mondragon-Rodriguez et al., 2012; Tai et al., 2014). Tau’s 
functions beyond its role as a microtubule stabilizer have been increasingly recognized 
over the past 10 years, and it seems likely that future studies will continue to implicate tau 
in additional cellular processes. 
1.2 Tauopathies 
Since neurofibrillary tangles were first identified as a defining feature of Alzheimer’s 
disease, tau has implicated in a growing list of neurodegenerative diseases collectively 
called tauopathies (Alzheimer et al., 1995). Although development and presentation differ 
across tauopathies, these conditions generally share deposition of pathologic tau and 
development of dementia. Tauopathies are generally divided into two classes depending 
on the nature of tau’s role in disease pathogenesis. In primary tauopathies, which include 
Pick’s disease (PiD), progressive supranacular palsy (PSP), corticobasal degeneration 
(CBD), argyrophillic grain disease (AGT), primary age-related tauopathy (PART), and 
globular glial tauopathy (GGT), pathologic tau is the primary factor driving pathogenesis 
(Kovacs, 2015). In secondary tauopathies, including Alzheimer’s disease and Down’s 
syndrome, tau pathology develops and contributes to pathogenesis but is not thought to be 
the primary disease-causing factor (Josephs, 2017). Furthermore, tau pathology has been 
identified in other disease processes that have not traditionally been considered tauopathies 
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(Fernandez-Nogales et al., 2014; Loomis et al., 1990; Puvenna et al., 2016; Tai et al., 2016), 
but the extent to which tau pathology may contribute to these processes or merely be a 
byproduct is not clear. 
Research involving secondary tauopathies, especially Alzheimer’s disease, has been 
instrumental in revealing many mechanisms of tau pathology. A discussion of tauopathy 
would be incomplete without considering tau’s interactions with disease related proteins, 
particularly amyloid-β. However, the following section will focus on pathological tau 
itself, and additional pathological processes will only be considered as they pertain to 
development of tau pathology. 
 Tau pathophysiology 
The transition from physiological to pathological tau is diverse but can involve a 
combination of mutations, post-translational modifications, and conformational changes 
which culminates in pathology. In the course of its pathological changes, tau’s solubility 
changes, leading to the deposition of soluble tau into insoluble aggregations. Although the 
specific roles of soluble and insoluble tau in disease are not fully understood, current 
evidence suggests each form of tau has a distinct set of roles. 
1.2.1.1 MAPT mutations 
Numerous mutations in MAPT on chromosome 17 have been associated with 
development of familial frontotemporal dementia (Goedert, 2005). Diseases arising from 
mutations in MAPT were initial collectively termed “frontotemporal lobar degeneration 
with tau-immunopositive inclusions (FTLD-tau)” or “frontotemporal degeneration with 
parkinsonism linked to chromosome 17 (FTDP-17).” However, it is now recognized that 
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many of these mutation-related cases are pathologically indistinguishable from sporadic 
cases of primary tauopathies which lack a clear genetic cause, leading some to suggest 
FTLD-tau should be categorized as early-onset, familial varieties of PiD, PSP, CBD, or 
GGT rather than as a separate disease process (Forrest et al., 2019; Forrest et al., 2018; 
Josephs, 2018). To avoid confusion with previous studies, this work will use the term 
FTDP-17 to refer to cases of dementia associated with MAPT mutations, but it should be 
noted that this nomenclature may not accurately capture the relationship between these 
familial and sporadic cases of dementia. The term “frontotemporal dementia” will also be 
used when referring collectively to FTDP-17 and the sporadic tauopathies (PiD, PSP, CBD, 
etc.). 
Although tauopathies caused by an identified MAPT mutation are less common than 
sporadic cases, studying the specific mutations has elucidated important mechanistic 
aspects of tau pathophysiology. MAPT mutations associated with FTDP-17 are typically 
found throughout the microtubule-binding domain and affect splicing or alter microtubule 
binding (Goedert, 2005). Mutations which promote aggregation of tau will be discussed in 
section 1.2.1.3. Approximately half of identified MAPT mutations exhibit their effect at the 
RNA level (Goedert, 2005). 
In normal adult human brain, 3R and 4R isoforms of tau are expressed in roughly 
equal amounts (Hong et al., 1998). However, this ratio is frequently perturbed in cases of 
frontotemporal dementia (Chambers et al., 1999; Connell et al., 2005; Hong et al., 1998). 
The predominant isoform of tau in most tauopathies is 4R, although PiD is a notable 
exception characterized by 3R tau (Gotz et al., 2019). Several specific MAPT mutations 
affect tau splicing and may be at least partially responsible for the change in the ratio 
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between 3R and 4R tau. N296 plays an important role in splicing of exon 10, and mutations 
at this site can promote alternative splicing of exon 10 and increase the ratio of 4R to 3R 
tau (Grover et al., 2002; Iseki et al., 2001; Spillantini et al., 2000; Yoshida et al., 2002). 
Several other mutations (including G272V, N279K, L284L, S305N, R406W, and 
mutations in the 5’ splice site of exon 10 and the following intron) similarly increase 
splicing of exon 10, presumably by influencing the folding of mRNA and altering 
interactions with regulatory elements during post-transcriptional processing (D'Souza et 
al., 1999; Hasegawa et al., 1999; Hutton et al., 1998; Miyamoto et al., 2001; Spillantini et 
al., 1998). Although MAPT mutations affecting tau splicing typically promote alternate 
splicing of exon 10, the ΔK280 abolishes expression of 4R tau, most likely by disrupting 
the binding site of a splicing enhancer (D'Souza et al., 1999). 
In addition to altering splicing of MAPT mRNA, many mutations associated with 
FTDP-17 reduce tau’s binding affinity for microtubules. Unsurprisingly, mutations located 
in the microtubule binding domain or flanking regions greatly inhibit microtubule binding 
(Hasegawa et al., 1998). The greatest reduction in binding has been observed with 
mutations affecting N280 and P301, both within exon 10 (Barghorn et al., 2000; D'Souza 
et al., 1999; Grover et al., 2002; Rizzu et al., 1999). The relative impact of these mutations 
on tau’s microtubule binding affinity depends in part on which isoform of tau is examined. 
Several mutations (G272V, V337M, and R406W) more significantly inhibit microtubule 
binding in 3R tau than 4R tau (Hasegawa et al., 1998). Interestingly, at least two mutation 
associated with FTDP-17 (S305N and Q336R) are associated with an increased 
microtubule binding affinity, demonstrating that excessive tau binding can also be 




Changes in the normal post-translational modification of tau, especially 
development of hyperphosphorylation, are a key steps in the development of tau 
pathogenesis. Since tau bound to microtubules may not be readily accessible for 
modification, some have suggested mutations which reduce tau’s affinity for microtubules 
promote aberrant modification of tau by increasing the pool of soluble tau (Rizzu et al., 
1999). Phosphorylation at several key residues has also been shown to strongly inhibit tau’s 
binding to microtubules. In particular, phosphorylation at S214 (Illenberger et al., 1998), 
T231 (Sengupta et al., 1998), S262 (Biernat et al., 1993; Drewes et al., 1995; Sengupta et 
al., 1998), and S396 (Kadavath et al., 2018) reduces tau’s ability to bind microtubules. 
Hyperphosphorylation is also associated with abnormal redistribution of tau to the soma 
and dendrites (Hoover et al., 2010). Phosphorylation is strongly implicated in aggregation 
of tau into insoluble paired helical filaments (PHFs), which is discussed in more detail in 
the next section (1.2.1.2). 
1.2.1.3 Aggregation and filamentous tau 
Aggregation of tau into filaments and tangles is a key step in development of 
tauopathic diseases. Tau aggregation depends on the hexapeptide sequences 275VQIINK280 
(located in the second repeat domain) and 306VQIVYK311 (located in the third repeat 
domain) which form β-sheets with adjacent tau molecules (von Bergen et al., 2000). The 
propensity to form β-sheets directly correlates with the rate of aggregation (Eckermann et 
al., 2007; Mocanu et al., 2008). Adjacent tau molecules form anti-parallel dimers which 
then assemble with other dimers to form larger sheets (Wille et al., 1992). Formation of β-
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sheets in vitro can be promoted by addition of polyanions to offset charge repulsion 
between the positively charged microtubule binding domains, suggesting these compounds 
may contribute to tau aggregation in vivo (Giustiniani et al., 2014; Goedert et al., 1996; 
Hernandez et al., 2004; Kampers et al., 1996).  
Phosphorylation at specific sites can promote aggregation, although the exact role 
and mechanism is debated. Abnormal phosphorylation of tau precedes aggregation into 
tangles (Braak et al., 1994), and dephosphorylation of tau by PP2A promotes release of tau 
from PHFs (Drewes et al., 1993; Wang et al., 1995). Aggregation requires tau to be 
disassociated from microtubules, so phosphorylation at certain epitopes commonly found 
in PHFs, including T231, S262, and S396, which reduce tau’s affinity for microtubules 
may contribute to aggregation (Biernat et al., 1993; Drewes et al., 1995). However, the 
relationship between phosphorylation and aggregation is more complicated than these 
studies might suggest. Phosphorylation at some sites associated with decreased 
microtubule affinity have been shown to inhibit aggregation (Schneider et al., 1999), and 
PHF-like phosphorylation occurs naturally and reversibly during hibernation in some 
species (Arendt et al., 2003). These studies suggest the effect of tau phosphorylation on 
aggregation may be contextual. Furthermore, phosphorylation may influence aggregation 
through by inducing conformational changes. Phosphorylation at S202/T205 or S396/S404 
(but not at both sites) loosens tau’s paperclip conformation, which may promote tau 
aggregation by exposing the repeat domains (Jeganathan et al., 2008; von Bergen et al., 
2000). Phosphorylation at S202/T205 does not impact microtubule binding affinity, 
indicating the relationship between phosphorylation and aggregation is not simply 
dependent on microtubule binding (Amniai et al., 2009). Further work is needed to better 
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understand how phosphorylation influences aggregation of tau, but the answer is likely to 
be highly context dependent. 
Several MAPT mutations (including G272V, ΔK280, ΔN296, P301L, V337M, and 
R406W) which are associated with impaired microtubule affinity also promote tau 
aggregation (Barghorn et al., 2000; Grover et al., 2002; Iseki et al., 2001; Nacharaju et al., 
1999). Decreased microtubule binding increases the amount of tau in solution (Nagiec et 
al., 2001), therefore increasing the opportunities for tau-tau binding to occur. However, 
mutations that promote aggregation likely contribute to pathology beyond simply 
increasing the amount of tau available for aggregation. Pro-aggregation mutations increase 
the rate and extent of tau aggregation, suggesting they change tau in a way that directly 
promotes aggregation beyond simply releasing it from microtubules (Gamblin et al., 2000; 
Nacharaju et al., 1999). Further supporting this idea, the P301L, G272V, and V337M 
mutations also increase heparin-filament formation (Goedert et al., 1999). Furthermore, the 
ΔK280 and P301L mutations both affect the hexapeptide sequences which are central to 
aggregation, increasing their propensity to form β-sheets (von Bergen et al., 2001). Finally, 
at least one MAPT mutation promotes aggregation without inhibiting microtubule binding. 
The mutation Q336R increases tau’s binding affinity for microtubules as well as promoting 
aggregation (Pickering-Brown et al., 2004). This mutation would ostensibly cause more 
tau to be bound to microtubules at any given time, but also leads to increased tau-tau 
interactions between unbound tau molecules. 
Although PHFs are a characteristic feature of tauopathies, some evidence suggests 
these filamentous aggregations are not lethal to neurons. Although neuron death and 
neurofibrillary tangle (NFT) formation often occur together, NFTs correlate poorly with 
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neuron death in some models of tauopathy (Andorfer et al., 2005; Spires-Jones et al., 2008). 
Neuron death exceeds NFT formation in Alzheimer’s disease, and neurons can live for 
years with stable NFTs (Gomez-Isla et al., 1997; Morsch et al., 1999). Furthermore, 
functional deficits do not correlate well with presence of NFTs and repression of tau 
expression often ameliorates deficits despite the persistence of tangles (Crimins et al., 
2012; Rocher et al., 2010; Santacruz et al., 2005; Sydow et al., 2011). Rather than NFTs, 
many now believe tau oligomers are the primary toxic species responsible for much of the 
observed pathology. Tau oligomers can form from hyperphosphorylated tau and exhibit 
toxicity at low concentrations (Tepper et al., 2014; Tian et al., 2013). Tau oligomers are 
also an early stage in the aggregation process which culminates in NFT formation, so that 
the processes shown to contribute to NFT formation also likely promote oligomerization 
(Lasagna-Reeves et al., 2012; Maeda et al., 2007).  
1.2.1.4 Trans-synaptic spread of tau 
Each distinct tauopathy typically exhibits a consistent, disease-specific pattern of 
development, usually primarily affecting the same, often interconnected brain regions. In 
cases of Alzheimer’s disease, tau pathology first develops in the entorhinal cortex before 
spreading to the hippocampus and other limbic structures, and finally to the temporal lobe 
and cortex broadly (Braak and Braak, 1991). The sequential development of tau pathology 
in anatomically connected brain areas has led some to suggest tau spreads directly from 
neuron to neuron by a variety of mechanisms. Injection of pathologic tau into the 
hippocampus of mice induces tau pathology that can spread to distant brain areas 
(Clavaguera et al., 2009; Peeraer et al., 2015). Entorhinal cortex-specific expression of 4R 
P301L tau results in development of tau pathology along the circuitry of the hippocampus, 
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suggesting synaptic transmission of pathologic tau (de Calignon et al., 2012; Liu et al., 
2012). Microfluidic experiments have further supported this idea, demonstrating that 
pathologic tau travels along axons and spreads to post-synaptic neurons (Dujardin et al., 
2014). Tau release into the synapse is associated with neuronal activity, and tau may be 
released with pre-synaptic vesicles (Pooler et al., 2013; Yamada et al., 2014). The ability 
of tau to spread across synapses is consistent with the apparent spread of pathology 
observed in clinical cases and suggests tau pathology may initially develop in specific, 
focal brain areas.  
 Mouse models of tauopathy 
Many different mouse models of tauopathy have been developed to study specific 
aspects of tau function and pathology. Broadly, these can be divided into mice that are 
deficient in or entirely lacking tau, and those that express various forms of pathological 
tau. Additionally, to better understand tau’s role in secondary tauopathies, many mouse 
models have been developed which express pathological tau alongside other types of 
disease pathology. In the following sections, several important mouse models of tauopathy 
will be discussed in detail. 
1.2.2.1 Mouse models expressing pathological tau  
Mouse models of tauopathy have been an indispensable tool in the study of 
tauopathy. These model are usually characterized by expression/overexpression of human 
tau protein, often with disease-associated mutations. The first transgenic tau mouse model 
expressed non-mutant 2N4R human and developed somatodendritic mislocalization, 
hyperphosphorylation, and additional pathology consistent with early tauopathy (Gotz and 
Nitsch, 2001; Gotz et al., 1995; Probst et al., 2000). Following the discovery of MAPT 
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mutations, additional transgenic models were developed which expressed human tau with 
the G272V (Gotz et al., 2001c), P301L (Gotz et al., 2001a; Lewis et al., 2000), P301S 
(Allen et al., 2002), V337M (Tanemura et al., 2001), K369I (Ittner et al., 2008), and 
R406W mutations (Tatebayashi et al., 2002; Zhang et al., 2004). Mice expressing the 
P301L mutation in particular have since been used in many studies of AD and FTDP-17  
(David et al., 2005; Eckert et al., 2008; Gotz et al., 2001b; Kohler et al., 2010; Pennanen 
et al., 2004; Pennanen et al., 2006). Many transgenic tau models, including all of those 
discussed here, express only a single isoform of (usually 4R) tau. One notable exception to 
this trend is the 8c mouse, which overexpresses all six isoforms of human tau without any 
mutations (Duff et al., 2000). 
Another major breakthrough in the development of transgenic tau models came 
with the development of the first regulatable transgenic model. The rTG4510 mouse model 
expresses 0N4R P301L tau under the control of a tetracycline-off promoter (Ramsden et 
al., 2005; Santacruz et al., 2005). Treatment with doxycycline suppresses tau expression, 
resulting in a rapid decrease in transgene mRNA and a halt in progression of tau pathology 
(Santacruz et al., 2005). However, any pretangle or tangle pathology that formed prior to 
doxycycline treatment usually remains stable. In addition to allowing tau expression to be 
controlled, this model allows the effects of tangle pathology to be studied independently of 
soluble tau. Although subsequent research has found that placement of the transgene 
disrupts the Fgf14 gene and may introduce pathology that is not tau-related (Gamache et 
al., 2019), the model has still been useful in demonstrating tau expression can be regulated 
in transgenic models. Additional regulatable transgenic models of tauopathy have since 
been developed (Eckermann et al., 2007; Mocanu et al., 2008; Sydow et al., 2011). 
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1.2.2.2 Tau deficient mouse models 
The first strain of tau-/- mice was developed by deleting exon 1 through the use of 
a targeting vector (Harada et al., 1994). The same approach was later used to generate 2 
additional tau-/- strains via deletion of exon 1 (Dawson et al., 2001; Fujio et al., 2007). A 
fourth strain of tau-/- mice has also been developed by inserting cDNA encoding EGFP into 
the MAPT gene to disrupt exon 1 (Tucker et al., 2001). While the effect on tau expression 
is the same in this model as in others, it has an advantage of also labeling neurons 
throughout the developing nervous system. Subsequent studies have primarily used the 
models developed by Tucker et al. and Dawson et al. to study the effects of tau deletion. 
Initial studies of tau-/- mice surprisingly found no overt phenotypic changes, 
although further testing has identified some deficits. Other microtubule associated proteins, 
particularly MAP1A, were found to be elevated in young tau-/- mice and thought to 
compensate for the loss of tau (Dawson et al., 2001; Fujio et al., 2007; Harada et al., 1994). 
Fear conditioning is impaired in tau-/- mice (Ikegami, 2000), though cognitive function is 
broadly unaffected as late as 1 year of age (Dawson et al., 2010; Ikegami, 2000; Roberson 
et al., 2007). Short term memory was impaired in a tau-/- model on a different background 
strain, indicating memory and learning may be affected differently across strains/species 
(Biundo et al., 2018). Tests of motor function have produced varied results, with deficits 
identified in some studies (Ikegami, 2000; Lei et al., 2012; Ma et al., 2014) but not others 
(Dawson et al., 2010; Li et al., 2014). These discrepancies in motor testing could indicate 
that loss of tau has subtle effects on motor function, and minor differences in testing 
conditions may contribute to the differences observed. 
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Although gross effects of tau deletion are relatively minor, the developmental and 
cellular changes are more significant. Axonal development and organization are impaired 
(Dawson et al., 2010; Dawson et al., 2001; Harada et al., 1994), and these effects are 
exacerbated if MAP1B is also absent (Takei et al., 2000). Tau deficiency also increases 
expression of BAF-57, which normally represses expression of neuron-specific genes in 
non-neuronal cells and may further contribute to developmental deficits (de Barreda et al., 
2010). Tau-/- mice exhibit EEG changes including impaired sleep and hippocampal theta 
slowing, indicating tau plays a role in synchronization of signals between brain regions 
(Cantero et al., 2010; Cantero et al., 2011). Synaptic function and neuronal excitability is 
significantly affected by loss of tau expression, and this topic will be covered in detail in 
section 1.4.6. 
1.2.2.3 The htau mouse model 
Most transgenic tau models express human tau protein in addition to endogenous 
murine tau. These models are good for studying toxic functions gained by pathological tau, 
but could potentially miss effects from the loss of tau function that can also develop in 
advanced tauopathy. The htau mouse model addresses this issue. The htau mouse was 
developed by crossing the human tau expressing 8c mouse (Duff et al., 2000) with a tau-/- 
mouse (Tucker et al., 2001) to produce a mouse that expresses six isoforms of human tau 
without endogenous murine tau. The htau mice are hemizygous for the transgene encoding 
human tau, and homozygous transgene expression is assumed to be embryonic lethal 
(Andorfer et al., 2003). To account for this, only one mouse in each breeding pair expresses 
the transgene, although both lack murine tau expression. As a result, approximately half of 
the offspring produced lack both human and murine tau, and are essentially the same as the 
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tau-/- model developed by Tucker et al. While this breeding scheme reduces the number of 
htau mice per litter, it has the advantage of also producing litter-mate tau-/- mice and is 
especially useful for comparative studies of tau function. 
These mice develop progressive tau pathology including hyperphosphorylation by 
1.5 months of age, somatodendritic distribution by 3 months of age, and tangle pathology 
by 9 months of age (Andorfer et al., 2003; Dickstein et al., 2010). They undergo a dramatic 
increase in neuronal death after 12 months of age, and exhibit dramatic atrophy and 
enlargement of the ventricles by 18 months of age (Andorfer et al., 2005). Adult 
neurogenesis is also impaired compared to non-transgenic mice, especially when 
comparing young mice (Komuro et al., 2015). No deficits in neuronal function have been 
described to date in young mice, but synaptic dysfunction develops in CA1 by 1 year of 
age (Alldred et al., 2012; Polydoro et al., 2009). In the prefrontal cortex, basal dendrite 
length is shorter and dendrite spine morphology is altered in htau mice compared to non-
transgenic mice (Dickstein et al., 2010). Cognitive, sensory, and behavioral testing is 
largely normal, although deficits in visuospatial processing and food burrowing have been 
identified (Geiszler et al., 2016; Phillips et al., 2011). 
The htau mouse model has also been used in conjunction with several other models 
of tauopathy and AD. Increasing expression of 4R isoforms of tau, which occurs in several 
tauopathies, exacerbates tau phosphorylation/aggregation and impairs nesting behavior 
(Schoch et al., 2016). This group also showed that 4R tau expression could be reduced by 
administration of an antisense oligonucleotide (ASO) to induce exon skipping, but did not 
demonstrate whether this reduction abrogates the changes observed. Models have also been 
developed which introduce AD-related pathology to the htau mouse. Crossing htau mice 
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with mice expressing AD-related mutations in the amyloid precursor protein (APP) and 
presenilin 1 (PS1) produces a triple-transgenic mouse which develops age-dependent tau 
and Aβ pathology (Guo et al., 2013). These APP/PS1/htau mice exhibit synergistic 
interaction between Aβ and tau pathology, and may better recapitulate aspects of AD than 
models that express only 1 or 2 of these genetic modifications. Interestingly, another group 
crossed the htau mouse with a different strain of APP mice, and found no evidence of 
interaction between the tau and Aβ pathology (Yetman et al., 2016). While the difference 
in results could be attributable to the different APP mutations expressed in each model, it 
is also possible that the inclusion of the PS1 mutation in the APP/PS1/htau mouse is 
necessary for interaction to occur. Given the lack of murine tau which could confound 
efforts at studying human disease, the htau mouse is a powerful tool for generating models 
of disease.  
1.3 The Dentate Gyrus of the Hippocampus 
The hippocampus has long been recognized for its crucial role in regulation of 
memory. The hippocampus receives its major inputs from the entorhinal cortex via the 
perforant pathway and sends its major outputs via the fornix to the rest of the limbic system 
(Andersen, 1975). The hippocampus is composed of the dentate gyrus and Ammon’s Horn, 
which itself is usually subdivided into three major regions (CA1, CA2, and CA3). In overly 
simple terms, information passes through the hippocampus along the “trisynaptic circuit”, 
entering from the entorhinal cortex via the perforant pathway to the synapse at the dentate 
gyrus, then to passing to CA3 via the mossy fibers, and finally passing to CA1 via the 
Schaffer collateral fibers (Andersen, 1975). In reality, the passage of information through 
the hippocampus is much more complicated, with feedback loops and additional signaling 
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pathways between different regions of the hippocampus and extrahippocampal structures. 
However, the simplified trisynaptic circuit captures the overall unidirectional flow of 
information through the hippocampus. Due to the key roles of the dentate gyrus in both 
tauopathy and epilepsy (discussed further in sections 1.2 and 1.4), the current section will 
focus primarily on the dentate gyrus granule cells and the major pathways associated with 
their function. 
 Dentate gyrus organization and major cell types 
The dentate gyrus is a V-shaped formation folded around the end of CA3 (Amaral 
et al., 2007). Grossly, the dentate gyrus is composed of two blades connected by a region 
called the crest. The portion of the dentate gyrus that projects between CA1and CA3 is the 
suprapyramidal blade, and the other portion is called the infrapyramidal blade.  It is 
separated into three principal layers: the molecular layer, the granule cell layer, and the 
polymorphic layer. The molecular layer, which is furthest away from CA3, is mostly 
acellular, composed primarily of the perforant pathway fibers and dendrites of the granule 
cells. The granule cell layer is mostly composed of tightly packed granule cells, although 
some other cell types can be found at the boundary with the polymorphic layer, a region 
called the subgranular zone. The polymorphic layer/hilus (sometimes called CA4), which 
is the closest layer to CA3, is composed of the axons from the granule cells in addition to 
a variety of additional cell types including the mossy cell. Detailed drawings originally 
produced by Ramón y Cajal can be found in published works and are valuable resources 
for understanding hippocampal anatomy (Andersen, 1975; Ramón y Cajal, 1909). 
Three principal dentate gyrus neuron types will be discussed here. Many other 
classes of neurons/interneurons have been identified, primarily in the hilus/subgranular 
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zone. These neurons will be not discussed in detail here, but they can influence 
hippocampal function in important ways and are an area of ongoing study. 
1.3.1.1 Dentate granule cells 
The dentate granule cell (DGC) is the principal neuron type in the dentate gyrus. 
Each DGC has 1-4 primary dendrites that project from the soma toward the molecular 
layer, branching to form extensive dendrite trees that extend throughout the molecular layer 
to form synapses with the perforant pathway fibers (Claiborne et al., 1990). DGCs in the 
suprapyramidal blade have longer dendrite trees than those in the infrapyramidal blade 
(Claiborne et al., 1990). DGCs are the smallest and most tightly packed neuron type in the 
hippocampus, with 8-15 rows of neurons in the granule cell layer  (West et al., 1991). 
DGCs exhibit a low basal rate of action potential firing, typically less than 0.5Hz (Jung and 
McNaughton, 1993). DGCs are also hyperpolarized compared to most neurons, with a 
resting membrane potential that is typically below -70mV (Cronin et al., 1992; Staley et 
al., 1992). The low firing rate and hyperpolarized membrane potential of DGCs is likely 
due to high degree of inhibitory signaling and diversity of GABAA subunits expressed by 
DGCs (Brooks-Kayal et al., 1998). DGCs express a specific subtype of extrasynaptic α4βδ 
GABAA receptors which have a high affinity for GABA and do not desensitize to any 
significant degree (Mtchedlishvili and Kapur, 2006; Stell and Mody, 2002; Wei et al., 
2003). These receptors respond to spillover GABA from the synapse and are thought to 
contribute to the tonic GABA inhibition tight control over firing patterns. 
DGCs are primarily glutamatergic, though they form numerous synapses with 
inhibitory neurons so that DGC activity frequently drives inhibitory signaling (Acsády et 
al., 1998; Crawford and Connor, 1973). Furthermore, DGCs can synthesize and release 
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other compounds including γ-aminobutyric acid (GABA) under specific conditions, 
leading some to challenge the glutamatergic characterization (Gutierrez, 2003; Walker et 
al., 2002). The dentate gyrus is one of the few brain regions with persistent neurogenesis 
throughout adulthood, producing new DGCs and other cell types (Altman and Das, 1965; 
Cameron and McKay, 2001; Kaplan and Hinds, 1977). 
1.3.1.2 Dentate basket cells 
The hilus and subgranular zone contain a large number of primarily inhibitory 
interneurons that modify neuronal function (Houser, 2007). Inhibitory neurons are 
particularly abundant and are crucial to maintaining tight inhibitory regulation over dentate 
gyrus function (discussed further in sections 1.3.4 and 1.4.4). One important class of 
inhibitory interneurons are the dentate basket cells. Dentate basket cells are key 
GABAergic inhibitory neurons found primarily at the border of the granule cell layer and 
polymorphic layer (Amaral, 1978). Basket cells display varied morphology, with 5 
different subtypes identified (Ribak and Seress, 1983; Seress and Pokorny, 1981). 
Although these subtypes vary in gross morphology, they share key characteristics including 
aspinous dendrites which extend through all layers of the dentate gyrus, axons which 
extend into the granule cell and molecular layers, and GABAergic signaling (Ribak and 
Seress, 1983; Ribak et al., 1986). Basket cells are far less abundant than DGCs, at a ratio 
of around 200 DGCs per basket cell in rats (Seress and Pokorny, 1981). Basket cells are 
also asymmetrically distributed throughout the hippocampus, with higher concentrations 




1.3.1.3 Mossy cells 
Mossy cells are the most common neuron type in the hilus (Amaral, 1978). Each 
mossy cell has three or more dendrites that project throughout the hilus, giving off a small 
number of side branches along the way. Most of the dendrites remain in the hilus, but a 
few extend as far as the molecular layer (Amaral, 1978). The proximal dendrites are 
covered in distinctive large spines called “thorny excrescences” which serve as termination 
sites for mossy fibers. Mossy cells are primarily glutamatergic, and form synapses with 
many neuron types, including DGCs, throughout all 3 layers of the dentate gyrus 
(Scharfman, 1995; Wenzel et al., 1997). Mossy cells are more abundant than basket cells, 
but are still about 50 fold less abundant than DGCs in rats (Amaral et al., 1990). 
 Major inputs to the dentate gyrus 
The dentate gyrus receives its primary inputs from the ipsilateral entorhinal cortex 
via the perforant pathway. The fibers of the perforant pathway originate primarily from 
stellate cells in layer II of the entorhinal cortex (Hevner and Kinney, 1996; Steward and 
Scoville, 1976; van Groen et al., 2003; Witter et al., 1989). Projections from the entorhinal 
cortex to the dentate gyrus are topographically organized. Inputs to the dorsal dentate gyrus 
arise primarily from the lateral entorhinal cortex, whereas inputs to the ventral dentate 
gyrus arise primarily from the medial entorhinal cortex (van Groen et al., 2003). The fibers 
of the perforant pathway terminate primarily in the outer two thirds of the molecular layer 
of the dentate gyrus, where they form at least 85% of the synapses in this region (Matthews 
et al., 1976). The synapses formed by perforant pathway fibers are essentially all excitatory 
in nature (Leranth et al., 1990; Matthews et al., 1976; White et al., 1977). 
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While the major inputs to the dentate gyrus originate from the entorhinal cortex, 
other brain regions also project to the dentate gyrus. The dentate gyrus receives a 
combination of cholinergic and GABAergic inputs originating in the septal nuclei. The 
cholinergic inputs, which appear to form mostly excitatory synapses, primarily terminate 
on DGCs and mossy cells (Amaral and Kurz, 1985; Lubke et al., 1997). GABAergic 
neurons in the septal nucleus also project to the dentate gyrus, forming synapses primarily 
with inhibitory neurons (Amaral and Kurz, 1985; Bilkey and Goddard, 1985; Kohler et al., 
1984). The overall effect of septal projections to the dentate gyrus is increased flow of 
information due to a net increase in excitatory signaling. 
The dentate gyrus receives hypothalamic inputs originating primarily in the 
supramammillary nucleus. Fibers originating primarily from the supramammillary nucleus 
terminate in the molecular and granule cell layers, synapsing on the somata and proximal 
dendrites of DGCs (Dent et al., 1983; Magloczky et al., 1994; Vertes, 1992). These inputs 
originate in the bilateral supramammillary nuclei, although the ipsilateral nucleus 
contributes the majority of the fibers, and they terminate in the suprapyramidal blade about 
twice as often as the infrapyramidal blade (Kiss et al., 2000; Vertes, 1992; Wyss et al., 
1979). Although the earliest work suggested these hypothalamo-hippocampal connections 
were inhibitory in nature (Segal, 1979), subsequent work has shown the synapses on DGCs 
are primarily excitatory and likely glutamatergic (Dent et al., 1983; Kiss et al., 2000; 
Magloczky et al., 1994). Activation of the supramammillary nucleus results in an increase 




The final inputs to the dentate gyrus considered here originate from a few locations 
in the brainstem. The dentate gyrus receives noradrenergic input from the locus coeruleus 
and serotonergic input from the raphe nuclei. Noradrenergic fibers from the locus coeruleus 
form synapses on the somata and dendrites of DGCs and at interneurons in the hilus 
(Loughlin et al., 1986; Milner and Bacon, 1989; Pickel et al., 1974). The locus coeruleus 
fibers primarily form excitatory synapses with DGCs, whereas they form roughly equal 
number of excitatory and inhibitory synapses with interneurons (Milner and Bacon, 1989). 
Noradrenergic innervation enhances long-term potentiation (LTP) in the dentate gyrus, 
allowing the locus coeruleus to influence dentate gyrus function over time (Dahl and 
Sarvey, 1989; Izumi and Zorumski, 1999; Neuman and Harley, 1983; Walling and Harley, 
2004). 
Serotonergic inputs to the dentate gyrus originate primarily in the caudal portion of 
the dorsal raphe nucleus and peripheral part of the median raphe nucleus (Köhler and 
Steinbusch, 1982; McKenna and Vertes, 2001; Vertes et al., 1999). These fibers terminate 
throughout the molecular layer and hilus, especially targeting the subgranular zone, and 
account for nearly 75% of the serotonergic input to the hippocampus (Moore and Halaris, 
1975). Increased serotonergic input suppresses the theta rhythm and inhibits LTP (Vertes 
et al., 1994). This disruption in activity may serve to prevent encoding of irrelevant 
information into memory (Vertes and Kocsis, 1997). 
 Major outputs from the dentate gyrus 
The dentate gyrus projects primarily to CA3 via the mossy fibers, which are 
composed of the unmyelinated axons of the DGCs. Mossy fibers give rise to several 
collateral branches in the hilus before extending through CA3, terminating on pyramidal 
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cells (Blackstad et al., 1970; Claiborne et al., 1986). Mossy fibers form three different types 
of presynaptic terminals. The synapses onto CA3 pyramidal neurons are made through 
large mossy terminals, but filopodial extensions can also form from the axon end bouton 
that synapse onto interneurons through smaller terminals (Acsády et al., 1998; Claiborne 
et al., 1986). Mossy fibers can also form en passant varicosities that synapse with 
interneurons through small terminals (Acsády et al., 1998; Amaral, 1979; Frotscher et al., 
1991). The smaller filopodial and en passant terminals, which typically form synapses with 
inhibitory neurons, are far more numerous than the large terminals, so that the majority of 
mossy fiber synapses form on inhibitory neurons (Acsády et al., 1998). 
Mossy fibers synapse directly onto CA3 pyramidal neurons in addition to nearby 
inhibitory interneurons which project to the same pyramidal neurons or back to DGCs 
(Gulyas et al., 1993). This increases the complexity of the circuit between the DGC and 
CA3 pyramidal neurons since the same fibers drive excitatory and inhibitory input. Single 
stimulations from the mossy fiber activate AMPA receptors at glutamatergic synapses 
while simultaneously triggering GABA release at the GABAergic synapse via activation 
of the inhibitory interneuron (Larson and Munkacsy, 2015). The resulting excitatory post-
synaptic current (EPSC) and inhibitory post-synaptic current (IPSC) partially offset each 
other, curtailing the resulting depolarization in the CA1 pyramidal cell. However, GABA 
released at the GABAergic synapse activates presynaptic GABAB autoinhibitory receptors 
on the interneuron presynaptic terminal, inhibiting further release of GABA. Following 
repeated stimulation from the mossy fiber (which is typical during normal entorhinal 
cortex-driven DGC firing patterns), EPSCs strengthen while IPSCs diminish. With 
sufficient stimulation, long-term potentiation can occur, further strengthening the activity 
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at the glutamatergic synapse. This complexity plays an important role in shaping the flow 
of information from the dentate gyrus to CA3, improving precision of signals and 
contributing to memory formation (Henze et al., 2002; Jung and McNaughton, 1993; 
Torborg et al., 2010). 
 Local circuits in the dentate gyrus 
Dentate granule cells exhibit a low overall level of activity due largely to the high 
degree of inhibitory signals they receive and their low resting potential. The high inhibitory 
tone results in the dentate gyrus forming a “gate” of information passing through the 
hippocampus and has major implications in the development epilepsy (see section 1.4.4). 
Ironically, this inhibitory tone relies heavily on glutamatergic signals from mossy cells and 
perforant pathway fibers, in conjunction with inhibitory neurons. 
As previously discussed, mossy fibers have collateral branches that form frequent 
synapses with mossy cells and inhibitory interneurons in the hilus. These mossy cells in 
turn project back to the inner molecular layer, forming synapses with the interneurons and 
proximal dendrites of the DGCs (Buckmaster et al., 1992; Buckmaster et al., 1996; 
Frotscher et al., 1991; Scharfman, 1995; Wenzel et al., 1997). Mossy cells form 
monosynaptic connections directly to DGCs which are excitatory, but under normal 
conditions activation of mossy cells has an inhibitory effect on DGCs (Scharfman, 1995). 
The inhibitory effect is disynaptic and disappears in the presence of the GABAA antagonist 
bicuculline methiodide, indicating the involvement of an inhibitory interneuron. The result 
of this circuit is that increased DGC activity feeds back to inhibit DGCs. Interestingly, the 
inhibitory effect is relatively weak in DGCs at the same septotemporal level as the mossy 
cell, but becomes stronger in DGCs more distant along the septotemporal axis from the 
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mossy cell (Amaral and Witter, 1989). Therefore, DGC activity in one lamella of the 
dentate gyrus can influence DGC activity in nearby lamellae, allowing for local modulation 
of information as it passes through the dentate gyrus. 
Mossy cell activity has a critical role in the function of inhibitory basket cells in the 
subgranular zone. Animal models of epilepsy will be discussed in more detail in section 
1.4.5, but the effects of seizures on circuitry in the dentate gyrus reveal an important 
relationship between mossy cells, basket cells, and the tonic inhibitory input to DGCs. 
Mossy cells are highly sensitive to status epilepticus, whereas basket cells are relatively 
robust and more likely to survive (Sloviter, 1991). Despite the loss of glutamatergic 
neurons, mossy cell death is associated with increased DGC activity. Loss of mossy cells 
removes much of the excitatory drive to basket cells, causing them to fall dormant and 
removing inhibitory signals to DGCs (Sloviter et al., 2003). 
1.4 Temporal Lobe Epilepsy  
Epilepsy is one of the oldest known disorders and has been recognized in some form 
since ancient times (Wilson and Reynolds, 1990). Epilepsy affects around 1% of the global 
population, although incidence and prevalence vary significantly in different parts of the 
world (Asadi-Pooya et al., 2017; Hirtz et al., 2007; Thurman et al., 2011). Although 
epilepsy has historically been more common in children, in recent decades prevalence and 
incidence have been highest in adults older than 60 years (Sander, 2003; Sen et al., 2020). 
Epilepsy is not truly a single disorder, but rather refers to a spectrum of disorders 
characterized by recurrent seizures (Jensen, 2011). The minimum diagnostic criteria for 
epilepsy is the occurrence of 2 or more unprovoked seizures at least 24 hours apart (Fisher 
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et al., 2014). “Unprovoked” in this context is used to exclude seizures of known, discrete 
etiology that do not suggest a likelihood of recurrence, such as those associated with 
concussion, fever, or alcohol-withdrawal. An important exception are the seizures 
associated with reflex epilepsies that can be reliably provoked by specific sensory stimuli 
because these reflect a prolonged tendency toward seizures (Harding, 2004). This 
definition of epilepsy does not address the underlying etiology, however, so more 
information is needed to further classify any specific case of epilepsy. 
 Classification and description of seizures  
Given epilepsy’s long history, it’s not surprising that the terminology used to 
describe seizures and epilepsy has changed over the years. Consistent classifications are 
crucial for proper care, leading the International League Against Epilepsy (ILAE) to release 
and revise its operational classifications of seizure types (Fisher et al., 2017). The ILAE 
defines a seizure as “a transient occurrence of signs and/or symptoms due to abnormal 
excessive or synchronous neuronal activity in the brain” (Fisher et al., 2005). The most 
recent classification system recognizes 3 categories of seizures defined by onset. Focal 
seizures, formerly called partial seizures, originate within networks of one hemisphere, 
potentially originating from subcortical structures. Generalized seizures originate from and 
rapidly engage networks bilaterally (Fisher et al., 2017). Seizures can further be classified 
as unknown-onset, but this should be viewed as a place holder classification until more 
information becomes available. Further classification based on seizure characteristics is 
optional but can provide a better description of the seizure. 
Focal seizures can be further described based on awareness, defined as knowledge 
of self and environment. During focal seizures with intact awareness, formerly called 
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simple partial seizures, consciousness is maintained for the full duration of the seizure. If 
consciousness is lost for any duration during the seizure, it is classified as a focal seizure 
with impaired awareness, formerly called a complex partial seizure (Fisher et al., 2017). In 
addition to describing awareness, focal seizures are often described in terms of associated 
motor or non-motor symptoms. Motor descriptors include automatism (repetitive, 
coordinated movement usually associated with impaired awareness), atonic, clonic, 
epileptic spasm (sudden flexion, extension, or mixed extension-flexion of proximal and 
truncal muscles, lasting around 1 second; formerly called an infantile spasm), hyperkinetic, 
myoclonic, and tonic (Fisher et al., 2017). Non-motor descriptors include autonomic, 
behavioral arrest (lasting the entire seizure), cognitive (involving déjà vu, jamais vu or 
hallucinations, formerly called psychic), emotional, and sensory. Finally, the classification 
should describe whether the focal seizure evolves into a bilateral, tonic-clonic seizure. 
Classification of generalized seizures follows similar conventions as focal seizures. 
Awareness is normally impaired during generalized seizures and therefore does not need 
to be specified. Generalized motor seizures can be described with some of the same 
descriptors as focal seizures (clonic, tonic, myoclonic, atonic, epileptic spasms). Motor 
involvement associated with generalized seizures can also develop through distinct patterns 
of motor involvement, including tonic-clonic (formerly called grand mal), myoclonic-
tonic-clonic, and myoclonic-atonic (formerly called myoclonic-astatic). Generalized non-
motor seizures (also called generalized absence, formerly called petit mal) usually consist 
of sudden interruption of ongoing activities accompanied by unresponsiveness lasting up 
to a half minute with rapid recover (Fisher et al., 2017). Generalized absence seizures are 
further classified as typical or atypical based on EEG findings. Generalized absence 
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seizures can also involve rhythmic movements of the upper limbs (myoclonic absence 
seizure) or eyelid myoclonus. 
 Temporal lobe epilepsy 
Epilepsy is generally classified as focal or general depending on where the seizures 
originate. This classification is important in considering clinical management (discussed in 
section 1.4.3). Approximately 60% of epilepsy cases are focal in nature (Pascual, 2007; 
Wiebe, 2000). Cases of epilepsy are further classified into cases of primary epilepsy with 
idiopathic or cryptogenic etiology and cases of secondary epilepsy with known etiology 
(ILAE, 1989). Idiopathic epilepsy is often assumed to have a genetic etiology, whereas 
secondary epilepsy is associated with a CNS injury or disorder. Cryptogenic epilepsy is 
typically presumed to also be attributable to some injury, but does not have an identifiable 
etiology. 
The primary focus of this work will be focal epilepsy affecting the temporal lobe. 
Temporal lobe epilepsy (TLE) is the most common type of focal epilepsy (Manford et al., 
1992; Wiebe, 2000). Since TLE is highly focal in nature and has a high tendency to be 
resistant to medical management, cases are often referred for surgery (Engel et al., 2012; 
Quarato et al., 2005). As a result, the etiology of drug-resistant TLE is frequently identified. 
Hippocampal sclerosis is the most common histopathological finding, in addition to 
neoplasm, focal malformation, and necrosis (Helmstaedter et al., 2014; Salanova et al., 
2004; Zentner et al., 1995). Many of the patients in these studies became seizure free or at 
least had significant seizure reduction (>75%), suggesting these pathologies are closely 
associated with the epileptic focus (Salanova et al., 2004). 
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 General clinical management of epilepsy 
The primary goal of epilepsy treatment is reducing/preventing occurrence of 
seizures. Epilepsy is considered “resolved” if an individual remains seizure free for at least 
10 years and off medication for at least five years or has past the applicable age for age-
dependent epilepsy syndromes (Fisher et al., 2014). The first line therapy for epilepsy is 
typically medical management with antiseizure medications (ASMs). Many studies use the 
term “antiepileptic drug (AED)” rather than ASM to refer to medications used to manage 
epilepsy. While these drugs are often very effective at controlling seizures, they should be 
viewed as symptom management rather disease modification. Calling them antiepileptic 
drugs is therefore inaccurate, leading some to call for a change in terminology (French and 
Perucca, 2020). Despite significant advances in ASMs, about one third of cases remain 
refractory to pharmacological management and require further intervention, often surgical 
resection of the epileptic focus (Cockerell et al., 1995; Engel, 1993; Kwan and Brodie, 
2000). Management of epilepsy, especially drug resistant cases, remains a significant 
global socioeconomic burden (Ali, 2018; Begley et al., 2000). 
1.4.3.1 Medical management of epilepsy 
Pharmacotherapy is effective for many patients with epilepsy, and about half of 
patients achieve seizure control with the first ASM (Kwan and Brodie, 2000). In general, 
monotherapy is preferred to polytherapy. Polytherapy increases the risks of adverse effects 
while usually providing only minor improvement to seizure control (Carpay et al., 2005; 
Liu et al., 2017a; St Louis et al., 2009). It is generally recommended, therefore, to exhaust 
options for monotherapy with first line agents before initiating polytherapy. Early seizure 
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control after diagnosis is associated with a better long-term prognosis (Elwes et al., 1984; 
Ettore Beghi et al., 1992; Kwan and Brodie, 2000). 
ASMs generally suppress seizures by inhibiting neuronal ion channels or increasing 
GABAergic signaling (White et al., 2007). Most ASMs routinely used for management of 
seizures block voltage-gated sodium (phenytoin, carbamazepine, topiramate, lamotrigine, 
valproic acid) or calcium (ethosuximide, valproic acid, gabapentin) channels, though many 
exhibit more than one mechanism of action. One notable exception which is commonly 
used as a first line therapy is levetiracetam, which suppresses seizures by modulating 
synaptic transmission via inhibition of SV2A (Lambeng et al., 2005). Benzodiazepines 
(diazepam, lorazepam, midazolam), which are agonists of the GABAA receptor, are 
recommended as first line therapy for cases of status epilepticus (Sirven and Waterhouse, 
2003). 
Most ASMs in use today have not undergone placebo-controlled studies due to the 
ethical concerns of withholding treatment. However, non-inferiority trials comparing 
several common ASMs have largely found comparable efficacy rates for different ASMs 
(Brodie et al., 2007; Costa et al., 2011; de Silva et al., 1996; Vazquez, 2004). Lamotrigine 
and valproic acid are strongly recommended as the first line therapy for newly diagnosed 
focal epilepsy and generalized epilepsy, respectively (Marson et al., 2021; Marson et al., 
2007a, b). Lamotrigine and levetiracetam are acceptable alternatives to valproic acid for 
treating generalized seizures in women who are or may become pregnant (Nevitt et al., 
2017). Ethosuximide and valproic acid demonstrate the best efficacy in treatment of 
generalized absence epilepsy in children, but ethosuximide is recommended due to its 
reduced rate of adverse effects (Brigo et al., 2021; Glauser et al., 2010). 
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Often, the selection of monotherapy ultimately depends on tolerability. The most 
common adverse effects associated with ASM therapy are fatigue/tiredness and memory 
impairment, although life threatening adverse events are possible with most ASMs (Brodie, 
2017; Carpay et al., 2005). While all ASMs are associated with teratogenicity, the risk is 
highest with valproic acid and lowest with levetiracetam (Tomson et al., 2015). The goal 
in medical management of epilepsy should be to quickly find a monotherapy which 
provides adequate seizure control with tolerable side effects. While newer ASMs are often 
associated with more favorable adverse event profiles, the trials discussed comparing 
efficacy of older and newer ASMs have largely found them to be equally effective 
(Schmidt, 2011). This demonstrates a lack of major improvement in ASM efficacy and 
underscores the need for improved therapeutics, requiring better understanding on the 
mechanisms of epilepsy. 
1.4.3.2 Surgical intervention in epilepsy 
Although most cases of epilepsy respond to medical management with ASMs, 
about one third of cases, mostly TLE, remain refractory (Engel et al., 2012). Cases of TLE 
often respond well to surgical resection of the epileptic focus (Cersosimo et al., 2011; Engel 
et al., 2012; Engel et al., 2003; Salanova et al., 2004). Most patients who undergo resection 
experience significant reduction in seizures, and around half of patients remain seizure free 
10 years after surgery (Cohen-Gadol et al., 2006; de Tisi et al., 2011; Mohan et al., 2018; 
Tellez-Zenteno et al., 2005). Early freedom from seizures predicts better long-term 
outcomes, with at least 75% of patients who are seizure free for the first two years 
remaining seizure free after 10 years (Cohen-Gadol et al., 2006; McIntosh et al., 2004). 
Presence of histopathology in the resected tissue, which may indicate a discrete epileptic 
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focus, is associated with higher probability of remaining seizure free (Zentner et al., 1995). 
In contrast, a history of tonic-clonic seizures, especially in the year preceding surgery, 
predicts a higher chance of seizure recurrence after resection (Asadi-Pooya et al., 2016). 
1.4.3.3 Other treatment options 
In addition to medical management and surgical resection, several additional 
therapeutic options are available. Given the epilepsy’s long history, it is no surprise that 
numerous herbal remedies have been used. While some of these compounds have been 
shown to have anticonvulsant properties in animal studies, they have the potential to 
interact with common ASMs and have not been shown to be effective in clinical trials 
(Tyagi and Delanty, 2003). Limited clinical data is available for some treatments such as 
melatonin and acupuncture, but suggests these are not effective for treatment of seizures or 
epilepsy (Brigo and Del Felice, 2012; Cheuk and Wong, 2006). Despite these examples of 
ineffective treatments, some alternatives to mainstream ASM therapy and surgical 
resection have been found effective for managing epilepsy, particularly cases that remain 
refractory to other treatments. In particular, ketogenic diets and vagal nerve stimulation 
can provide effective seizure control despite failure of other options, and each will be 
briefly discussed here. 
Several different types of ketogenic diets have been developed, but all consist of a 
diet that is primarily fat-based with little to no carbohydrates, which causes the body to 
begin producing ketone bodies from stored fat in a process called ketosis. The efficacy of 
the ketogenic diet for treating epilepsy was recognized in the 1920s (Barborka, 1928; 
Peterman, 1924) and recent trials have similarly found a ketogenic diet effective for 
treatment of pharmacoresistant epilepsy (Klein et al., 2010; Mady et al., 2003; Neal et al., 
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2008). To promote adherence and reduce adverse effects, a modified Atkins diet with fewer 
restrictions was developed which has also been shown to be effective at treating epilepsy 
(Kossoff et al., 2006). The exact anti-epileptogenic mechanism of a ketogenic diet has not 
been identified, but several possibilities have been suggested. Ketone bodies seem to have 
a direct anticonvulsant effect (Keith, 1933; Rho et al., 2002). Some evidence suggests 
ketones promote an increase in production of GABA from glutamate (Dahlin et al., 2005; 
Yudkoff et al., 2005), while others have suggested direct modulation of ion channels to 
reduce neuronal excitability (Ma et al., 2007; Won et al., 2013). Additionally, many studies 
have suggested the ketogenic diet works through a variety of metabolic and bioenergetics 
mechanism. In particular, animals on a ketogenic diet exhibit resistance to oxidative stress, 
a process which is commonly upregulated in epilepsy (Kim et al., 2010; Maalouf et al., 
2007; Milder et al., 2010). Finally, ketogenic diets result in significant metabolic changes 
including reduction in blood glucose, production of polyunsaturated fatty acids, and 
upregulation of the tricarboxylic acid cycle, which may contribute to the antiseizure 
potential of ketogenic diets (Fraser et al., 2003; Mantis et al., 2004; Willis et al., 2010). 
None of these individual mechanisms seems to fully account for the efficacy of ketogenic 
diets in treating refractory epilepsy, so it is likely that several of these mechanisms 
contribute to the overall antiseizure effect. 
Vagal nerve stimulation (VNS) is a relatively new treatment that can be an effective 
adjunctive therapy for reducing seizure burden. The potential of VNS as an antiseizure 
therapy was recognized by the early 1990s (Clarke et al., 1991; Penry and Dean, 1990), 
and successful clinical trials resulted in FDA approval for treatment of refractory epilepsy 
in 1997 (Handforth et al., 1998; Morris and Mueller, 1999). Efficacy of VNS improves 
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over time (DeGiorgio et al., 2000; Morris et al., 2013), and patients undergoing VNS may 
be able to reduce their ASM dose while maintaining seizure control (Tatum et al., 2001). 
Several mechanisms are thought to contribute to the antiseizure effect on VNS. Stimulation 
of the vagus nerve induces changes in many brain areas, including the solitary nucleus, 
dorsal motor nucleus of the vagus, locus coeruleus, thalamus, hypothalamus, amygdala, 
and occipital, cingulate, and temporal cortex (Ko et al., 1996; Krahl et al., 1998; Naritoku 
et al., 1995), indicating the effects of VNS are not limited to the vagal system. Stimulation 
of vagal afferent fibers can modulate EEG activity in cortical and subcortical brain regions 
(Chase et al., 1967; Chase et al., 1966), which may disrupt seizures by preventing or 
disrupting synchronized activity. Further studies have found an increase in GABAergic 
inhibitory signaling after VNS which may suppress seizure development (Di Lazzaro et 
al., 2004; Marrosu et al., 2003). VNS is generally well-tolerated, although respiratory 
symptoms and vocal changes develop commonly after stimulation (Handforth et al., 1998). 
Given the significant reduction in seizure occurrence and improvement in quality of life 
reported by patients in the same study, these adverse events do not offset the value of VNS 
in treating refractory epilepsy. 1/2 
 Potential mechanisms of epileptogenesis  
As the first step in the trisynaptic circuit of the hippocampus, the dentate gyrus 
plays an important role controlling the flow of information into the hippocampus. Since 
DGCs are normally not highly active, they effectively filter signals entering the 
hippocampus and are thought to protect hippocampal neurons downstream, forming a 
“dentate gate.” The dentate gate normally prevents epileptiform bursts from the entorhinal 
cortex from propagating to CA3, but this gating breaks down in epileptic animals (Ang et 
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al., 2006; Behr et al., 1998). DGC gating is GABA-dependent and is mediated primarily 
by extrasynaptic GABAA receptors (Iijima et al., 1996; Maguire et al., 2005). Optogenetic 
restoration of DGC gating stops spontaneous seizures in epileptic mice, further supporting 
the role of the dentate gate in epilepsy (Krook-Magnuson et al., 2015). 
Given the importance of GABA signals in the dentate gate, it is reasonable to expect 
a loss of GABAA receptors to accompany disrupted gating epileptic animals. However, 
numerous studies have found a paradoxical upregulation of GABAA receptors in TLE 
models (Nusser et al., 1998; Otis et al., 1994). Instead, a modulation of GABAA receptor 
composition occurs in DGCs from epileptic animals. The specific effects of these 
modulations have not been fully elucidated, though several important functional changes 
have been identified. DGCs from epileptic animals exhibit a downregulation in the δ-
subunit of GABA receptors, which reduces the tonic GABAA current and may contribute 
to loss of gate function (Boychuk et al., 2016; Peng et al., 2004). Modulated GABAA 
receptors are also sensitive to inhibition by zinc, which is released in large amounts from 
sprouted mossy fibers (Assaf and Chung, 1984; Buhl et al., 1996; Cohen et al., 2003; Gibbs 
et al., 1997). While exogenously applied zinc effectively inhibits these GABAA receptors, 
it seems that zinc endogenously released at excitatory synapses is unable to reach and 
inhibit GABAA receptors, so an alternate explanation is needed to support zinc-induced 
inhibition of GABAA receptors (Molnar and Nadler, 2001). Finally, GABAA receptors in 
DGCs from epileptic animals show reduced sensitivity to benzodiazepine activation, 
further suggesting functional changes (Leroy et al., 2004). While the exact mechanism is 




Other changes in excitatory and inhibitory signaling in the dentate gyrus have been 
identified which may further contribute to the loss of gating ability. Following 
epileptogenesis, animal models frequently develop abnormal sprouting of mossy fibers. 
Sprouted fibers aberrantly extend to the inner molecular layer and form synapses with 
nearby DGCs. These synapses create recurrent excitatory circuits which promote 
synchronization of aberrant activity within dentate gyrus (Bhaskaran and Smith, 2010; 
Cronin et al., 1992; Hunt et al., 2010; Lynch and Sutula, 2000; Patrylo and Dudek, 1998; 
Winokur et al., 2004; Wuarin and Dudek, 2001). In addition, several types of inhibitory 
neurons in the dentate gyrus are susceptible to death or dysfunction following 
epileptogenesis (Buckmaster and Dudek, 1997; Butler et al., 2017; Hunt et al., 2011; 
Lowenstein et al., 1992; Sloviter, 1991; Sloviter et al., 2003). Since many hilar inhibitory 
neurons receive excitatory inputs from mossy fibers, their activity is actually increased 
after mossy fiber sprouting (Halabisky et al., 2010; Hunt et al., 2011). While this likely 
represents a compensatory mechanism to prevent excessive DGC activity, chronic over 
activation of hilar interneurons may also negatively impact their survival and contribute to 
further loss of inhibitory signals to DGCs in epileptic brains. Overall, the changes in 
excitatory and inhibitory signaling observed in animal models of TLE, taken along with 
the changes in GABAA receptor function, create an environment that favors the 
development and propagation of seizures in epileptic brains. 
 Animal models to study seizures and epilepsy  
Because epileptogenesis is a complex process affecting several interconnected 
neuron types, studying epilepsy requires complex models. Several animal models of 
seizure induction and/or acquired epilepsy have been developed for this purpose. Models 
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of seizure induction commonly used to study epileptogenesis can broadly be divided into 
chemically induced epilepsy, post-traumatic epilepsy (PTE), and kindling models. 
Electrical kindling is the classic model of induced seizures, involving repeated electrical 
stimulation of specific brain areas to induce seizures. While kindling has been replaced as 
the primary seizure model by newer, easier to implement models, it is still used in epilepsy 
research (Gorter et al., 2016). Epilepsy commonly develops as a result of traumatic brain 
injury, and several models mostly using rodents are commonly implemented to recapitulate 
aspects of PTE for study (D'Ambrosio et al., 2004; Hunt et al., 2009; Kharatishvili et al., 
2006; McIntosh et al., 1989). The focus of the rest of this section will be models involving 
the use of chemoconvulsants to induce seizures. Models involving focal or systemic 
administration of chemoconvulsant agents can be used to study the process of seizure 
induction, or to induce status epilepticus in order to study epileptogenesis. Three 
chemoconvulsant agents (kainic acid, pilocarpine, and pentylenetetrazole) are particularly 
common in models of seizures/epilepsy, and each will be discussed in some detail here. 
Kainic acid (KA), an analog of L-glutamate, was one of the earliest 
chemoconvulsant agents used to study the effects of seizures in rodents (Ben-Ari et al., 
1979; Ben-Ari et al., 1980; Nadler et al., 1978). KA activates non-NMDA ionotropic 
receptors (AMPA and kainate) at a much higher affinity than glutamate (Sharma et al., 
2007). Administration of KA and subsequent SE recapitulates the mossy fiber sprouting 
that is a key histopathological characteristic of TLE in human patients (Cronin and Dudek, 
1988; Cronin et al., 1992; Sutula et al., 1989; Tauck and Nadler, 1985). When appropriate 
doses are used, systemic administration of KA reliably induces status epilepticus in rats 
and some strains of mouse without excessive mortality (Dudek and Staley, 2017), although 
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C57BL/6 mice in particular have been shown to exhibit resistance to this model (McKhann 
et al., 2003; McLin and Steward, 2006; Schauwecker and Steward, 1997). Focal 
administration of KA directly to the hippocampus (intrahippocampal kainate, IHK) or 
amygdala (intra-amygdala kainate, IAK) increases efficacy and avoids strain-resistance, 
with rates of SE approaching 100% in C57BL/6 mice (Welzel et al., 2020). IHK in C57BL6 
mice reliably results in epileptogenesis and is associated with a short latent period to 
spontaneous seizures with EEG abnormalities apparent within days of treatment (Raedt et 
al., 2009; Welzel et al., 2020). 
Pilocarpine is a muscarinic acetylcholine agonist that was another early 
chemoconvulsant agent used in rodents (Turski et al., 1984; Turski et al., 1983). Excessive 
muscarinic activation triggers seizures by creating an imbalance between excitatory and 
inhibitory signals (Priel and Albuquerque, 2002). Pilocarpine is frequently administered 
systemically via intraperitoneal injection. To prevent excessive systemic muscarinic 
activation, animals are typically pretreated with methylscopolamine, an anticholinergic 
agent that does not readily cross the blood-brain barrier. In rats, pretreatment with lithium 
reduces drastically reduces the dose of pilocarpine needed to induce seizures while also 
reducing mortality (Clifford et al., 1987; Honchar et al., 1983). Lithium has not frequently 
been used in pilocarpine-treated mice, but the limited data available suggest lithium does 
not potentiate pilocarpine-induced seizures in mice (Muller et al., 2009). Pilocarpine-
induced status epilepticus induces mossy fiber sprouting in addition to widespread neuronal 
lesions (Turski et al., 1984; Turski et al., 1983). In contrast to systemic KA, C57BL/6 mice 
do not exhibit resistance to seizures induced by systemic pilocarpine (Shibley and Smith, 
2002). Like kainic acid, pilocarpine can also be focally administered to the hippocampus, 
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resulting in reduced mortality while reliably inducing status epilepticus and epileptogenesis 
(Furtado Mde et al., 2002). 
Pentylenetetrazole (PTZ) is a GABAA antagonist that has long been used to induce 
seizures in animal models (Squires et al., 1984). Unlike KA and pilocarpine, a single dose 
of PTZ typically triggers a single seizure. Repeated doses of PTZ gradually reduce the 
threshold required to induce seizures, making PTZ a good candidate for chemical kindling 
(Angelatou et al., 1991; Corda et al., 1991). While this makes PTZ more labor intensive in 
studies of epileptogenesis, PTZ is an ideal model for assessing seizure threshold and 
latency, and it is frequently used for this purpose (Garcia-Cabrero et al., 2013; Li et al., 
2014; Roberson et al., 2011; Roberson et al., 2007; Van Erum et al., 2020). 
 Seizures and epilepsy associated with tauopathy 
A growing body of evidence from human and animal studies suggests that tau may 
have a role in the development of seizures and epilepsy. Patients with AD have an increased 
likelihood to have unprovoked seizures, and many are diagnosed with epilepsy (Amatniek 
et al., 2006; Friedman et al., 2012; Hesdorffer et al., 1996; Horvath et al., 2018). These 
seizures are mostly non-motor focal seizures with intact awareness, making them easy to 
overlook without EEG (Horvath et al., 2018). Onset of seizures can occur at any point in 
the course of AD, but is most common early and frequently precedes AD diagnosis (Vossel 
et al., 2013). Earlier onset and severity of are correlated with a higher risk of seizures 
(Amatniek et al., 2006). Increased risk of new onset seizures is associated with AD and 
non-AD dementia, but may be more significant in cases of AD-dementia (Hesdorffer et al., 
1996; Sherzai et al., 2014). Patients with AD but no confirmed history of seizures or 
56 
 
epilepsy also exhibit epileptiform abnormalities on EEG at a higher rate compared to 
healthy controls (Lam et al., 2020; Vossel et al., 2016). 
Animal studies have supported and built upon findings from human studies. Mouse 
models expressing tau pathology commonly exhibit aberrant excitatory neuronal activity, 
particularly in the frontal cortex and hippocampus (Crimins et al., 2012; Crimins et al., 
2011; Palop et al., 2007; Rocher et al., 2010; Yoshiyama et al., 2007). In tauopathic models, 
these changes are not correlated with development of tangle pathology, suggesting soluble 
rather than aggregated tau is responsible (Rocher et al., 2010; Yoshiyama et al., 2007). To 
further support this idea, hippocampal synaptic defects in a regulatable tauopathy model 
recover over time when pathological tau expression is suppressed despite persistence of 
tangles formed prior to tau suppression (Sydow et al., 2011). These observations are 
consistent with other studies showing that soluble tau oligomers, rather than insoluble 
tangles, are likely the primary toxic species (Berger et al., 2007; Flach et al., 2012; 
Lasagna-Reeves et al., 2012; Ondrejcak et al., 2018; Puangmalai et al., 2020; Spires et al., 
2006). Given these observations, it is likely that soluble oligomers are also responsible for 
the synaptic dysfunction observed in tauopathic animal models. 
Consistent with observations from human studies, animal models of tauopathy 
exhibit increased susceptibility to seizures. Mouse models of frontotemporal dementia 
exhibit lower thresholds to induced seizures in several seizure induction models (Garcia-
Cabrero et al., 2013; Liu et al., 2017b; Van Erum et al., 2020). Increasing the expression 
of 4R tau, which increases the formation of oligomeric tau in htau mice, increases 
susceptibility to PTZ induced seizures (Schoch et al., 2016). In contrast, tau deficient mice 
have improved outcomes in some genetic epilepsy models (Gheyara et al., 2014; Holth et 
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al., 2013) and are resistant to induced seizures (DeVos et al., 2013; Liu et al., 2017b; 
Roberson et al., 2011; Roberson et al., 2007). Many animal models expressing other AD 
pathology also develop increased susceptibility to seizure induction (Chan et al., 2015; 
Miszczuk et al., 2016; Reyes-Marin and Nunez, 2017). Amyloid-β is associated with 
neuronal hyperexcitability, possibly due to impairment of inhibitory interneurons (Busche 
et al., 2008; Perez et al., 2016; Verret et al., 2012). Although neurofibrillary tangles are not 
generally found in amyloid-β animal models lacking tau modification, amyloid-β can 
induce tau hyperphosphorylation and soluble tau pathology including oligomers has been 
identified in some of these same models (Castillo-Carranza et al., 2015; Cohen et al., 
2013a; Echeverria et al., 2004; Gotz et al., 2001b; Radde et al., 2006; Shipton et al., 2011; 
Sturchler-Pierrat et al., 1997; Takashima et al., 1996). Taken together with the observation 
that tau deficient animals are protected against amyloid-β induced seizure susceptibility 
and synaptic dysfunction (Roberson et al., 2011; Roberson et al., 2007; Shipton et al., 
2011), it is likely that amyloid-β induced tau pathology is responsible for the pro-epileptic 
changes in these animal models. 
Epilepsy appears to accelerate the development of tauopathy. Patients with AD and 
epilepsy experience more rapid cognitive decline compared to patients with AD but not 
epilepsy (Volicer et al., 1995; Vossel et al., 2013). Tau hyperphosphorylation is also 
correlated with cognitive decline in patients with TLE (Tai et al., 2016). One possible 
explanation for this observation in patients with diagnosed/treated epilepsy is that ASM 
therapy, rather than tau dysfunction, accelerates cognitive decline. Although studies of the 
effect of ASM therapy on cognitive decline are limited, the existing data do not strongly 
support this idea. One study reported accelerated cognitive decline in patients with AD 
58 
 
(Fleisher et al., 2011), but this effect has not been observed in other studies (Herrmann et 
al., 2007; Porsteinsson et al., 2001; Profenno et al., 2005; Tariot et al., 2011). Still, valproic 
acid is not recommended as first line therapy in patients with AD due to the high occurrence 
of other adverse events. In contrast, treatment with levetiracetam has been associated with 
reduced rate of cognitive decline (Cumbo and Ligori, 2010). Furthermore, occurrence of 
epileptiform activity in patients with AD but no history of epilepsy is likewise associated 
with more rapid cognitive decline (Vossel et al., 2016), suggesting ASM therapy is not 
responsible.  
An alternate explanation for accelerated cognitive decline in patients with AD and 
epilepsy is that seizures promote tau pathology. Seizures have been associated with tau 
hyperphosphorylation in several human and animal models. Temporal lobe tissue resected 
as treatment for intractable epilepsy frequently exhibits tauopathy-like tau 
hyperphosphorylation decades earlier than in typical cases of tauopathy (Jones et al., 2018; 
Puvenna et al., 2016; Smith et al., 2019; Tai et al., 2016). Supporting this finding, 
hyperphosphorylated tau and increased activity of tau kinases are common findings after 
induced seizures in animal models (Alves et al., 2019; Bracey et al., 2009; Crespo-Biel et 
al., 2007; Jiang et al., 2005; Liang et al., 2009). The promotion of tau phosphorylation and 
aggregation associated with seizures may explain the accelerated cognitive decline 
observed in patients with AD and epilepsy. 
1.5 Study Aims and Significance  
This study focuses on tau’s contribution to neuronal excitability in normal and disease 
conditions. One particular strength of the current study compared to previous work is the 
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use of the htau mouse. This model was chosen specifically to avoid the potential 
confounding effects of endogenous murine tau expressed in most other models of 
tauopathy. Endogenous murine tau does not develop pathology in the same manner as 
human tau, and may continue to function normally even after the human tau has become 
pathological and ceased its physiological function. Since other studies have shown deletion 
of tau ameliorates the hyperexcitability associated with other types of pathology, it is 
important to understand the contribution of tau pathology to excitability without 
endogenous tau. 
The specific aims of this project are as follows: 
1. Determine the effect of tau modulation on neuronal excitability in the 
normally aging mice. Expression of pathological mutant tau has been associated 
with hyperexcitability in mouse models of tauopathy. Furthermore, tau deletion 
appears to abrogate hyperexcitability associated with several models of AD. 
However, two key questions have not been answered. Does pathological tau 
promote hyperexcitability in the absence of normally functioning tau? How does 
loss of tau expression affect neuronal excitability in the absence of additional 
pathological processes? To address these questions, whole-cell patch-clamp 
electrophysiology was used to assess neuronal excitability in DGCs from tau-/-, 
htau, and non-transgenic C57BL/6J mice at 1.5, 4, and 9 months of age. 
2. Determine the effect of tau modulation on induced seizures and epileptogenesis 
following intrahippocampal injection of kainic acid. Tau deficient mice have 
been shown to be resistant to PTZ-induced seizures and exhibit improved survival 
in several genetic models of epilepsy. Conversely, tauopathic model exhibit 
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reduced seizure latency, increased seizure severity, and poorer survival in several 
seizure induction models. However, it is not known whether these differences in 
seizure development are associated with changes in epileptogenesis. Furthermore, 
the propensity of pathological tau to promote seizures has not been assessed in the 
absence of endogenous murine tau. To address these questions, tau-/-, htau, and non-
transgenic C57BL/6J mice underwent intrahippocampal injection of kainate. Initial 
seizure induction and development of spontaneous seizures were observed, 
including a small cohort monitored by video-electroencephalography. Neuronal 
excitability was assessed by whole-cell patch-clamp electrophysiology 1.5-2 




CHAPTER 2. MATERIALS AND METHODS 
2.1 Animals 
Transgenic B6.Cg-Mapttm1(EGFP)KltTg(MAPT)8cPdav/J mice (male and female; 
#005491) were produced in house from breeders obtained from The Jackson Laboratory 
(JAX; Bar Harbor, ME). This mouse line was generated previously by introducing a 
transgene encoding six isoforms of human tau without disease-associated mutations onto 
homozygous tau-/- mice (Andorfer et al., 2003). These mice lack any obvious disease 
phenotype at birth, but develop impairments in Morris Water Maze, spatial learning, and 
gross motor function (i.e. food burrowing) with age, particularly in mice older than 9 
months (Geiszler et al., 2016; Phillips et al., 2011; Polydoro et al., 2009). This mouse strain 
was originally generated on a hybrid Swiss Webster/B6D2F1 hybrid background but has 
been backcrossed to C57BL/6J for more than 10 generations. Genetic analysis of SNPs 
performed by The Jackson Laboratory (a technique they frequently use to demonstrate 
cogenicity) was consistent with a pure C57BL/6J background, which served as the control 
strain. All breeding mice were homozygous for a deletion of the murine tau gene. One 
mouse in each breeding pair was hemizygous for a transgene expressing all six isoforms of 
non-mutant human tau protein. The offspring are therefore either full tau knockout (tau-/-) 
or express only human tau (htau).  
DNA was extracted from tail snips and genotype was confirmed via PCR according 
to the protocols supplied by Jackson labs. Disruption of the endogenous murine tau gene 
was confirmed using the primer pair 5’-CGTTGTGGCTGTTGTAGTTG-3’ and 5’-
TCGTGACCACCCTGACCTAC-3’, which amplifies a fragment at 270 bp in both tau-/- 
and htau mice. Presence of the human-tau transgene was confirmed using the primer pair 
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5’-CGAAGTGATGGAAGATCACG-3’ and 5’-GTCTTGGTGCATGGTGTAGC-3’, 
which amplifies a fragment at 79 bp in htau mice. Protein expression was confirmed via 
western blot of hippocampal homogenate using the H150 antibody (1:2000; Santa Cruz 
Biotechnology). Age matched male C57BL/6J control mice were obtained from Jackson 
labs (Jax#000664) and allowed to acclimate after delivery for at least one week prior to 
any experiments. All mice were housed under a 14 hour light / 10 hour dark cycle in an 
Association for Assessment and Accreditation of Laboratory Animal Care Internal 
(AALAC) facility. Food and water were available ad libitum. The University of Kentucky 
Institutional Animal Care and Use Committee approved all procedures. 
2.2 Intrahippocampal kainate (IHK) mouse model of epilepsy 
All surgical procedures were performed under isoflurane general anesthesia with 
0.05% bupivacaine local anesthesia. Kainic acid (100 nL, 20 mM in 0.9% saline, Tocris 
Bioscience) or saline (100 nL) was injected into the left dorsal hippocampus (2.0 mm 
posterior, 1.25 mm left, and 1.6 mm ventral to bregma) between 6 and 8 weeks of age 
(Krook-Magnuson et al., 2013). The injection rate was 20 nL/minute, and the needle was 
left in place for 5 minutes before and after injection. Buprenorphine (0.05 mg/kg) and 
carprofen (10 mg/kg) were administered subcutaneously after surgery. Mice were 
transferred to a heated cage for recovery and monitored for Racine scale seizures for 2 
hours to assess development of status epilepticus (SE). SE was defined as the occurrence 
of at least 3 seizures of Racine scale 3 or higher during the observation period (Shibley and 
Smith, 2002). After 2 hours, diazepam (7.5 mg/kg) was administered intraperitoneally to 
terminate status epilepticus (SE). Video monitoring for spontaneous seizures began 2 
weeks after the IHK surgery and continued for 6 weeks. Each animal underwent 7-8 
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recording sessions (average duration 7.8 hours), averaging 56 hours of monitoring per 
animal. The videos were reviewed by a reviewer blind to genotype and treatment.  
A separate cohort of mice (n=2-4 per group) were fitted with wireless transmitters 
to allow video-electroencephalographic (vEEG) recording (Data Sciences International; 
DSI; St. Paul, MN). Kainic acid or saline was injected as described above. Screws were 
placed (1.0mm anterior and 1.0mm right to bregma and 3.0mm posterior and 3.0mm left 
to bregma) after injection. A wireless transmitter (ETA-F10, DSI) was implanted 
intraperitoneally and connected to the screws by subcutaneous wires. vEEG began 
immediately after surgery and continued for 2 hours until administration of diazepam as 
described above. EEG recordings were collected using Ponema (v6.42, DSI). Mice 
underwent a total of 5 sessions of 24 hour vEEG recording between 1 and 3 weeks after 
IHK. EEG recordings were manually reviewed for seizure-like activity, defined as 
rhythmic high amplitude (>3 fold larger than baseline), high frequency (>10Hz) activity 
lasting at least 20 seconds, using NeuroScore (v3.3.1, DSI). Potential seizures identified 
on EEG were confirmed by corresponding Racine behavior on video recorded in Open 
Broadcaster Software (v21.0.1) using a Logitech C270 HD camera. Seizure prevalence and 
average daily seizure frequency recorded via vEEG was calculated for each group. 
2.3 Hippocampal slice preparation 
Mice were deeply anesthetized via inhalation of isoflurane to effect (lack of tail 
pinch response) and decapitated while anesthetized. The brain was rapidly removed from 
the skull and immersed in ice-cold oxygenated (95% O2/5% CO2) cutting/holding artificial 
cerebrospinal fluid (aCSF). The cutting/holding aCSF contained (in mM): 85 NaCl, 75 
sucrose, 2.5 KCl, 25 glucose, 1.25 NaH2PO4·H2O, 4 MgCl2·6H2O, 0.5 CaCl2·2H2O, and 
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24 NaHCO3 (pH 7.2-7.4). Coronal sections (300 µm) were cut on a vibrating microtome 
(Vibratome Series 1000; Technical Products International, St. Louis, MO). Each slice was 
divided with a midsagittal cut and hippocampi were isolated and transferred to a holding 
chamber with warmed (30-32° C), oxygenated cutting/holding aCSF and incubated for >1 
hour before recordings. In a subset of animals, 5-8 hippocampal slices were set aside for 
protein analysis. Extrahippocampal tissue was removed from these slices. Approximately 
30mg of hippocampal tissue was collected and flash frozen in liquid nitrogen. One slice at 
a time was transferred to a chamber mounted under an upright microscope (BX51WI; 
Olympus) and was superperfused with warmed (30-32° C) oxygenated recording aCSF. 
The recording aCSF contained (in mM): 124 NaCl, 3 KCl, 2 CaCl2, 1.3 MgCl, 1.4 
NaHCO3, and 11 glucose (pH 7.2-7.4). Each slice was equilibrated in the microscope 
chamber for >10 min to allow the cutting aCSF to wash off before recording. 
2.4 Electrophysiological recordings 
Whole-cell patch-clamp recordings were obtained from hippocampal DGCs, 
identified by location and morphological characteristics. Recording pipettes were pulled 
from borosilicate glass (open tip resistance 3-5 MΩ; King Precision Glass Co.). The pipette 
recording solution contained (in mM): 126 K+-gluconate, 4 KCl, 10 HEPES, 4 MgATP, 
0.3 NaGTP, and 10 PO-creatine (pH 7.2). Electrophysiological recordings were performed 
using a Multiclamp 700B amplifier (Molecular Devices), low pass filtered at 2 kHz, 
digitized at 20 kHz (Digidata 1440A; Molecular Devices), and recorded onto a computer 
using pClamp 10.2 software (Molecular Devices). Seal resistance was typically 2-5 GΩ. 
Series resistance was <25 MΩ (mean: 10.8±0.1 MΩ) and was monitored periodically 
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during the recordings. Recordings were discontinued if series resistance changed by more 
than 20% during the recording. 
Resting membrane potential and input resistance were measured in current clamp 
mode. Current steps (-100 pA to 400 pA in 50 pA steps) were injected to record membrane 
voltage response. The input resistance was calculated from the slope of the linear portion 
of the resulting current-voltage curve. The resting membrane potential was averaged from 
the portions of recorded traces between current steps. Spontaneous and electrically-evoked 
excitatory post-synaptic currents (i.e., sEPSCs and eEPSCs) were recorded in voltage-
clamp mode at a holding potential of -70 mV. To elicit evoked EPSCs, a platinum-iridium 
concentric-bipolar electrode (125 µM diameter; FHC, Bowdoin, ME) was positioned on 
the lateral perforant pathway (Figure 2.1) and 30 pairs of current pulses (30-50 µA; 400 
µs; interpulse interval 75 ms; 5 seconds between pulse pairs) were administered to evoke 
paired eEPSCs (i.e., paired pulse response; PPr). The stimulus intensity was adjusted so 
that responses occurred after >80% of pulses. Stimulus sweeps that failed to elicit a 
response with both stimuli were excluded from analysis. 
2.5 Tissue Homogenization and Western Blot 
The hippocampal tissue from each mouse was homogenized as described 
previously (Koren et al., 2019). Tissue samples were mechanically homogenized in RIPA 
lysis buffer (VWR) with phosphatase inhibitor cocktails 2 and 3 (Sigma), cOmplete 
protease inhibitor (Sigma), and PMSF (1 mM final concentration, Roche Diagnostics). 
Homogenates were centrifuged at 4°C at 13,000 rpm for 30 minutes. The fresh supernatant 
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from each sample was divided into aliquots and stored at -80°C. Protein concentration was 
quantified using the Pierce BCA kit (Thermo Fisher, 23225). 
Sample protein concentrations were normalized with lysis buffer and denatured by 
boiling for 5 minutes in 4x Laemmli buffer (BioRad) plus 10% β-mercaptoethanol (Sigma). 
The samples were separated on a 10% tris-glycine gel (BioRad) and transferred to a 
polyvinylidene fluoride membrane (Millipore). Membranes were blocked in 6% non-fat 
dry milk (w/v) in 0.01M tris buffered saline (TBS). All antibodies were diluted in 6% non-
fat milk in TBS. Primary antibodies used are as follows: AT8 (pS202/pT205 tau; 1:2000; 
ThermoFisher), H-150 (human tau; 1:2000; Santa Cruz), GAPDH (1:5000; Cell Signaling 
Technology). Goat anti-mouse and goat anti-rabbit secondary antibodies conjugated to 
horseradish peroxidase (Southern Biotech) used were diluted in 6% non-fat dry milk in 
TBS (w/v). Images were collected on an Amersham Imager 600 (General Electric). 
2.6 Data Analysis 
All electrophysiological measures (evoked action potential frequency, resting membrane 
potential, input resistance, spontaneous EPSC frequency, and paired pulse responses) were 
analyzed with MiniAnalysis (Synaptosoft, Fort Lee, NJ). Statistical measures were 
performed with Prism (GraphPad, San Diego, CA). Data were disaggregated by sex and no 
sex-dependent differences were detected for any measure, so sexes were combined for all 
analyses. All data were tested for normality with a Shapiro Wilk test and, except where 
noted, all data were found to be normally distributed. Specific statistical tests used for each 
comparison will be described in sections 3.2.5 and 4.2.5 as appropriate. Data are presented 




Figure 2.1 Approximate location of stimulating and recording electrodes 
The stimulating electrode was positioned preferentially over the lateral perforant pathway 
to reduce stimulation of the medial perforant pathway. The stimulating electrode was 




CHAPTER 3. EFFECTS OF ALTERED TAU EXPRESSION ON DENTATE GRANULE CELL 
EXCITABILITY IN MICE 
A similar version of this chapter was published on May 21, 2021 in Experimental 
Neurology with John Koren 3rd, Jose F. Abisambra, and Bret N. Smith as additional 
authors (doi: 10.1016/j.expneurol.2021.113766). 
3.1 Introduction 
Microtubule dynamics are critical for central nervous system (CNS) function. 
Disruptions in microtubule homeostasis are associated with a variety of CNS dysfunctions 
including Alzheimer’s disease and other tauopathies, epilepsy, Parkinson’s disease, 
congenital brain malformations, psychiatric disorders, and autism spectrum disorder 
(Chang et al., 2018; Gardiner and Marc, 2010; Goncalves et al., 2018; Marchisella et al., 
2016; Pellegrini et al., 2017; Saha and Sen, 2019). The microtubule-associated protein tau 
(MAPT, tau) plays an important role in the assembly and stabilization of microtubules. To 
allow normal microtubule dynamics, phosphorylated tau has reduced affinity for 
microtubules, promoting their dismantling (Lindwall and Cole, 1984). The equilibrium of 
tau phosphorylation, which is tightly regulated under physiological conditions (Martin et 
al., 2013a; Martin et al., 2013b), becomes disrupted in Alzheimer’s disease and other 
tauopathies, to allow accumulation and aggregation of hyperphosphorylated tau (pTau) 
(Castellani and Perry, 2019). Tau solubility decreases as hyperphosphorylation increases, 
eventually forming insoluble neurofibrillary tangles, which are a hallmark of Alzheimer’s 
disease and other tauopathies (Castellani and Perry, 2019).  
Hyperphosphorylated tau promotes increased neuronal excitability. In mouse 
models expressing mutant human tau protein, principal neurons in the frontal cortex and 
hippocampus exhibit depolarized neuronal resting membrane potentials (Crimins et al., 
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2012; Crimins et al., 2011; Rocher et al., 2010), increased evoked action potential firing 
and spontaneous excitatory postsynaptic currents (sEPSCs) (Crimins et al., 2012; Crimins 
et al., 2011; Rocher et al., 2010), increased glutamate release and decreased glutamate 
reuptake (Decker et al., 2016; Hunsberger et al., 2015), and abnormal neuron morphology 
and synaptic organization (Crimins et al., 2012; Crimins et al., 2011; Rocher et al., 2010; 
Yoshiyama et al., 2007). Consistent with this increased neuronal excitability, mice 
expressing mutant human tau protein exhibit increased vulnerability to induced epilepsy 
(Garcia-Cabrero et al., 2013; Liu et al., 2017b), a finding consistent with studies 
demonstrating increased seizure prevalence in patients with Alzheimer’s disease (Pandis 
and Scarmeas, 2012; Vossel et al., 2013; Vossel et al., 2016). 
In addition to establishing a correlation between tau hyperphosphorylation and 
neuronal hyperactivity in animals, previous work has studied the effect of removing or 
reducing tau expression on seizures. Disruption of Mapt expression reduces seizure burden 
and improves survival in some genetic epilepsy models (Gheyara et al., 2014; Holth et al., 
2013), confers resistance to chemically induced seizures (DeVos et al., 2013; Li et al., 
2014), and prevents glutamate excitotoxicity in cultured neurons (Miyamoto et al., 2017). 
Furthermore, reducing tau phosphorylation by administration of the protein phosphatase 
2A (PP2A) activator, sodium selenate, reduces seizure burden and promotes survival in 
multiple seizure models (Jones et al., 2012; Liu et al., 2016). Taken together, these studies 
suggest involvement of tau hyperphosphorylation in epilepsy due to its effects on neuronal 
excitability. 
While previous studies have outlined an important role for tau in promoting 
neuronal hyperexcitability, the full impact of tau’s effect on neuronal function remains 
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unknown. Age related functional changes in tau knockout mice may impact neuronal 
activity and animal survival at later ages. Furthermore, the effect of pTau on excitability 
has been studied in mouse models that express mutant human tau, without suppressing 
endogenous mouse tau. The presence of two different tau species could thus confound 
results, since the murine tau may remain functional despite the presence of pathologic 
human tau. It is unclear whether the presence of wild-type murine tau in most tauopathy 
models modulates the pathological functions conferred by hyperphosphorylation. This 
study will address these gaps in current knowledge by measuring neuronal excitability in 
tau-/- mice and in the htau mouse model, which expresses six isoforms of non-mutant 
human tau with a concurrent deletion of endogenous murine tau (Andorfer et al., 2003). 
The htau model recapitulates features of tau pathology and cognitive deficits present in 
Alzheimer’s disease, which include appearance of hyperphosphorylated tau species as 
early as 1.5mo, deposition of late-stage tangle pathology at 9mo, and presentation of 
substantial cognitive deficits by 12mo. Given these considerations and previous data 
demonstrating profound hippocampal deficits in tauopathy models (Abisambra et al., 2010; 
Abisambra et al., 2013; Fontaine et al., 2017), we tested the hypotheses that pTau promotes 
hyperexcitability of dentate gyrus granule cells (DGCs) in the absence of functional 
endogenous tau, and that complete tau ablation reduces neuronal excitability throughout 
the life of the animal. We chose to study DGCs because they contribute to epileptogenesis 
and tauopathy-associated cognitive decline (Alcantara-Gonzalez et al., 2021; Boychuk et 
al., 2016; Hunt et al., 2010; Lee et al., 2012; Martin-Belmonte et al., 2020), and epilepsy-
related changes in the dentate gyrus were ameliorated by tau deletion (Gheyara et al 2014). 
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Despite their importance in cognition and disease processes, the electrophysiological 
effects of modifying tau expression have not been studied extensively in DGCs. 
3.2 Materials and Methods 
 Animals 
Transgenic B6.Cg-Mapttm1(EGFP)KltTg(MAPT)8cPdav/J mice (male and female) 
were produced in house from breeders obtained from The Jackson Laboratory (Jax# 
005491; Bar Harbor, ME). This mouse line was generated previously by introducing a 
transgene encoding six isoforms of human tau without disease-assocaited mutations onto 
homozygous tau-/- mice (Andorfer et al., 2003). These mice lack any obvious disease 
phenotype at birth, but develop impairments in Morris Water Maze, spatial learning, and 
food burrowing with age (Geiszler et al., 2016; Phillips et al., 2011; Polydoro et al., 2009). 
This mouse strain was originally generated on a hybrid Swiss Webster/B6D2F1 hybrid 
background but has been backcrossed to C57BL/6J for more than 10 generations. SNP 
analysis performed by The Jackson Laboratory was consistent with a pure C57BL/6J 
background, which served as the control strain. All breeding mice were homozygous for a 
disruption of the murine tau gene. One mouse in each breeding pair was hemizygous for a 
transgene expressing all six isoforms of non-mutant human tau protein. The offspring are 
therefore either full tau knockout (tau-/-) or express only human tau (htau).  
DNA was extracted from tail snips and genotype was confirmed via PCR according 
to the protocols supplied by Jackson labs. Disruption of the endogenous murine tau gene 
was confirmed using the primer pair 5’-CGTTGTGGCTGTTGTAGTTG-3’ and 5’-
TCGTGACCACCCTGACCTAC-3’, which amplifies a fragment at 270 bp in both tau-/- 
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and htau mice. Presence of the human-tau transgene was confirmed using the primer pair 
5’-CGAAGTGATGGAAGATCACG-3’ and 5’-GTCTTGGTGCATGGTGTAGC-3’, 
which amplifies a fragment at 79 bp in htau mice. Protein expression was confirmed via 
western blot of hippocampal homogenate using the H150 antibody (Figure 3.1; 1:2000; 
Santa Cruz Biotechnology). Age matched male C57BL/6J control mice were obtained from 
Jackson labs (Jax#000664) and allowed to acclimate after delivery for at least one week 
prior to any experiments. All mice were housed under a 14 hour light / 10 hour dark cycle 
in an Association for Assessment and Accreditation of Laboratory Animal Care Internal 
(AALAC) facility. Food and water were available ad libitum. The University of Kentucky 
Institutional Animal Care and Use Committee approved all procedures. 
 Hippocampal slice preparation 
Mice were deeply anesthetized via inhalation of isoflurane to effect (lack of tail 
pinch response) and decapitated while anesthetized. The brain was rapidly removed from 
the skull and immersed in ice-cold oxygenated (95% O2/5% CO2) cutting/holding artificial 
cerebrospinal fluid (aCSF). The cutting/holding aCSF contained (in mM): 85 NaCl, 75 
sucrose, 2.5 KCl, 25 glucose, 1.25 NaH2PO4·H2O, 4 MgCl2·6H2O, 0.5 CaCl2·2H2O, and 
24 NaHCO3 (pH 7.2-7.4). Coronal sections (300 µm) were cut on a vibrating microtome 
(Vibratome Series 1000; Technical Products International, St. Louis, MO). Each slice was 
divided with a midsagittal cut and hippocampi were isolated and transferred to a holding 
chamber with warmed (30-32° C), oxygenated cutting/holding aCSF and incubated for at 
least 1 hour before recordings. In a subset of animals, 5-8 hippocampal slices were set aside 
for protein analysis. Extrahippocampal tissue was removed from these slices. 
Approximately 30mg of hippocampal tissue was collected and flash frozen in liquid 
nitrogen. One slice at a time was transferred to a chamber mounted under an upright 
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microscope (BX51WI; Olympus) and was superperfused with warmed (30-32° C) 
oxygenated recording aCSF. The recording aCSF contained (in mM): 124 NaCl, 3 KCl, 2 
CaCl2, 1.3 MgCl, 1.4 NaHCO3, and 11 glucose (pH 7.2-7.4). Each slice was equilibrated 
in the microscope chamber for >10 minutes before recording. 
 Electrophysiological recordings 
Whole-cell patch-clamp recording were obtained from hippocampal DGCs, 
identified by location and morphological characteristics. Recording pipettes were pulled 
from borosilicate glass (open tip resistance 3-5 MΩ; King Precision Glass Co.). The pipette 
recording solution contained (in mM): 126 K+-gluconate, 4 KCl, 10 HEPES, 4 MgATP, 
0.3 NaGTP, and 10 PO-creatine (pH 7.2). Electrophysiological recordings were performed 
using a Multiclamp 700B amplifier (Molecular Devices), low pass filtered at 2 kHz, 
digitized at 20 kHz (Digidata 1440A; Molecular Devices), and recorded onto a computer 
using pClamp 10.2 software (Molecular Devices). Seal resistance was typically 2-5 GΩ. 
Series resistance was <25 MΩ (mean: 11.4 MΩ) and was monitored periodically during 
the recordings. Recordings were discontinued if series resistance changed by more than 
20% during the recording. 
Spontaneous excitatory post-synaptic currents (sEPSCs) were recorded in voltage-
clamp mode at a holding potential of -70 mV. Resting membrane potential and input 
resistance were measured in current clamp mode. Current steps (-100 pA to 400 pA in 50 
pA steps) were injected to record membrane voltage response. The input resistance was 
calculated from the slope of the linear portion of the resulting current-voltage curve. The 
resting membrane potential was averaged from the portions of recorded traces between 
current steps. A platinum-iridium concentric-bipolar electrode (125 µM diameter; FHC) 
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was positioned on the lateral perforant pathway of each slice. A series of 30 pairs of current 
pulses (10-60 µA; 400 µs; interpulse interval 75 ms; 5 seconds between pulse pairs) were 
administered to evoke EPSCs. The stimulus intensity was adjusted so that responses 
occurred after >80% of pulses. Stimulus sweeps that failed to elicit a response with both 
stimuli were excluded from analysis. 
 Tissue Homogenization and Western Blot 
The hippocampal tissue from each mouse was homogenized as described 
previously (Koren et al., 2019). Tissue samples were mechanically homogenized in RIPA 
lysis buffer (VWR) with phosphatase inhibitor cocktails 2 and 3 (Sigma), cOmplete 
protease inhibitor (Sigma), and PMSF (1 mM final concentration, Roche Diagnostics). 
Homogenates were centrifuged at 4°C at 13,000 rpm for 30 minutes. The fresh supernatant 
from each sample was divided into aliquots and stored at -80°C. Protein concentration was 
quantified using the Pierce BCA kit (Thermo Fisher, 23225). 
 Sample protein concentrations were normalized with lysis buffer and denatured by 
boiling for 5 minutes in 4x Laemmli buffer (BioRad) plus 10% β-mercaptoethanol (Sigma). 
The samples were separated on a 10% tris-glycine gel (BioRad) and transferred to a 
polyvinylidene fluoride (PVDF) membrane (Millipore). Membranes were blocked in 6% 
non-fat dry milk (w/v) in 0.01M tris buffered saline (TBS). All antibodies were diluted in 
6% non-fat milk in TBS. Primary antibodies used are as follows: AT8 (pS202/pT205 tau; 
1:2000; ThermoFisher), H-150 (human tau; 1:2000; Santa Cruz), GAPDH (1:5000; Cell 
Signaling Technology). Goat anti-mouse and goat anti-rabbit secondary antibodies 
conjugated to horseradish peroxidase (Southern Biotech) used were diluted in 6% non-fat 
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dry milk in TBS (w/v). Images were collected on an Amersham Imager 600 (General 
Electric). 
 Data Analysis 
All electrophysiological measures (evoked action potential frequency, resting 
membrane potential, input resistance, spontaneous EPSC frequency, and paired pulse 
responses) were analyzed with MiniAnalysis (Synaptosoft, Fort Lee, NJ). Statistical 
measures were performed with Prism (GraphPad, San Diego, CA). Data were tested for 
normality by a Shapiro-Wilk test and log-transformed where appropriate. Data were 
normally distributed except where noted. A two-way ANOVA with age and genotype as 
factors was used to compare mean values for each electrophysiological value. All data for 
each electrophysiological measurement were analyzed together. Some control data are 
presented in multiple figures for presentation clarity. Data were disaggregated by sex and 
no sex-dependent differences were detected for any measure, so sexes were combined for 
all analyses. Total cell counts for each electrophysiological measurement are summarized 
in Table 3.1. Data are presented as mean ± SEM and statistical significance was set to 
p<0.05 for all tests. 
3.3 Results 
 Resting membrane potential and input resistance in tau-/- and htau mice 
Overexpression of hyperphosphorylated tau is associated with a depolarized resting 
membrane potential in neocortical pyramidal neurons of Tg4510 mutant mice (Crimins et 
al., 2012; Crimins et al., 2011; Rocher et al., 2010), but the electrophysiological effects of 
modifying tau expression in DGCs have not been studied in detail. Additionally, the 
insertion of pathologic human tau in other models (e.g., Tg4510) may compete with  
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Frequency Paired Pulse Ratio 
1.5 
months 
tau-/- 26 20 21 
htau 25 16 26 
control 25 13 22 
4 months 
tau-/- 24 15 17 
htau 19 11 17 
control 35 21 16 
9 months 
tau-/- 28 23 23 
htau 18 16 12 





endogenous mouse tau to regulate microtubule assembly and function (Alonso Adel et al., 
2006). To better understand the contribution of tau to intrinsic properties, resting  
membrane potential and input resistance were measured in DGCs from non-transgenic 
control, tau-/-, and htau mice at 1.5, 4, and 9 months of age, which represent time points in 
which early pTau species are detected, mid-stage pathological processes occur, and 
insoluble tangle pathology is evident, respectively (Andorfer et al., 2003). 
Differences in resting membrane potential and input resistance were analyzed 
between control, tau-/-, and htau mice at each age by a two-way ANOVA with age and 
genotype as factors. In DGCs from tau-/- mice, the resting membrane potential was 
depolarized compared to those from age-matched control mice at 1.5 months of age 
(F=11.83; p<0.05; Table 3.2). No difference in resting membrane potential was detected at 
4 months or 9 months of age (p>0.05; Table 3.2). No difference in resting membrane 
potential was detected between htau and control mice at any age (p>0.05). Input resistance 
was also not different between DGCs from control mice and either tau-/- or htau mice at 
any age (p>0.05; Table 3.2). With the exception of resting membrane potential differences 
in young tau-/- mice, differences in passive membrane properties were not detected across 
genotypes at any age.  
 The effect of age on resting membrane potential and input resistance was 
determined within each genotype. Resting membrane potential was hyperpolarized in 
DGCs from 9 month old tau-/- mice, relative to 1.5 and 4 month old tau-/- mice (F=11.83; 
p<0.05). Resting membrane potential was also hyperpolarized in DGCs from 9 month old 
control mice compared to 4 month old control mice (F=11.83; p<0.05). Resting membrane 
potential did not change with age in DGCs from htau mice (p>0.05), and no age-related   
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Table 3.2 Summary of Resting Membrane Potential and Input Resistance 








tau-/- 25 -68.8±1.8* 278.7±28.4MΩ 
htau 26 -71.1±1.8 288.5±27.8MΩ 




tau-/- 35 -70.1±1.9 287.4±22.5MΩ 
htau 24 -70.8±1.7 278.4±32.4MΩ 




tau-/- 30 -73.9±1.3tǂ 236.4±15.3MΩ tǂ 
htau 28 -73.2±1.7 227.1±17.4MΩ tǂ 
control 18 -73.8±1.7ǂ 234.1±21.5MΩ 
*significant difference versus control. 
t significant difference versus 1.5 month. 





difference in input resistance was detected in control mice (p>0.05). Input resistance in 
DGCs from 9 month old tau-/- mice, however, was lower compared to those from 1.5 or 4 
month old tau-/- mice (F=14.11; p<0.05). Similarly, input resistance was lower in DGCs 
from 9 month old htau mice compared to 1.5 or 4 month old htau mice (F=14.11; p<0.05). 
Thus, input resistance was lower at the oldest ages examined for DGCs in both tau-/- and 
htau mice. Input resistance was not different between DGCs from tau-/- and htau mice at 
any age (p>0.05). 
 Lower action potential firing frequency in young tau-/- and htau mice 
At 4 and 8-9 months of age, neocortical pyramidal cells from the Tg4510 tau mouse 
model exhibit a higher frequency of evoked action potentials in response to depolarizing 
current injection, relative to control mice (Crimins et al., 2012; Crimins et al., 2011; Rocher 
et al., 2010), but lower action potential threshold and reduced action potential frequency 
was reported in CA1 pyramidal cells from the same mouse strain (Hatch et al., 2017), and 
age-related effects of tau expression on intrinsic excitability of DGCs has not been 
assessed. To better understand the role of tau in determining evoked action potential 
frequency, depolarizing and hyperpolarizing currents were injected into DGCs from non-
transgenic control, tau-/-, and htau mice at 1.5, 4, and 9 months of age. 
 Dentate granule cells from 1.5 month old tau-/- mice had a lower peak action potential 
frequency relative to cells from age-matched control mice (F=7.216; p<0.05; Figure 3.1B). 
Action potential frequency response at any current injection magnitude did not differ 
between DGCs from tau-/- and control mice at 4 or 9 months (p>0.05; Figure 3.1C&D). 




Figure 3.1 Membrane voltage response to injected current in DGCs from tau-/- and htau 
mice compared to non-transgenic control mice.  
(A) Sample recordings showing voltage response from -100, 0, and 200pA current steps in 
DGCs from 1.5 month old tau-/-, htau, and control mice. Inset: representative Western blot 
showing absence of tau protein in tau-/- and presence of human tau protein in htau mice. 
(B) Comparison of evoked action potential frequency in response to injection of 200pA 
current. At 1.5 months, DGCs from control mice fire more actions potentials than those 
from tau-/- and htau mice. In tau-/- mice, DGCs from 9 month old mice fire more action 
potentials than at 1.5 or 4 months. *: Different from 1.5 month control (p<0.05) t: Different 
from 1.5 month tau-/- (p<0.05) ǂ: Different from 4 month tau-/- (p<0.05). Error bars indicate 
SEM. Statistical comparisons were made between all groups by two-way ANOVA with 
age and genotype as factors.  
81 
 
potentials to cells from control mice (F=7.216; p<0.05; Figure 3.1B). Action potential 
frequency in these neurons did not differ in response to any current injection between htau 
and control mice at 4 or 9 months (p>0.05). Thus, versus age-matched controls, lower 
action potential frequency was observed in DGCs at 1.5 months of age in both tau-/- and 
htau mice, but not at older ages. No differences in action potential frequency were detected 
between DGCs from tau-/- and htau mice at any age (p>0.05). 
Membrane voltage response to injected current was analyzed at different time 
points to assess the effect of aging within each genotype. In DGCs from control mice, cells 
from 4 month old mice had a lower peak frequency of evoked action potentials compared 
to 1.5 month old mice (p<0.05; Figure 3.2A). DGCs from both 9 month old tau-/- and htau 
mice had a higher peak frequency of evoked action potentials compared to 1.5 or 4 month 
old mice (F=7.216; p<0.05; Figure 3.2B,C). Thus, higher peak action potential frequency 
emerged at 9 months of age in both htau and tau-/- mice, but this was not evident in control 
mice. Together, these results suggest intrinsic properties in both tau-/- and htau mice 
develop age-related changes that are not observed in control mice. DGCs from both 
transgenic strains exhibit reduced cellular excitability compared to control early in life, but 
these differences are abrogated with age. Furthermore, the intrinsic properties of DGCs 
from tau-/- and htau mice change with age in a similar fashion. 
 Spontaneous EPSC frequency was not impacted by tau 
Excitatory synaptic input to DGCs is thought to contribute to network excitability and 
seizure generation in several models of acquired epilepsy (Butler et al., 2015; Hunt et al., 
2010; Winokur et al., 2004), and changes in sEPSC frequency related to changes in tau 
expression could contribute to the changes in seizure susceptibility observed by others 




Figure 3.2 Membrane voltage responses change with age in DGCs. 
Same data from figure 1 re-presented to show age-related changes in evoked action 
potential frequency. (A) DGCs from 4 month old non-transgenic control mice fire fewer 
action potentials compared to DGCs from 1.5 month old control mice in response to current 
injection of 250 and 300pA. No differences in firing pattern were found between DGCs 
from 1.5 and 9 month old control mice. (B) DGCs from 9 month old tau-/- mice fire more 
action potentials compared to DGCs from 1.5 month old tau-/- mice in response to current 
injections of 200 and 250pA. DGCs from 9 month old tau-/- mice also fire more action 
potentials compared to DGCs from 4 month old tau-/- mice in response to current injection 
of 200pA and higher. No differences in firing pattern were found between DGCs from 1.5 
and 4 month old tau-/- mice. (C) DGCs from 9 month old htau mice fire more action 
potentials compared to DGCs from 1.5 month old htau mice in response to current 
injections of 250 and 300pA. DGCs from 9 month old htau mice also fire more action 
potentials compared to DGCs from 4 month old htau mice in response to current injection 
of 300 and 350pA. No differences in firing pattern were found between DGCs from 1.5 
and 4 month old htau mice. Error bars indicate SEM.  *: 1.5 month different from 4 month 






expression influences overall excitatory synaptic input to DGCs, sEPSC frequency was 
measured in DGCs from tau-/-, htau, and control mice. A Shapiro-Wilk test found the data 
were not normally distributed but were positively skewed, so a log transformation was 
performed on the raw data. Log-transformed sEPSC frequencies were compared with a 
two-way ANOVA with age and genotype as factors and did not differ between groups at 
any ages (p>0.05; Figure 3.3A). Overall, there was not a strong influence of age or strain 
on sEPSC frequency. 
 Paired pulse facilitation is enhanced in young tau-/- and htau mice 
Altered probability of glutamate release can also influence DGC activity and may 
be susceptible to tau hyperphosphorylation or mutation (Yoshiyama et al., 2007). To 
determine effects of tau expression on paired pulse facilitation in the dentate gyrus, pairs 
of stimuli were administered to the lateral perforant path and evoked EPSCs were recorded 
in DGCs from tau-/-, htau, and control mice. The paired pulse ratio, which is calculated as 
the amplitude of the second evoked EPSC divided by the amplitude of the first evoked 
EPSC, is inversely proportional to the probability of neurotransmitter release from the 
presynaptic terminal (i.e. a higher paired pulse ratio indicates a lower probability of 
neurotransmitter release; Graziane and Dong, 2016). The paired pulse ratio of evoked 
EPSCs was compared between all groups with a two-way ANOVA with age and genotype 
as factors. The paired pulse ratio of evoked EPSCs was significantly greater in DGCs from 
tau-/- mice compared to age-matched control mice at 1.5 months (control: 1.27±0.10; tau-/-
: 1.56±0.16; F=6.480; p=0.002) but did not differ at 4 or 9 months (p>0.05; Figure 3.4A-
C). The paired pulse ratio was lower in DGCs from 9 month old tau-/- mice compared to 




Figure 3.3 Average spontaneous EPSC frequency in tau-/-, htau, and non-transgenic control 
mice. 
(A) No differences sEPSC frequency were found between DGCs from tau-/- or htau mice 
and control mice at any age. sEPSC frequency did not change with age in DGCs from  
tau-/-, htau, or control mice (p>0.05). A Shapiro-Wilk test found the data are not normally 
distributed, so raw data were log transformed prior to further analysis. Statistical 
comparisons were made between all groups by two-way ANOVA with age and genotype 
as factors. (B) Representative traces of sEPSCs in DGCs from tau-/-, htau, or control mice 




Figure 3.4 Paired pulse ratio in tau-/- mice compared to non-transgenic control mice. 
(A) The paired pulse ratio is higher in DGCs from 1.5 month old tau-/- mice compared to 
1.5 month old control mice. *: p<0.05 (B, C) No differences in paired pulse ratio were 
found between DGCs from tau-/- and control mice at 4 (B) or 9 (C) months old. (D) The 
paired pulse ratio is lower in DGCs from 9 month old tau-/- mice compared to 1.5 month 
old tau-/- mice. The paired pulse ratio did not change with age in DGCs from control mice. 
Statistical comparisons were made between all groups by two-way ANOVA with age and 
genotype as factors. *: different from 1.5 month (p<0.05) Error bars indicate SEM. 
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Figure 3.4D). Similar to results from tau-/- mice, the paired pulse ratio was greater in DGCs 
from htau mice compared to control mice at 1.5 months (control: 1.27±0.10; htau: 
1.43±0.09; F=6.480; p=0.023) but did not differ at 4 or 9 months of age (p>0.05; Figure 
3.5A-C). The paired pulse ratio did not change with age in DGCs from htau mice (p>0.05; 
Figure 3.5D). Thus, in both transgenic mouse strains, the paired pulse ratio in DGCs after 
stimulation of the lateral perforant pathway was greater compared to those from non-
transgenic control mice at 1.5 months of age, but not later in life. The paired pulse ratio in 
DGCs after stimulation of the perforant pathway did not differ between tau-/- and htau 
animals at any age (p>0.05). The paired pulse ratio decreased with age in tau-/- mice. This 
contrasted with results from htau mice and non-transgenic control mice, in which age-
related changes in paired pulse ratio were not detected (p>0.05). The amplitudes of evoked 
EPSCs varied significantly across all cells but were not different between any groups (data 
not shown). 
3.4 Discussion 
Tau pathology is associated with greater excitability and increased susceptibility to seizures 
in epilepsy models (Garcia-Cabrero et al., 2013; Liu et al., 2017b). Similarly, loss of tau 
through genetic deletion or suppression with antisense oligonucleotides is associated with 
decreased mossy fiber sprouting in the dentate gyrus, reduced seizure burden, and 
improved cognition and survival in models of epilepsy (DeVos et al., 2013; Gheyara et al., 
2014; Holth et al., 2013) and ameliorates the increased susceptibility to seizures associated 
with some models of Alzheimer’s disease (Ittner et al., 2010; Roberson et al., 2007).  This 
study measured several intrinsic and synaptic membrane properties in tau-/- and htau mice 




Figure 3.5 Paired pulse ratio in htau mice compared to non-transgenic control mice. 
(A) The paired pulse ratio is higher in DGCs from 1.5 month old htau mice compared to 
1.5 month old control mice. *: p<0.05 (B, C) No differences in paired pulse ratio were 
found between DGCs from htau and control mice at 4 (B) or 9 (C) months old. (D) The 
paired pulse ratio did not change with age in DGCs from htau or control mice. Statistical 
comparisons were made between all groups by two-way ANOVA with age and genotype 
as factors.*: different from 1.5 month (p<0.05) Error bars indicate SEM   
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hypothesized to play a role in genetic epilepsies and, possibly, seizure disorders associated 
with neurodegeneration (Decker et al., 2016; Garcia-Cabrero et al., 2013; Gheyara et al., 
2014; Holth et al., 2013; Ittner et al., 2010; Roberson et al., 2011; Roberson et al., 2007).  
Although other studies have measured the influence of tau expression and 
hyperphosphorylation on neuronal properties, most have used forms of tau with disease-
related mutations such as P301L (Crimins et al., 2012; Crimins et al., 2011; Hatch et al., 
2017; Hunsberger et al., 2015; Liu et al., 2017b; Rocher et al., 2010), P301S (Yoshiyama 
et al., 2007), and A152T (Decker et al., 2016). In contrast, the htau mouse used in this study 
expresses six isoforms of human tau without any disease-related mutations (Andorfer et 
al., 2003). This model was selected for two reasons. First, the non-mutated human tau 
expressed in this model results in slower development of pathology that more reasonably 
resembles human aging than in more aggressive pathologic tau models. The htau mouse 
exhibits progressive tau pathology, developing pTau by 1.5 months, somatodendritic 
redistribution of tau around 3 months, and neurofibrillary tangles around 9 months 
(Andorfer et al., 2003). Additionally, the endogenous murine tau gene is deleted in the htau 
mouse, setting it apart from other commonly used tauopathy models. The deletion of 
endogenous murine tau is important because tau hyperphosphorylation leads to concurrent 
loss of normal tau function and consequently increased pathology due to the increase in 
soluble pTau. Tau hyperphosphorylation reduces the pool of functional tau available to 
stabilize microtubules, resulting in a loss of physiologic function (Lindwall and Cole, 
1984). At the same time, soluble pTau itself is neurotoxic through several mechanisms, 
including mislocalization of pathologic tau, inhibition of protein translation, and abnormal 
interaction with other cellular components (Flach et al., 2012; Fulga et al., 2007; Hoover 
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et al., 2010; Koren et al., 2019; Meier et al., 2015; Meier et al., 2016; Thies and 
Mandelkow, 2007; Tian et al., 2013). Because tauopathy results in loss of function as well 
as development of neurotoxicity, the presence of normal murine tau expression in other tau 
mouse models confounds the interpretation of outcomes based on tau 
hyperphosphorylation. Some inconsistency between the results across previous studies in 
different tau models, along with the similarities found between the htau and tau-/- animals 
in the current study, demonstrate the importance of separating the effects of removing tau 
and adding hyperphosphorylated tau in interpreting electrophysiological outcomes. 
While previous work suggests an important role for tau in the electrophysiological 
function of the neuron, the direct effects of tau deletion on neuronal excitability have not 
been extensively studied without the presence of additional pathology. Previous studies on 
the electrophysiological effects of hyperphosphorylated tau have primarily used the 
rTg4510 transgenic mouse, which expresses 4R0N human tau with the pathogenic P301L 
mutation with endogenous murine tau expression intact (Santacruz et al., 2005). The major 
effects on the intrinsic properties of frontal cortex pyramidal neurons in these studies were 
depolarized resting membrane potential and increased frequency of evoked action 
potentials (Crimins et al., 2012; Crimins et al., 2011; Rocher et al., 2010). A decrease in 
paired pulse facilitation in the hippocampus has also been reported in other transgenic tau 
models (Maeda et al., 2016; Roberson et al., 2011; Sydow et al., 2011; Yoshiyama et al., 
2007). Based on these studies, we hypothesized that similar results would be detected in 
DGCs from htau mice, but this hypothesis was not supported. Instead we found no changes 
in resting membrane potential in the htau mice, and reduced evoked action potential firing 
and increased paired pulse facilitation was detected in both htau and tau-/- mice, but only at 
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1.5 months of age. Thus, deletion of murine tau tended to reduce intrinsic and synaptic 
excitability of DGCs early, but not later in life, and replacing murine tau with human tau 
did not reinstate normal excitability.   
Our results in htau mice might be linked to pathogenic mechanisms of Alzheimer’s 
disease. Unlike rTg4510 mice, which overexpress 13x more human mutant 4R0N P301L 
tau in the forebrain, htau mice express all six splice variants of non-mutant human tau 
(Andorfer et al., 2003; Santacruz et al., 2005). The P301L mutation is associated with 
fronto-temporal dementia (Hutton et al., 1998); meanwhile, tau pathology in Alzheimer’s 
brains has accumulation of the six splice variants of non-mutant human tau. The difference 
in tau pathogenicity between the htau and rTg4510 mice may explain why no change in 
resting membrane potential was detected in DGCs from htau mice. Other factors, including 
the endogenous properties of the different neuron types studied (i.e., pyramidal cells versus 
DGCs) or the continued expression of endogenous mouse tau in the rTg4510 mice, could 
also contribute substantially to these outcomes. However, the differences in tau species, or 
even cell type examined, do not adequately explain the patterns of evoked action potentials 
or paired pulse facilitation observed in each mouse model: A difference in relative 
pathogenicity could result in a smaller magnitude of difference between these measures, 
but it does not fully explain the opposite direction of effects (i.e., action potential frequency 
decreased in htau but increased in rTg4510 and paired pulse ratio increased in htau but 
decreased in rTg4510).  
Because the htau mice lack endogenous tau, physiological tau function is likely 
reduced because the transgenically expressed human tau may not function normally. This 
notion is supported by the similar patterns of evoked action potentials observed in dentate 
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granule cells from htau and tau-/- mice early in life, when human tau may not function 
normally in the htau mouse. Similar to studies demonstrating that the pro-excitatory effects 
of amyloid-beta rely on the presence of functional tau (Roberson et al., 2011; Shipton et 
al., 2011), our results suggest that excitatory effects associated with pathologic tau in other 
models requires a pool of functional tau as well, which is not expressed in either strain used 
here. Any potential pro-excitatory effects may therefore have been abrogated by the 
absence of functional tau. 
This study found important similarities between dentate granule cell responses in 
tau-/- and htau mice, consistent with the hypothesis that the substitution of tau species in 
the htau mouse contributes to the loss of normal tau function. In both tau-/- and htau mice, 
peak evoked action potential frequency in DGCs was reduced relative to age-matched 
controls early in life, but not at later ages. Similarly, peak evoked action potential frequency 
in DGCs increased with age in both tau-/- and htau mice, becoming comparable to that seen 
in controls. These results together indicate that absence of functional tau, due to 
hyperphosphorylation and/or gene deletion, has an effect on intrinsic neuronal function 
early in life that is not evident as the animals age. Tau deletion reduces excitability in both 
young tau-/- and htau mice, but this does not persist in older mice. 
Tau’s ability to affect synaptic function, either on its own or in conjunction with 
other Alzheimer’s disease pathology, has been established in several transgenic animal 
models. The major effect of pathologic tau on synaptic function is impairment of long term 
potentiation (LTP) and a decrease in the paired pulse ratio at several hippocampal synapses  
(Decker et al., 2016; Maeda et al., 2016; Roberson et al., 2011; Shipton et al., 2011; Sydow 
et al., 2011; Yoshiyama et al., 2007). The impairment of LTP likely contributes to deficits 
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in learning and memory in these models. The decrease in paired pulse ratio suggests an 
increased probability of neurotransmitter release and may at least partially explain the 
hyperexcitability and susceptibility to seizures observed in these models. Previous studies 
have found that removal of tau rescues synaptic deficits associated with Alzheimer’s 
disease, particularly amyloid-β induced impairment of LTP (Roberson et al., 2011; Shipton 
et al., 2011). These studies reported minimal differences between tau-/- and non-transgenic 
mice in the absence of additional pathology. In the current study we measured the 
frequency of spontaneous excitatory post-synaptic currents (sEPSCs) and found no 
differences between genotypes at any age. Conversely, changes in presynaptic release 
associated with absence of functional murine tau protein were observed in both transgenic 
strains used herein. We measured the dentate granule cell response after stimulation of the 
lateral perforant path to assess synaptic release probability, based on paired pulse response 
ratios. DGCs from both tau-/- and htau mice exhibited greater paired pulse facilitation 
compared to age-matched, non-transgenic control mice early in life, but the paired pulse 
ratio was not different from controls in either tau-/- or htau mice later in life. The paired 
pulse ratio decreased significantly with age in tau-/- mice, whereas it did not change with 
age in htau or non-transgenic mice. Our study found similar presynaptic neurotransmitter 
release in both transgenic strains, suggesting a loss of tau function in both groups.  
Taken together, the reduced frequency of evoked action potentials and increased 
paired pulse facilitation in young tau-/- mice provide a basis for the seizure resistance in 
genetic epilepsy models observed in tau-/- mice at similar ages (Gheyara et al., 2014; Holth 
et al., 2013). One limitation of those studies is the relatively young age at which the mice 
were, necessarily, assessed. The results of the present study suggest that the anti-epileptic 
93 
 
and anti-SUDEP effect of tau deletion evident in mutant mice, which express 
channelopathies that underlie seizures, may not fully translate to epilepsies with a later age 
of onset. These effects may be lost or reduced with age as excitability increases. Previous 
work found changes in expression of other microtubule-associated proteins in tau-/- mice 
(Harada et al., 1994; Ma et al., 2014). More work is required to understand how these 
changes in expression might affect electrophysiological function in tau-/- mice. 
3.5  Conclusions 
This study sheds new light on the role of tau in promoting neuronal excitability. We 
found that DGCs from mice lacking tau protein or in which endogenous mouse tau is 
replaced by human tau, which has previously been shown to become hyperphosphorylated 
early in life (Andorfer et al., 2003), exhibited reduced measures of excitability in the form 
of reduced peak evoked action frequency and increased paired pulse facilitation that were 
significant in young animals but were abrogated with age. The loss of excitability in the 
htau mouse contrasts with previous work showing a pro-excitatory role of pathologic tau 
in pyramidal neurons from other tauopathy models, but this may be due to differences in 
tau or other pathogenicity, endogenous tau expression in these models, or in the 
characteristics of the types of neurons and networks examined. Finally, our results suggest 
that, while early changes in tau expression may influence neuronal excitability and seizures 
in young mice, other compensatory mechanisms may participate in stabilizing neuronal 
circuits later in life. Identifying additional links between tau phosphorylation and neuronal 
network function may help resolve the influence of tauopathy on disease progression.  
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CHAPTER 4. LOSS OF TAU MODIFIES BUT DOES NOT PREVENT EPILEPTOGENESIS AFTER 
INTRAHIPPOCAMPAL KAINATE TREATMENT IN MICE 
A similar version of this chapter was submitted to Experimental Neurology for peer 
review with Rafael Roberts and Bret N. Smith as additional authors. 
4.1 Introduction 
Temporal lobe epilepsy (TLE) is the most common focal epilepsy and accounts for 
the majority of drug-resistant epilepsy cases (Asadi-Pooya et al., 2017; Pascual, 2007; 
Reynolds, 2000; Semah et al., 1998; Wiebe, 2000). Although drug resistant TLE with an 
identifiable focus often responds well to surgical resection (Engel, 1996; Engel et al., 2012; 
Engel et al., 2003), development of additional treatment options remains essential to reduce 
the burden of care and improve quality of life for patients with TLE. A better understanding 
of the mechanisms that drive development of TLE is crucial to developing new, specific 
therapies. One potential target that has received attention in recent years is the microtubule-
associated protein, tau. 
Hyperphosphorylated tau plays a key disease-promoting role in tauopathies 
including Alzheimer’s disease (AD) and has been associated with epilepsy in human and 
animal studies (Gheyara et al., 2014; Holth et al., 2013; Puvenna et al., 2016; Tai et al., 
2016). The relationship between tau pathology and epilepsy is complex and bidirectional. 
Brain tissue resected as treatment for intractable epilepsy shows advanced tau pathology 
much earlier in life than typical tauopathies (Gourmaud et al., 2020; Puvenna et al., 2016; 
Smith et al., 2019), and animal studies have demonstrated an increase in tau 
phosphorylation after seizure induction (Jones et al., 2012; Liu et al., 2016). Current 
evidence suggests pathological tau maybe involved in seizure susceptibility. Animal 
95 
 
models of tauopathy that express mutant forms of tau that are associated with human 
disease display increased susceptibility to seizure induction (Garcia-Cabrero et al., 2013; 
Liu et al., 2017b), and human patients with Alzheimer’s disease have an increased risk of 
having seizures and developing epilepsy (Lam et al., 2020; Pandis and Scarmeas, 2012; 
Tabuas-Pereira et al., 2019; Vossel et al., 2013). Subclinical epileptiform activity is more 
common in patients with AD but no history of clinical seizures, and predicts faster 
progression of cognitive impairment (Vossel et al., 2016). Reducing tau phosphorylation 
confers resistance to seizure induction in animal models (Jones et al., 2012; Liu et al., 
2016). Similar seizure resistance is observed in animals lacking tau expression due to 
genetic deletion or suppression with antisense oligonucleotides (DeVos et al., 2013; Li et 
al., 2014). Furthermore, loss of tau expression reduces seizure burden and improves 
survival in genetic models of epilepsy (Gheyara et al., 2014; Holth et al., 2013). The 
relationship between tau phosphorylation and seizures and epilepsy suggests that tau could 
be a target for novel treatments to modify epileptogenesis or treat seizures. 
Although many studies have demonstrated seizure resistance in animals lacking 
tau, whether this translates to resistance to epileptogenesis is not clear. Furthermore, the 
degree to which tau promotes seizures and epileptogenesis in the absence of additional 
pathology has not been adequately studied. The current experiment seeks to address these 
issues using the htau mouse model of tauopathy, which produces littermate mice that 
express either no tau of any type (i.e., tau-/- mice) or non-mutant human tau that becomes 
hyperphosphorylated by 1.5 months of age (Andorfer et al., 2003), but no murine tau (i.e., 
htau mice) . We previously showed that both htau and tau-/- mice exhibit lower neuronal 
excitability in dentate gyrus granule cells (DGCs) compared to non-transgenic control mice 
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at 1.5 months of age (Cloyd et al., 2021). In this study, we determined whether the reduced 
excitability associates with seizure resistance, modification of epilepsy development, or 
altered neuronal excitability in the intrahippocampal kainate (IHK) model of TLE. We 
tested the hypothesis that loss of native tau function confers protection against IHK induced 
epilepsy as assessed behaviorally and via 24-hour video-electroencephalogram (vEEG). 
We also assessed neuronal excitability in DGCs using whole cell patch-clamp 
electrophysiology 6-8 weeks after IHK treatment. Determining how tau expression 
influences cellular and behavioral correlates of acquired TLE provides important insight 
relevant to epileptogenesis, especially in the context of tauopathy related dementias. 
4.2 Materials and Methods 
 Animals 
Transgenic B6.Cg-Mapttm1(EGFP)KltTg(MAPT)8cPdav/J mice (male and female; 
#005491) were produced in house from breeders obtained from The Jackson Laboratory 
(JAX; Bar Harbor, ME). These mice lack any obvious disease phenotype at birth, but 
develop impairments in Morris Water Maze, spatial learning, and food burrowing with age, 
particularly in mice older than 9 months (Geiszler et al., 2016; Phillips et al., 2011; 
Polydoro et al., 2009).  The human tau becomes hyperphosphorylated by 1.5 months of age 
(Andorfer et al., 2003). This mouse strain was originally generated on a hybrid Swiss 
Webster/B6D2F1 hybrid background but has been backcrossed to C57BL/6J for more than 
10 generations. Single nucleotide polymorphism (SNP) analyses performed by JAX were 
consistent with a pure C57BL/6J background, which served as the control strain. All 
breeding mice were homozygous for a deletion of the murine tau gene. One mouse in each 
breeding pair was hemizygous for a transgene expressing all six isoforms of non-mutant, 
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human tau protein. The offspring are therefore either full tau knockout (tau-/-) or express 
only human tau (htau), and genotypes and protein expression phenotypes were confirmed 
in our recent report (Cloyd et al., 2021).  
DNA was extracted from tail snips and genotype was confirmed via PCR according 
to the protocols supplied by JAX. Disruption of the endogenous murine tau gene was 
confirmed using the primer pair 5’-CGTTGTGGCTGTTGTAGTTG-3’ and 5’-
TCGTGACCACCCTGACCTAC-3’, which amplifies a fragment at 270 bp in tau-/- and 
htau mice. Presence of the human-tau transgene was confirmed using the primer pair 5’-
CGAAGTGATGGAAGATCACG-3’ and 5’-GTCTTGGTGCATGGTGTAGC-3’, which 
amplifies a fragment at 79 bp in htau mice. Age matched male C57BL/6J control mice 
were bred in house from breeders obtained from JAX (#000664). All mice were housed 
under a 14 hr light / 10 hr dark cycle in an Association for Assessment and Accreditation 
of Laboratory Animal Care Internal (AALAC) approved facility. Food and water were 
available ad libitum. The University of Kentucky Institutional Animal Care and Use 
Committee approved all procedures. 
 Intrahippocampal kainate (IHK) mouse model of temporal lobe epilepsy 
All surgical procedures were performed under isoflurane general anesthesia with 
0.05% bupivacaine local anesthesia. Kainic acid (IHK; 100 nL, 20 mM in 0.9% saline, 
Tocris Bioscience; Minneapolis, MN) or saline (sham; 100 nL) was injected into the left 
dorsal hippocampus (2.0 mm posterior, 1.25 mm left, and 1.6 mm ventral to bregma) at 6-
8 weeks of age (Krook-Magnuson et al., 2013). The injection rate was 20 nL/minute, and 
the needle was left in place for 5 minutes before and after injection. Buprenorphine (0.05 
mg/kg) and carprofen (10 mg/kg) were administered subcutaneously after surgery. Mice 
were transferred to a heated cage for recovery and monitored for seizures for 2 hours to 
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assess development of status epilepticus (SE). SE was defined as the occurrence of at least 
3 seizures of Racine scale 3 or higher during the observation period (Racine, 1972; Shibley 
and Smith, 2002). After 2 hours, diazepam (7.5 mg/kg) was administered intraperitoneally 
to terminate SE. Video monitoring for spontaneous seizures began 2 weeks after the IHK 
surgery and continued for 6 weeks. Each animal underwent 7-8 recording sessions (average 
duration 7.8 hours), averaging 56 hours of monitoring per animal. The videos were 
reviewed at 3-4x speed by an investigator blind to genotype and treatment.  
A separate cohort of mice (n=2-4 per group) were fitted with wireless transmitters 
to allow video-electroencephalographic (vEEG) recording (Data Sciences International; 
DSI; St. Paul, MN). Kainic acid or saline was injected as described above. Screws were 
placed (1.0mm anterior and 1.0mm right to bregma and 3.0mm posterior and 3.0mm left 
to bregma) after injection. A wireless transmitter (ETA-F10, DSI) was implanted 
intraperitoneally and connected to the screws by subcutaneous wires. vEEG began 
immediately after surgery and continued for 2 hours until administration of diazepam as 
described above. EEG recordings were collected using Ponema (v6.42, DSI). Mice 
underwent a total of 5 sessions of 24 hour vEEG recording between 1 and 3 weeks after 
IHK. EEG recordings were manually reviewed for seizure-like activity, defined as 
rhythmic high amplitude (>3 fold larger than baseline), high frequency (>10Hz) activity 
lasting at least 20 seconds, using NeuroScore (v3.3.1, DSI). Potential seizures identified 
on EEG were confirmed by corresponding behavior on video recorded in Open Broadcaster 
Software (v21.0.1) with the Snaz file add-on to allow for 24 hour long recordings using a 
Logitech C270 HD camera. Seizure prevalence and average daily seizure frequency 
recorded via vEEG was calculated for each group. 
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 Hippocampal slice preparation 
Mice were sacrificed for electrophysiology 6-8 weeks after IHK or sham (i.e., saline 
injection) surgery. Mice were deeply anesthetized via inhalation of isoflurane to effect 
(lack of tail pinch response) and decapitated while anesthetized. The brain was rapidly 
removed from the skull and immersed in ice-cold oxygenated (95% O2/5% CO2) 
cutting/holding artificial cerebrospinal fluid (aCSF). The cutting/holding aCSF contained 
(in mM): 85 NaCl, 75 sucrose, 2.5 KCl, 25 glucose, 1.25 NaH2PO4·H2O, 4 MgCl2·6H2O, 
0.5 CaCl2·2H2O, and 24 NaHCO3 (pH 7.2-7.4). Coronal sections (300 µm) were cut on a 
vibrating microtome (Vibratome Series 1000; Technical Products International, St. Louis, 
MO). Each slice was divided with a midsagittal cut and hippocampi were isolated and 
transferred to a holding chamber with warmed (30-32° C), oxygenated cutting/holding 
aCSF and incubated for at least 1 hour before recordings. One slice at a time was transferred 
to a chamber mounted under an upright microscope (BX51WI; Olympus) and was 
superfused with warmed (30-32° C) oxygenated recording aCSF. The recording aCSF 
contained (in mM): 124 NaCl, 3 KCl, 2 CaCl2, 1.3 MgCl, 1.4 NaHCO3, and 11 glucose 
(pH 7.2-7.4). Each slice was perfused with recording aCSF in the microscope chamber for 
>10 minutes to allow the cutting aCSF to wash off before recording. 
 Electrophysiological recordings 
Whole-cell patch-clamp recordings were obtained from hippocampal DGCs 
identified by location and morphological characteristics. Recording pipettes were pulled 
from borosilicate glass (open tip resistance 3-5 MΩ; King Precision Glass Co. Claremont, 
CA). The pipette recording solution contained (in mM): 126 K+-gluconate, 4 KCl, 10 
HEPES, 4 MgATP, 0.3 NaGTP, and 10 PO-creatine (pH 7.2). Electrophysiological 
recordings were performed using a Multiclamp 700B amplifier (Molecular Devices, San 
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Jose, CA), low pass filtered at 2 kHz, digitized at 20 kHz (Digidata 1440A; Molecular 
Devices), and recorded onto a computer using pClamp 10.2 software (Molecular Devices). 
Seal resistance was typically 2-5 GΩ. Series resistance was <25 MΩ (mean: 10.3±0.1 MΩ) 
and was monitored periodically during the recordings. Recordings were discontinued if 
series resistance changed by more than 20% during the recording. Membrane voltage was 
not adjusted for liquid junction potential, calculated to be -15 mV. 
Resting membrane potential and input resistance were measured in current clamp 
mode. Current steps (-100 pA to 400 pA in 50 pA steps) were injected to record membrane 
voltage response. The input resistance was calculated from the slope of the linear portion 
of the resulting current-voltage curve. The resting membrane potential was averaged from 
the portions of recorded traces between current steps. Spontaneous and electrically-evoked 
excitatory post-synaptic currents (i.e., sEPSCs and eEPSCs) were recorded in voltage-
clamp mode at a holding potential of -70 mV. To elicit eEPSCs, a platinum-iridium 
concentric-bipolar electrode (125 µM diameter; FHC, Bowdoin, ME) was positioned on 
the lateral perforant pathway and 30 pairs of current pulses (30-50 µA; 400 µs; interpulse 
interval 75 ms; 5 seconds between pulse pairs) were administered to evoke paired eEPSCs 
(i.e., paired pulse response; PPr). The stimulus intensity was adjusted so that responses 
occurred after >80% of pulses. Stimulus sweeps that failed to elicit a response with both 
stimuli were excluded from analysis. 
 Data Analysis 
 All electrophysiological measures (evoked action potential frequency, resting 
membrane potential, input resistance, sEPSC frequency, and PPr) were analyzed with 
MiniAnalysis (Synaptosoft, Fort Lee, NJ). Statistical measures were performed with Prism 
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(GraphPad, San Diego, CA). Data were disaggregated by sex and no sex-dependent 
differences were detected for any measure, so sexes were combined for all analyses. Data 
were tested for normality by a Shapiro-Wilk test and non-parametric tests were used where 
appropriate. Seizure frequencies from tau-/-, htau, and control mice were compared by one-
way ANOVA. Survival curves were compared by Mantel-Cox logrank test and hazard 
ratios (HRs) were calculated between each transgenic strain and control. A 2-way ANOVA 
was used to compare action potential frequency in response to current injection at the 
current step which resulted in the highest frequency of action potentials (i.e. 200pA). An 
unpaired t-test was used to compare mean values for input resistance, RMP, and PPr from 
sham- and IHK-treated animals of each genotype. A Mann-Whitney test was used to 
compare mean values for sEPSC frequency from sham and IHK treated animals of each 
genotype. Summary data and cell counts for each electrophysiological measurement are 
presented in Table 4.1. Data are presented as mean ± SEM and statistical significance was 
set to p<0.05 for all tests. 
4.3 Results 
 Seizure induction after IHK differs in tau-/- mice 
 We previously determined that at least 3 convulsive seizures (Racine seizure scale 
3-5; Racine, 1972) after intraperitoneal pilocarpine injection constituted status epilepticus 
(SE), resulting in epileptogenesis in mice (Shibley and Smith, 2002; Winokur et al., 2004). 
Non-transgenic C57BL/6J mice reliably develop SE after IHK (Kang et al., 2021; Welzel 
et al., 2020). In the current study, 70% (7/10) of C57BL/6J mice developed SE after IHK, 
compared to 75% (9/12) of htau mice. No tau-/- mice (0/8) met the behavioral definition for 
SE. Although the tau-/- mice exhibited non-convulsive seizure-like behavior after IHK, they 
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Table 4.1 Summary of electrophysiological measurements 
   
Point Estimate ± SEM (n) 





Sham -72.4 ± 1.6 (9) 291.2 ± 22.1 (9) 0.133 ± 0.045 (8) 1.51 ± 0.04 (8) 
IHK -70.2 ± 1.7 (13) 271.2 ± 13.4 (13) 0.802 ± 0.246 (11)* 1.13 ± 0.04 (11)* 
Contralateral 
Sham -71.4 ±  1.5 (8) 257.3 ± 14.2 (8) 0.152 ± 0.064 (7) 1.63 ± 0.11 (8) 
IHK -72.9 ± 0.9 (13) 217.0 ± 15.8 (13) 0.565 ± 0.117 (10)* 1.29 ± 0.07 (13)* 
tau-/- 
Ipsilateral 
Sham -74.9 ± 0.9 (11) 230.8 ± 10.7 (11) 0.265 ± 0.106 (11) 1.41 ± 0.06 (12) 
IHK -67.2 ± 1.6 (16)* 294.2 ± 18.8 (16)* 0.356 ± 0.084 (13) 1.42 ± 0.07 (16) 
Contralateral 
Sham -73.9 ± 1.4 (12) 253.6 ± 19.1 (12) 0.163 ± 0.079 (10) 1.54 ± 0.10 (12) 
IHK -69.5 ± 1.2 (18)* 254.1 ± 13.5 (18) 0.607 ± 0.239 (11)* 1.34 ± 0.10 (13) 
htau 
Ipsilateral 
Sham -72.7 ± 1.6 (9) 250.8 ± 12.1 (9) 0.167 ± 0.056 (7) 1.35 ± 0.10 (7) 
IHK -71.0 ± 1.0 (8) 205.3 ± 19.0 (8) 0.654 ± 0.230 (7)* 1.10 ± 0.03 (8) 
Contralateral 
Sham -73.5 ± 1.2 (8) 251.3 ± 17.5 (8) 0.084 ± 0.017 (7) 1.43 ± 0.16 (8) 
IHK -74.0 ± 1.7 (10) 239.1 ± 11.9 (10) 0.130 ± 0.072 (7) 1.33 ± 0.09 (7) 
*: different from sham control 
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did not reliably develop convulsive seizures. 
Video EEG recordings from tau-/-, htau, and C57BL/6J mice during the 2 hour 
period after treatment showed extensive electrographic activity in all IHK-treated mice. No 
abnormal electrographic activity was observed in any saline-treated mice.  Discrete periods 
of electrographic seizure-like activity occurred throughout the induction period in all IHK-
treated mice, regardless of whether convulsive seizure behavior was observed. 
 Prevalence and frequency of spontaneous seizures in tau-/- and htau mice 
 All mice used for electrophysiology experiments underwent an average of 56 hours 
of video-recorded behavioral observation for spontaneous seizures during the 8 week 
period between the IHK treatment and electrophysiological recordings in order to assess 
the effectiveness of IHK in inducing epileptogenesis. During these limited observations, 
convulsive seizures (Racine scale 3-5) were observed in 0% (0/7) of tau-/- mice, 50% (3/6) 
of htau mice, and 22% (2/9) of C57BL/6J mice.  
Video-EEG was performed on a subset of mice from one to three weeks (total of 5 
separate 24 hour recordings) after IHK or saline treatment. Spontaneous seizures were 
detected in mice of each genotype within 21 days of IHK treatment. Average daily seizure 
frequencies were calculated (C57BL/6J: 1.6±1.0, range 0.2-2.6; Tau-/-: 0.8±0.5, range 0-
2.2; htau: 0.6±0.4, range 0.2-1.0). Convulsive spontaneous seizure prevalence in mice that 
underwent vEEG recording was 50% (2/4) in tau-/- mice, and 100% (4/4 each) in htau and 
C57BL/6J mice. Additionally, EEG spiking was observed in all IHK treated animals of 
each genotype (Figure 4.1B). No EEG spiking or seizures were observed in any sham-
control mice (n=6). These results confirmed that IHK treatment induced epileptogenesis in 




Figure 4.1 Daily seizure frequency recorded by vEEG 
(A) Electrographic seizures detected in C57BL/6J, tau-/-, and mice in the 21 days following 
IHK treatment. Each seizure began at the time indicated by the closed arrowhead and was 
followed by a period of post-ictal suppression (open arrowhead). (B) Interictal spiking was 
detected within the first 21 days after IHK treatment. Similar activity was detected in all 
IHK-treated mice regardless of genotype. Neither seizures not interictal spiking were 
detected in sham control mice of any genotype. 
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 All-cause mortality is greater in htau mice 
 Reduction or deletion of tau is associated with improved survival in some genetic 
models of epilepsy (Gheyara et al., 2014; Holth et al., 2013), whereas pathological tau is 
associated with increased mortality after peripheral chemoconvulsant administration 
(Garcia-Cabrero et al., 2013). In the current study, overall 40 day survival was calculated 
for tau-/-, htau, and non-transgenic C57BL/6J mice after IHK (Figure 4.2). Survival did not 
differ between tau-/- and C57BL/6J mice (HR=0.2, 95% CI 0.003 to 8.5; p>0.05). In 
contrast, mortality was significantly increased in the htau mice compared to C57BL/6J 
mice (HR=4.4, 95% CI 1.1 to 17.9; p<0.05). No sham-treated mice of any genotype died 
prematurely during the course of experiments.  
 Intrinsic membrane properties after IHK 
 We previously identified differences in intrinsic membrane properties in DGCs 
from 1.5 month old tau-/- and htau mice compared to age-matched non-transgenic 
C57BL/6J mice (Cloyd et al., 2021). To determine whether intrinsic membrane properties 
are altered after IHK, resting membrane potential (RMP), input resistance, and induced 
action potential firing were measured in DGCs from tau-/-, htau, and C57BL/6J mice at 6-
8 weeks after IHK or saline treatment. The RMP of DGCs from IHK-treated tau-/- mice 
was depolarized compared to that of DGCs from sham treated tau-/- mice, and this effect 
was observed both ipsilateral and contralateral to the injection site (Figure 4.3A; p<0.05 
for both comparisons). No differences in RMP were observed in DGCs from IHK-treated 
htau or C57BL/6J mice compared to sham (p>0.05). In tau-/- mice, DGCs ipsilateral to the 
IHK injection also had a higher input resistance compared to DGCs from sham-treated tau-




Figure 4.2 Survival after IHK in tau-/-, htau, and non-transgenic mice 
All-cause mortality within 40 days after IHK is increased in htau mice (7/13, 54%) 




Figure 4.3 Effect of IHK on resting membrane potential and input resistance in DGCs 
from tau-/-, htau, and non-transgenic mice 
(A) DGCs from tau-/- mice developed a depolarized resting membrane potential ipsilateral 
and contralateral to the injection site 6-8 weeks after IHK. No changes in resting membrane 
potential were observed in DGCs from htau or non-transgenic mice. (B) DGCs ipsilateral 
to the injection site developed an increased input resistance after IHK. No changes were 
observed in DGCs contralateral to the injection site in tau-/- mice or in DGCs from htau or 
non-transgenic mice after IHK. *: p<0.05. Error bars indicate SEM.  
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contralateral to the injection site in tau-/- mice (p>0.05). Input resistance was unaffected by 
IHK in DGCs from htau or C57BL/6J mice (p>0.05). 
 To determine how tau expression impacts epilepsy-related changes in action 
potential firing, membrane voltage responses to current injection were measured in DGCs 
from tau-/-, htau, and C57BL/6J mice (Figure 4.4). No changes in peak action potential 
frequency were detected ipsilateral to the injection site in C57BL/6J, tau-/-, or htau mice 
(Figure 4.4B; p<0.05). In non-transgenic C57BL/6J mice, IHK resulted in an increased 
peak frequency of action potentials in DGCs contralateral to the injection site relative to 
sham-treated mice (Figure 4.4C; p<0.05). Peak action potential in DGCs contralateral to 
the injection site in IHK-treated C57BL/6J mice was also increased relative to IHK-treated 
tau-/- and htau mice (Figure 4.4C; p<0.05). Overall, the effect of IHK on intrinsic properties 
in DGCs was relatively minor, affecting RMP and input resistance in DGCs from tau-/- 
mice. The impact on action potential firing was most significant contralateral to the IHK 
site in C57BL/6J mice. 
 IHK-related changes in synaptic function are abrogated in tau-/- and htau 
mice 
 Tau ablation is associated with protection against epilepsy-related excitability in 
some genetic models of epilepsy (Garcia-Cabrero et al., 2013; Gheyara et al., 2014), and 
altered synaptic excitability in the dentate gyrus is associated with TLE development 
(Cronin et al., 1992; Patrylo and Dudek, 1998; Winokur et al., 2004; Wuarin and Dudek, 
2001). To better understand how tau affects synaptic function in epileptogenesis, we 
measured sEPSCs 6-8 weeks after IHK or saline injection in DGCs from tau-/-, htau, and 




Figure 4.4 Effect of IHK on membrane voltage response in DGCs from tau-/-, htau, and 
non-transgenic mice 
(A) Sample membrane voltage responses in response to injection of -100, -50, and +200pA 
currents in DGCs contralateral to IHK injection. (B&C) Average peak frequency of action 
potentials in response to current injection in DGCs ipsilateral (B) and contralateral (C) to 
IHK injection. Action potential frequency was not affected by IHK in DGCs ipsilateral to 
the injection site in any genotype, but was increased in DGCs contralateral to the injection 
site in C57BL/6J mice.  *: difference between sham and IHK (p<0.05). t: different from 




Figure 4.5 Effect of IHK on spontaneous EPSC frequency in DGCs from tau-/-, htau, and 
non-transgenic mice 
Sample traces and sEPSC frequencies in DGCs from non-transgenic (A), tau-/- (B), and 
htau (C) mice. (A) DGCs ipsilateral and contralateral to the injection site from non-
transgenic mice receive more sEPSCs after IHK. (B) DGCs contralateral to the injection 
site from tau-/- mice receive more sEPSCs after IHK. No change in sEPSC frequency was 
observed ipsilateral to the injection. (C) DGCs ipsilateral to the injection site from tau-/- 
mice receive more sEPSCs after IHK. No change in sEPSC frequency was observed 
contralateral to the injection.  *: p<0.05. Error bars indicate SEM.  
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contralateral to the injection site was significantly greater than in sham-treated mice 
(Figure 4.5A; p<0.05).  In IHK-treated tau-/- mice, DGCs contralateral to the injection site 
received more sEPSCs compared to sham-treated mice (Figure 4.5B; p<0.05), but no 
difference in sEPSC frequency was observed in DGCs ipsilateral to the injection site 
(p>0.05).  In IHK-treated htau mice, DGCs ipsilateral to the injection site received more 
sEPSCs compared to sham-treated mice (Figure 4.5C; p<0.05), but no difference in sEPSC 
frequency was observed in DGCs contralateral to the injection site (p>0.05). 
To assess changes in presynaptic neurotransmitter release, we measured the DGC 
response to pairs of stimuli applied to the lateral perforant pathway and calculated the 
paired pulse ratio (PPr) of evoked EPSC amplitudes. In IHK-treated C57BL/6J mice, the 
PPr was lower in DGCs both ipsilateral and contralateral to the injection site compared to 
sham-treated mice (Figure 4.6A; p<0.05). No differences in PPr were detected in DGCs 
from IHK-treated tau-/- mice compared to sham-treated control (Figure 4.6B; p>0.05). In 
IHK-treated htau mice, the PPr was lower in DGCs ipsilateral to the injection site compared 
to sham-treated mice (Figure 4.6C; p>0.05), but no difference in PPr was detected in DGCs 
contralateral to the injection site (p>0.05). DGCs from both transgenic strains exhibited 
resistance to IHK-induced changes in synaptic function compared to non-transgenic, 
C57BL/6J mice. 
4.4 Discussion 
This study measured the effects of IHK on seizures, epileptogenesis, and intrinsic 
neuronal properties and synaptic function the DGCs from tau-/- and htau mice compared to 




Figure 4.6 Effect of IHK on paired pulse ratio in DGCs from tau-/-, htau, and non-
transgenic mice 
Sample traces and paired pulse ratio in DGCs from non-transgenic (A), tau-/- (B), and htau 
(C) mice after IHK. (A) PPr was reduced in DGCs ipsilateral and contralateral to the 
injection site in non-transgenic mice. (B) No change in PPr was observed in DGCs from 
tau-/- mice. (C) PPr was reduced in DGCs ipsilateral to the injection site in htau mice. No 
change in PPr was observed in DGCs contralateral to the injection site in htau mice.  




significant reduction in network excitability, mortality, and seizure burden in genetic 
models of epilepsy (Gheyara et al., 2014; Holth et al., 2013) and resistance to chemically 
induced seizures (DeVos et al., 2013; Li et al., 2014). Reduced tau expression also 
contributed to an abrogation of the increased susceptibility to induced seizures or the 
reduction in frequency of spontaneous seizures that is associated with some animal models 
of AD (Roberson et al., 2011; Roberson et al., 2007). We previously reported that 
presynaptic neurotransmitter release is inhibited by the loss of murine tau early in life in 
DGCs from tau-/- and htau mice (Cloyd et al., 2021). We hypothesized that the similarities 
we found in tau-/- and htau mice were attributable to the fact that neither strain expressed 
native, functional tau. Here we tested the hypothesis that the loss of native tau, through 
deletion in tau-/- mice or htau mice, would confer protection from seizure induction and 
epileptogenesis after IHK. This hypothesis was partially supported and the results 
presented here further our understanding of tau’s role in epileptogenesis. 
We found a striking difference in the immediate seizure-inducing effects of IHK on 
tau-/- mice compared to htau mice or non-transgenic, C57BL/6J mice. C57BL/6J and htau 
mice reliably displayed convulsive seizures immediately after IHK and most (70-75%) 
developed SE during the defined two hour observation period. In contrast, very few tau-/- 
mice exhibited any behavioral seizures and none met the definition for SE that results in 
epileptogenesis after systemic pilocarpine treatment (Shibley and Smith, 2002). However, 
EEG analysis revealed extensive electrographic activity in all mice after IHK, regardless 
of genotype, which was consistent with electrographic activity during convulsive SE 
reported by others (Haussler et al., 2012). Additionally, all htau and C57BL/6J mice, and 
two of four tau-/- mice, developed epilepsy with spontaneous seizures within 3 weeks of 
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IHK treatment. Thus, partial seizures that are not associated with generalized convulsive 
behavior at the time of IHK treatment may be sufficient to induce epileptogenesis within 
three weeks in this model.  All IHK-treated mice also exhibited EEG spiking, a finding 
previously described in a posttraumatic epilepsy model (Statler et al., 2009). These results 
address an important gap in understanding of tau’s effect on epileptogenesis. Although 
numerous studies have shown seizure resistance in various tau-/- models (DeVos et al., 
2013; Li et al., 2014; Pallo et al., 2016; Roberson et al., 2011; Roberson et al., 2007; Tan 
et al., 2018), little is currently known about how this resistance affects the process of 
epileptogenesis. The results of the current study suggest tau deletion does not prevent 
development of acquired epilepsy, but may instead alter the process or rate of 
epileptogenesis after IHK treatment. Notably, EEG monitoring was not continuous during 
the observation period and seizures frequently occur in clusters (Lim et al., 2018; Williams 
et al., 2009). Furthermore, the frequency of spontaneous seizures detected in the individual 
tau-/- mice that developed epilepsy was similar to the seizure frequency in C57BL/6J mice. 
Taken together with the observation of EEG spiking in all IHK-treated animals, we cannot 
exclude the possibility that epileptogenesis occurred, even in cases where spontaneous 
behavioral seizures were not documented. Compared to mice monitored by vEEG, 
spontaneous seizure prevalence in mice that underwent monitoring for behavioral seizures 
without EEG was lower for all genotypes. It should be noted, however, that all of the 
behavioral observations occurred during the day. Approximately 75% of spontaneous 
convulsive seizures recorded by vEEG occurred at night, so these behavioral observations 
likely underestimated the actual prevalence of spontaneous seizures in the mice used for 
electrophysiology. Furthermore, electrophysiological data collected from mice that were 
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observed to have spontaneous convulsive seizures did not obviously differ from those that 
were not observed to have spontaneous convulsive seizures. 
Loss of tau expression is associated with reduced mortality in genetic epilepsy and 
induced seizure models (Gheyara et al., 2014; Holth et al., 2013; Roberson et al., 2011; 
Roberson et al., 2007), whereas expression of disease-related mutant tau is associated with 
increased mortality after pentylenetetrazole (PTZ) induced seizures (Garcia-Cabrero et al., 
2013) and may increase epilepsy-related death in some models of AD (Maeda et al., 2016). 
The results of the current study were largely consistent with previous findings. Overall 
survival in htau mice was significantly lower than in tau-/- and C57BL/6J mice. The human 
tau expressed by htau mice lacks disease related mutations common in other transgenic tau 
mice, but total tau expression and phosphorylation is elevated (Andorfer et al., 2003), a 
finding we previously confirmed (Cloyd et al., 2021). Our results indicate that disease 
related mutations are not required for tau to exacerbate epilepsy-related mortality. Rather, 
accumulation of hyperphosphorylated tau, which occurs in human patients with epilepsy 
(Puvenna et al., 2016; Tai et al., 2016), may be associated with epilepsy-related mortality. 
We did not detect a difference in survival between tau-/- and non-transgenic C57BL/6J 
mice. Previous work using IHK in C57BL/6J mice found a low rate of mortality in this 
model (Kang et al., 2021; Welzel et al., 2020), similar to our results. Due to the low 
mortality rate in both groups, it is not possible from the current data to determine whether 
tau deletion improves survival after IHK in tau-/- mice compared to C57BL/6J mice. 
Temporal lobe epilepsy results in increased and recurrent excitatory signaling in 
the dentate gyrus (Buckmaster et al., 2002; Cronin et al., 1992; Hunt et al., 2010; Winokur 
et al., 2004; Wuarin and Dudek, 2001). The current study found evidence of increased 
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excitability in DGCs from IHK-treated C57BL/6J mice that was less or absent in DGCs 
from tau-/- and htau mice. The effects on synaptic function were most apparent. DGCs from 
IHK treated C57BL/6J mice received more sEPSCs and the probability of neurotransmitter 
release after perforant pathway stimulation was also increased compared to DGCs from 
sham-control C57BL/6J mice. These effects were observed in DGCs both ipsilateral and 
contralateral to the IHK injection site, indicating widespread changes in DGC excitability. 
These effects on excitatory synaptic connectivity were partially abrogated in DGCs from 
both tau-/- and htau mice.  
DGCs contralateral, but not ipsilateral, to the IHK site exhibited an increased peak 
frequency of induced action potentials in response to current injection compared to sham-
control in C57BL/6J mice (Figure 4.4). This finding suggests that commissural inputs to 
the dentate gyrus, or the secondary generalization of seizure activity that involves both 
hemispheres, may play important roles in mediating changes in intrinsic excitability over 
time, possibly more so than local circuitry. The DGCs recorded in this study were located 
in the ventral dentate gyrus, relatively distant from the IHK site in the dorsal CA1, further 
implicating commissural connections in the induction of altered intrinsic excitability in 
DGCs. The absence of changes in peak action potential firing in IHK treated tau-/- and htau 
mice suggests that generalization of seizures may be impaired in mice lacking functional 
tau, which may be related to the protection against IHK-induced synaptic dysfunction we 
detected.  
Although increased susceptibility to seizure induced cellular excitability has been 
demonstrated in other animal models of tauopathy (Decker et al., 2016; Garcia-Cabrero et 
al., 2013; Liu et al., 2017b; Maeda et al., 2016), we found the opposite in DGCs from htau 
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mice. The htau mouse was selected for this study because, unlike other transgenic tau 
models, it lacks murine tau. We previously showed that DGCs from htau mice exhibit 
reduced excitability compared to non-transgenic mice at 1.5 months of age, the age at 
which mice were treated with IHK in the current study, suggesting that the pro-excitatory 
effects of hyperphosphorylated tau require the presence of normal murine tau (Cloyd et al., 
2021). The abrogation of IHK-induced changes in DGC excitability observed in htau 
animals further supports this notion. Interestingly, survival after IHK was significantly 
poorer in htau mice, which is more consistent with previous studies of the seizure-related 
survival in animal models of tauopathy (Garcia-Cabrero et al., 2013) and AD (Chan et al., 
2015), which develop hyperphosphorylated tau despite lacking neurofibrillary tangles 
(Castillo-Carranza et al., 2015). This suggests that tau impacts animal survival and cellular 
excitability by separate mechanisms after IHK treatment. 
4.5 Conclusions 
 Our results are inconsistent with the hypothesis that loss of tau prevents 
epileptogenesis, though we did find evidence that seizure expression, and possibly the 
process of epileptogenesis, are altered in mice lacking native tau. Tau-/- mice did not 
develop SE as conventionally defined by the occurrence of convulsive seizures, but 
exhibited electrographic activity consistent with subconvulsive seizures. Spontaneous 
generalized seizures and EEG spiking were documented 1-3 weeks after IHK treatment in 
all strains, but was not present in sham-treated animals. Although eliminating native tau 
did not prevent epilepsy in tau-/- or htau mice, it abrogated several of the IHK-related 
changes in DGC electrophysiology identified in C57BL/6J mice. The specific mechanisms 
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by which tau and/or hyperphosphorylation of tau influences epileptogenesis and epilepsy 
related mortality warrants further study.  
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CHAPTER 5. DISCUSSION 
5.1 Summary of findings 
This dissertation focused on studying the effects of tau expression on DGC 
electrophysiology in normally aging and IHK-treated tau-/- and htau mice. The principal 
findings of this work are as follows: 1) DGCs from both tau-/- and htau mice are intrinsically 
less excitable compared to non-transgenic control early in life, but this effect is lost with 
age, 2) presynaptic neurotransmitter release from perforant pathway fibers is inhibited in 
both tau-/- and htau mice, 3) aging-related changes in neuronal function depend more upon 
loss of tau expression than by development of hyperphosphorylated tau, 4) tau-/- mice 
display an altered behavioral phenotype during IHK-SE compared to htau or C57BL/6J 
mice, but reliably experience SE as measured electrographically after IHK, 5) survival after 
IHK is significantly impaired in htau mice, but appears unaffected or improved in tau-/- 
mice, 6) changes in tau expression may not significantly impact the development of 
spontaneous seizures after IHK, and 7) modulation of tau expression reduces synaptic 
dysfunction and may limit spread of seizure. This dissertation is the first direct comparison 
of the effects of complete removal of tau and introduction of mild tau pathology in the 
absence of endogenous murine tau on electrophysiological function in DGCs. This 
dissertation is also the first work to perform IHK in htau mice and compare survival, 
epileptogenesis, and DGC function in epileptic tau-/- and htau mice. 
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5.2 DGC function tau-/- and htau mice 
 Synaptic function in DGCs from tau-/- and htau mice 
Several studies have examined synaptic function in tau-/- mice (Ahmed et al., 2014; 
Biundo et al., 2018; Kimura et al., 2014) or in mouse models expressing pathological tau 
(Hoover et al., 2010; Sydow et al., 2011; Tracy et al., 2016; Yoshiyama et al., 2007). 
Several studies have also examined on the effect of tau deletion on hyperexcitability 
associated with AD pathology (Ittner et al., 2010; Roberson et al., 2011; Shipton et al., 
2011). Introduction of soluble tau oligomers (exogenously or via intracellular recording 
solution during a whole cell recording) can induce impairments in LTP (Hill et al., 2019; 
Ondrejcak et al., 2018). The majority of previous work has studied the synapse between 
Schaffer collateral fibers and CA1 pyramidal neurons, but some work has focused on the 
synapses between the perforant pathway and DGCs and between the mossy fibers and CA3 
pyramidal neurons.  
Tau-/- mice and mice expressing pathological tau both exhibit deficits in synaptic 
plasticity, particularly impairment of LTP. Impairments in LTP may be attributable in part 
to derangements in glutamate signaling and post-synaptic receptor function. Tau pathology 
promotes glutamate release and inhibits its reuptake, promoting excitotoxicity which can 
be abrogated by stimulating astrocytic reuptake of glutamate (Decker et al., 2016; 
Hunsberger et al., 2015). Tau also contributes to the organization and function of the post-
synaptic density, primarily through interactions with the Src-kinase Fyn (Ittner et al., 2010; 
Lopes et al., 2016; Miyamoto et al., 2017; Mondragon-Rodriguez et al., 2012). Although 
most evidence implicates pathological tau in NMDA receptor function, it has also been 
shown to inhibit AMPA receptor trafficking (Tracy et al., 2016). The impairment of LTP 
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associated with different tau models could therefore be due to a combination of 
derangements of post-synaptic organization and excessive glutamate signaling resulting in 
excitotoxic neuron death, which may explain why tau-/- and pathological tau models 
frequently exhibit similar deficits in synaptic plasticity. 
It is not entirely clear from the studies discussed why loss of tau expression 
improves synaptic plasticity in models expressing Aβ pathology. One explanation is that 
Aβ induces synaptic dysfunction through induction of tau pathology. This explanation is 
consistent with observations of Aβ-associated hyperexcitability (Busche et al., 2008). Aβ-
associated changes of pre- and post-synaptic function are largely consistent to those 
observed in pathological tau models (Roberson et al., 2011; Shipton et al., 2011). 
Abrogation of excitotoxicity after tau loss in these models is straightforward given 
pathological tau’s association with excessive glutamate release. However, the 
improvement in LTP after tau deletion in several studies of Aβ models is counterintuitive 
(Ittner et al., 2010; Roberson et al., 2011; Shipton et al., 2011) given that tau deficient mice 
develop LTP deficits. One explanation is that Aβ is not inherently detrimental to synaptic 
function. Supporting this idea, low dose (picomolar) infusion of Aβ enhances LTP in CA1 
pyramidal neuron (Puzzo et al., 2008). With this in mind, it is possible that in tau-/- animals 
with increased Aβ expression, there is actually an improvement in LTP. However, this 
hypothesis is largely untested and mostly speculative. The idea that Aβ-induced pathology 
is mainly tau-mediated is not novel and is supported by studies of synaptic function in  




In contrast to synaptic plasticity, which is affected similarly by tau deficiency or 
pathology, presynaptic function in the trisynaptic circuit is affected differently in tau-/- mice 
and mice which express pathological tau. Neurotransmitter release probability is generally 
increased in pathological tau models (Sydow et al., 2011; Yoshiyama et al., 2007), but is 
appears to be unaffected in tau-/- models (Ahmed et al., 2014; Kimura et al., 2014). 
Consistent with these observations, other studies have suggested tau does not have a major 
role in physiological presynaptic function, although the evidence is relatively sparse 
(McInnes et al., 2018; Zhou et al., 2017). The increased neurotransmitter release in 
pathological tau models is consistent with the increased glutamate release previously 
described, though the specific mechanism remains to be determined. Although the limited 
evidence of pathological tau’s role in presynaptic function suggests it impairs fusion of 
synaptic vesicles with the plasma membrane (McInnes et al., 2018; Zhou et al., 2017), these 
studies were conducted in the neuromuscular junction of Drosophila which expressed 
human 0N4R tau. While vesicle fusion is largely assumed to be conserved across different 
synapses and species, the body of evidence summarized here suggests the same cannot be 
said of tau’s role in vesicle fusion. The tau species expressed does not represent tau 
expression in human (mixture of all 6 isoforms) or mouse (3 isoforms of 4R tau). Therefore, 
the results from these studies may not be generalizable to tau’s pathologic pre-synaptic 
function. Still, taken along with studies demonstrating little effect of tau deletion on 
presynaptic function in tau-/-, these studies suggest tau does not play a major physiologic 
role in the presynaptic space. 
Despite several studies examining tau’s role in synaptic function, only one study 
was found which studied synaptic function specifically in the htau mouse. This study found 
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normal function at the synapse between Schaffer collateral fibers and CA1 pyramidal 
neurons from 4 month old htau (Polydoro et al., 2009). Synaptic function was impaired at 
1 year of age, consisting of reduced presynaptic neurotransmitter release and impaired LTP 
in response to high frequency stimulation. LTP induced by theta-burst stimulation 
functioned normally, suggesting the high-frequency LTP impairment may be related to the 
presynaptic deficit (i.e. the Schaffer collateral fibers could not adequately release 
neurotransmitter in response to high frequency stimulation). 
Most previous work into the effects of tau on synaptic function studied synapses 
onto CA1 and CA3 pyramidal neurons. In contrast, the current work studied DGCs and is 
the first to study DGC function in the htau mouse model. Despite studying different cell 
populations, the results of this study are largely consistent with previous studies. No 
difference in paired pulse ratio was detected in mice at 4 months of age and older. However, 
previous studies did not measure paired pulse ratio in younger mice. In this study, the 
paired pulse ratio was increased in both tau-/- and htau mice at 1.5 months of age compared 
to C57BL/6J mice, indicating reduced neurotransmitter release from perforant pathway 
fibers to DGCs. This reduction in presynaptic function suggests tau deletion reduces 
excitatory signaling, consistent with previous work (Decker et al., 2016; Hunsberger et al., 
2015). Furthermore, the effect waning with age is consistent with observations of tau’s role 
in neuronal development. Tau-/- neurons display impairments in development that seem to 
be partially compensated by other MAPs (Dawson et al., 2001; Harada et al., 1994). Tau 
isoform expression also varies throughout development, transitioning from 0N3R tau in 
the fetal brain to all six isoforms in the adult brain (Goedert and Jakes, 1990; Goedert et 
al., 1989a; Kosik et al., 1989). No difference in presynaptic neurotransmitter release was 
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detected at 9 months of age, the latest age studied. This may indicate a difference in the 
neurons studied, suggesting DGC function is less affected by age compared to CA1 
pyramidal neurons. Alternatively, it may suggest that function declines between 9 and 12 
months. Since this is the general age range where NFTs become increasingly prominent, 
this may suggest increased development of oligomeric tau in this timeframe (discussed 
more below). 
A notable finding from this study was the overwhelming similarity between 
synaptic function measured in tau-/- and htau mice at all ages. Based on previous studies, 
significant differences in excitability were expected between the two models. Perforant 
pathway-DGC synaptic excitability in the tau-/- mice largely met expectations, but this 
synapse in htau mice was less excitable compared to C57BL/6J mice early in life. DGCs 
from tau-/- and htau mice displayed few differences in synaptic function at any age. A 
couple of important factors may explain the difference in excitability in htau mice 
compared to tau models. The htau mouse was chosen in part because it lacks MAPT 
mutations commonly expressed in other tau models. These mutations are valuable in better 
understanding tau’s behavior in many pathologic contexts. However, they are relatively 
rare in the human population so findings in these models may not be widely generalizable. 
In contrast, the htau mouse expresses human tau lacking additional mutations. Mouse 
models that express non-mutant human tau are more resistant to tau pathology than models 
expressing mutant tau. For example, the first transgenic mouse model, which expressed 
2N4R tau, developed somatodendritic distribution of hyperphosphorylated tau but lacked 
significant NFT formation, neurodegeneration, and functional impairment (Gotz et al., 
1995). When the P301L mutation was introduced to the same model, significant pathology 
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associated with tauopathies developed (Gotz et al., 2001a). The absence of disease-related 
mutations in the htau mouse therefore likely reduces the severity of the tau pathology and 
lack of obvious synaptic deficits. Although the lack of pathogenic mutations may 
contribute to the reduced synaptic excitability in htau mice, this explanation does not fully 
account for the findings. Despite lacking disease related mutations, overall tau expression 
is increased in htau mice compared to C57BL/6J mice (Andorfer et al., 2003). 
Overexpression of endogenous murine tau alone has been shown to induce pathology 
including hyperphosphorylation and aggregation similar to that observed in the htau model, 
demonstrating that mutations or additional sources of pathology are not necessary for tau 
pathogenesis (Adams et al., 2009). Furthermore, htau mice develop tau aggregation (i.e. 
oligomers) by 2 months of age, and exhibit mature tangles by 9-12 months of age (Andorfer 
et al., 2003). Since soluble tau oligomers are likely the primary toxic tau species (Tian et 
al., 2013), and readily form from hyperphosphorylated tau without pathogenic mutations 
during the process of aggregation (Maeda et al., 2007; Tepper et al., 2014), the htau mice 
should have the same pathogenic potential as other models. Therefore, the lack of 
pathogenic mutations is unlikely to be the sole explanation for the current findings. 
The htau mouse model has a second important characteristic that sets it apart from 
most tau mouse models. Whereas most transgenic models express additional forms of tau 
with murine tau expression intact, the htau model expresses a homozygous deletion of 
murine tau in addition to the human transgene so that they only express human tau. Both 
3R and 4R tau are highly expressed in htau mice, though 3R tau is more abundant (Andorfer 
et al., 2003). In contrast, since murine tau is 4R only, intact murine tau expression greatly 
increases the ratio of 4R to 3R tau. Increasing relative 4R expression promotes aggregation 
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of tau (Schoch et al., 2016; von Bergen et al., 2000). Therefore, htau mice likely develop 
tau oligomers at a lower rate than transgenic models which co-express human and murine 
tau, especially compared to models that express pro-aggregation mutations such as P301L 
(Barghorn et al., 2000). Tau oligomer development has not been thoroughly studied in htau 
mice or directly compared between to other models, so the exact difference in oligomer 
burden is not known. Furthermore, because synaptic function has not been thoroughly 
studied in htau mice, it’s not clear how much these potential changes impact function. The 
limited data suggest some impairment to LTP develops late in life, but even then LTP in 
response the theta burst was intact (Polydoro et al., 2009) 
 Intrinsic neuronal properties in DGCs from tau-/- and htau mice 
Compared to studies of synaptic function, which typically involve extracellular 
field recordings, relatively few studies have examined the tau’s role in intrinsic neuronal 
properties. Most work has been conducted in the rTg4510 mouse, in frontal cortical 
pyramidal neurons (Crimins et al., 2012; Crimins et al., 2011; Rocher et al., 2010) or CA1 
pyramidal neurons (Hatch et al., 2017). These studies found largely different results, 
possibly reflecting the different neuron populations examined. Overall, frontal cortical 
pyramidal neurons from rTg4510 mice were more excitable than those non-transgenic 
control, exhibiting resting membrane potentials that were depolarized and firing action 
potentials at higher frequency in response to current injection (Crimins et al., 2012; Crimins 
et al., 2011; Rocher et al., 2010). The action potential firing appeared to be a consequence 
of the depolarized membrane potential, because no difference in firing was observed when 
the neurons were clamped at the same voltage. 
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In contrast to studies in frontal cortical pyramidal neurons, CA1 pyramidal neurons 
in rTg4510 mice are less excitable compared to those from non-transgenic control, 
exhibiting decreased action potential firing frequency in response to current injection 
(Hatch et al., 2017). In addition, action potential threshold and rheobase were increased, 
and action potential amplitude was decreased. Comparable responses were elicited after 
administering soluble tau oligomers via intracellular patch-pipet to the soma of CA1 
pyramidal neurons in C57BL/6J mice (Hill et al., 2019).  
No studies were found that measured the effects of tau pathology in DGCs. 
Furthermore, no studies could be found which reported whole-cell patch-clamp data from 
tau-/- animals. Therefore, this study presents the first examination of intrinsic DGC function 
in both tau-/- and htau mice.  Overall, the effects were relatively minor in both models. 
Resting membrane potential was slightly depolarized in DGCs from tau-/- mice at 1.5 
months, but this effect was not observed at later ages, and no other changes in resting 
membrane potential were observed. Peak action potential firing frequency was decreased 
in DGCs from tau-/- and htau mice compared to those from C57BL/6J at 1.5 months, and 
peak frequency increased with age in both models. Consistent with other studies of 
hippocampal neurons, the current study suggests tau does not have a major role in intrinsic 
neuronal properties. This conclusion is overall in line with tau’s normal distribution and 
function, suggesting tau’s contribution to neuronal function is focused primarily at the 
synapse. However, given the relatively sparse data available, it is possible that tau plays 
subtle roles in intrinsic function that have not be discovered. 
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 Future directions 
While this study has provided new insight into tau’s role in neuronal excitability in 
tau-/- and htau mice, some key questions remain to be answered. Previous studies have 
identified a significant role for tau in the post-synaptic response, specifically in the 
processes of LTP. This study did not measure LTP or any other measure of synaptic 
plasticity. Future work should assess LTP at the major hippocampal synapses to better 
understand post-synaptic function in the htau mouse. Based on existing literature, it’s 
reasonable to expect the htau mice would exhibit deficits in LTP. However, the noted 
differences between tau and the models previously studied, particularly the potential 
difference in oligomeric tau, could prevent LTP deficits in the htau mice. Assessing the 
rate of tau oligomerization in htau mice compared other tau mice would also help in 
understanding tau’s role in synaptic function, especially the potential role of murine tau 
expression in tauopathy models. A side-by-side comparison between htau and 8c mice 
would clarify many questions since these models differ primarily only by the expression 
of murine tau. A clear understanding of the potential confounding influences of murine tau 
expression in models of tau pathology is crucial to interpreting existing and future studies. 
5.3 Epileptogenesis in tau-/- and htau mice 
 Induction of SE by IHK 
Tau’s role in seizure development has been the focus of several studies involving 
tau-/- and tauopathy models. Tau-/- mice exhibit resistance (characterized by delayed onset 
and reduced severity) to seizures induced by intraperitoneal injection of PTZ (Li et al., 
2014; Roberson et al., 2007; Tan et al., 2018) and KA (Pallo et al., 2016; Roberson et al., 
2007). Comparable resistance to picrotoxin-induced seizures was achieved after ASO-
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meditated inhibition of tau expression in adult mice (DeVos et al., 2013). Tau deletion also 
abrogates the increased susceptibility to PTZ-induced seizures associated with AD 
pathology (Palop et al., 2007; Roberson et al., 2011; Roberson et al., 2007). Interestingly, 
the seizure resistance is not limited to a single model, but has been demonstrated in several 
distinct tau-/- models (Dawson et al., 2001; Tan et al., 2018; Tucker et al., 2001), including 
several which had been crossed with other mouse models (Gotz et al., 2001a; Mucke et al., 
2000; Sturchler-Pierrat et al., 1997), demonstrating the effect is not unique to any single 
model. Furthermore, reducing tau phosphorylation through activation of PP2A in rats with 
normal tau expression similarly confers resistance to PTZ-induced seizures (Jones et al., 
2012). In contrast to tau-/- mice, mice expressing pathologic tau exhibit increased 
susceptibility to PTZ-induced seizures (Garcia-Cabrero et al., 2013). 
A few studies have investigated tau’s influence on kindling or SE models. One 
study found rTg4510 mice are more susceptible to amygdala kindling, but found no 
difference in kindling response between tau-/- and C57BL/6J mice (Liu et al., 2017b). 
Similarly, Tg2576 mice, an Aβ model which develops oligomeric tau pathology, showed 
similar susceptibility to kindling (Castillo-Carranza et al., 2015; Chan et al., 2015). 
Consistent with previous work, reducing tau phosphorylation by activating PP2A in rats 
with normal tau expression confers resistance to amygdala kindling and SE induced by 
repeated low dose KA (Liu et al., 2016). 
In the current work, tau-/- and htau mice underwent IHK treatment to determine how 
tau influences development of SE. Although htau mice developed generalized convulsive 
seizures after IHK in a manner largely similar to C57BL/6J mice, tau-/- mice did not exhibit 
convulsive seizures. This seemed to suggest that tau deficiency prevented IHK-induced 
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SE. However, EEG monitoring of tau-/- mice after IHK found extensive non-convulsive 
seizure activity consistent with that observed in htau and C57BL/6J mice as well as other 
reports of IHK-induced SE (Haussler et al., 2012). This study showed that tau deficiency 
modifies IHK-SE, but does not prevent it outright. This finding has important ramifications 
for any study inducing seizures or SE in tau-/- animals. Considering the shift from 
convulsive to non-convulsive seizures, apparent absence of seizures should be confirmed 
via EEG before concluding that tau deficiency confers protection in these models. 
 Survival after SE 
Consistent with the effect on seizure induction, tau expression is correlated with 
survival in seizure and epilepsy models. Expression of pathological tau is associated with 
poorer survival following PTZ-induced seizures (Garcia-Cabrero et al., 2013) and 
electrical kindling (Chan et al., 2015). In contrast, tau-/- animals exhibit improved survival 
in several models of seizure induction and epilepsy. Genetic models of epilepsy are often 
associated with sudden unexpected death in epilepsy (SUDEP). Tau deficient mice exhibit 
a dose dependent (tau-/- > tau+/- > tau +/+) reduction in mortality associated with some 
genetic models of epilepsy (Gheyara et al., 2014; Holth et al., 2013). 
The results of the current study are consistent with previous work. Mortality in htau 
mice (55% mortality overall, 35% SUDEP) was increased compared to C57BL/6J mice 
(14% SUDEP). Tau-/- mice may have exhibited reduced mortality compared to C57BL/6J 
(8% SUDEP), but the sample size was insufficient to draw this conclusion. Overall, the 
results of this study confirmed previous results demonstrating a correlation between tau 
expression and seizure/epilepsy related death. Impaired survival in htau mice demonstrates 
that the reduced synaptic excitability previously described at a similar age did not confer 
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protection against mortality. The increased rate of SUDEP may indicate involvement of 
extrahippocampal circuits, particularly the nucleus tractus solitarius (NTS) which has been 
implicated in SUDEP after pilocarpine-induced SE (Derera et al., 2017; Derera et al., 
2019). 
 Development of spontaneous seizures after SE 
Relatively few studies have examined tau’s role in spontaneous seizures. Tau 
deletion reduces the frequency of spontaneous seizures in some genetic models of epilepsy 
(Gheyara et al., 2014; Holth et al., 2013). Similarly, tau deletion improves the epileptic 
phenotype associated with at least one AD mouse model. The hAPPJ9/Fyn mouse double 
transgenic model overexpresses Fyn alongside human amyloid precursor protein with two 
disease-related mutations, and develops spontaneous convulsive seizures (Roberson et al., 
2011). Tau reduction resulted in a dose-dependent reduction in spontaneous epileptiform 
activity and shifted seizure phenotype to less severe, nonconvulsive seizures. Targeting tau 
phosphorylation by activation of PP2A in rats reduced the frequency of spontaneous 
seizures after amygdala kindling, fluid percussion injury, and KA-induced SE (Liu et al., 
2017b). 
The results of this study suggest a reduction in prevalence and frequency of 
spontaneous seizures, but lacked the statistical power to find a difference. C57BL/6J mice 
monitored by vEEG (two 24 hour recordings per week) all developed spontaneous 
convulsive seizures 1-3 weeks after IHK, mostly at a higher frequency than tau-/- or htau 
mice. Two out of four tau-/- mice were not observed to have a convulsive seizure or vEEG 
correlate, but seizure frequency in the other tau-/- mice was similar to C57BL/6J mice. 
Interestingly, although all htau mice were observed to have spontaneous seizures, the 
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frequency was lower than observed in C57BL/6J or tau-/- mice. All IHK-treated mice 
exhibited spiking on EEG regardless of whether convulsive seizures were observed. This 
spiking was not observed in any sham-treated mice. 
The study of spontaneous seizures in the IHK-treated mice reveals two major 
points. First, convulsive seizure prevalence determined by 24 hour vEEG monitoring 
differed dramatically from prevalence determined by behavior monitoring. Whereas 
convulsive seizures were observed in 50-100% of vEEG monitored mice, convulsive 
seizure prevalence assessed by video monitoring of behavior in tau-/-, htau, and C57BL/6J 
mice was 0%, 50%, and 22%, respectively. Notably, 75% of seizures observed on vEEG 
occurred at night while the animals were most active, whereas all behavioral monitoring 
occurred during the day. Therefore, studies which only monitor for seizures during the day 
likely underrepresent actual seizure prevalence.  
Additionally, although htau mice experienced a high mortality rate after IHK, they 
were observed to develop fewer spontaneous seizures compared to C57BL/6J mice or  
tau-/- mice that developed spontaneous seizures. This finding suggests tau affects survival 
and epileptogenesis by different mechanisms. IHK treatment occurred at 1.5-2 months of 
age, when htau mice exhibit reduced excitability at the perforant pathway-DGC synapse. 
Although this reduction in excitability did not improve overall survival, it may have 
contributed to the apparent reduction in seizure frequency. It is not known whether other 
hippocampal synapses exhibit similar patterns of excitability at this age. Reduced synaptic 
excitability throughout the hippocampus would likely inhibit seizure propagation and could 
underlie the reduced frequency of convulsive seizures in htau mice. However, the 
frequency of spontaneous seizures in tau-/- complicate this picture. Tau-/- mice exhibited 
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similar synaptic activity described in htau mice. Spontaneous seizures were not observed 
in two of four tau-/- mice during 24 hour vEEG after IHK, but the frequency of seizures in 
the other two tau-/- did not differ from C57BL/6J mice. One possible conclusion is that tau 
deficiency inhibits epileptogenesis, but has little effect on seizures in animals that do 
become epileptic. This conclusion is not fully supported from the current data, however, 
because EEG spikes were present in all IHK treated mice. Although not conclusive, this 
observation raises the possibility that the mice without observed seizures had become 
epileptic. Since seizures often develop in clusters (Lim et al., 2018; Williams et al., 2009) 
and EEG monitoring was not continuous throughout the observation period, it is possible 
that these two mice had seizures between vEEG recordings. 
 Future directions 
While the current study provides new insight on tau’s role in epileptogenesis, more 
work is needed to clearly define this role. The data presented here suggest a reduction in 
epileptogenesis in tau-/- mice, but limitations in monitoring could be responsible for this 
finding. Longer term, continuous vEEG monitoring would provide a better assessment of 
epileptogenesis after IHK. Furthermore, IHK in the current study was performed at 1.5-2 
months of age, corresponding with reduced excitability at the perforant pathway-mossy 
fiber synapse as previously discussed. It is not clear from the current data whether this 
reduced excitability influenced development of SE or epileptogenesis. However, since this 
synapse exhibited normal excitability later in life, performing IHK at later ages could 
clarify this question. A small cohort of older tau-/- and htau mice displayed no obvious 
differences after IHK compared to the current study, but full investigation is warranted 
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before making any conclusions. Given the increased rate of SUDEP in htau mice, NTS 
function should be assessed after IHK in tau-/- and htau mice. 
5.4 Dentate granule cell excitability after IHK in tau-/- and htau 
 Electrophysiology in IHK treated mice 
Epilepsy is associated with extensive changes in DGC function. Mossy fibers form 
aberrant synapses with DGCs, resulting in recurrent excitatory circuits (Butler et al., 2015; 
Hunt et al., 2010; Winokur et al., 2004). Animal models of epilepsy also frequently develop 
inhibitory neuron dysfunction (Butler et al., 2017; Hunt et al., 2011; Kang et al., 2021) and 
alterations to GABAA receptor function (Boychuk et al., 2016; Peng et al., 2004). Although 
C57BL/6J mice exhibit resistance to epileptogenesis after SE induced by systemic KA 
administration (McKhann et al., 2003; McLin and Steward, 2006; Schauwecker and 
Steward, 1997), IHK reliably induces epileptogenic changes (Kang et al., 2021; Welzel et 
al., 2020). 
This study describes the first application of IHK in tau-/- and htau mice. DGC 
excitability was measured 6-8 weeks after IHK. In IHK-treated C57BL/6J mice, the 
perforant pathway-DGC synapse exhibited increased excitability compared to sham 
control, demonstrated by increased neurotransmitter release and more frequent sEPSCs. 
These changes were detected both contralateral and ipsilateral to the injection. 
Additionally, peak evoked action potential frequency was increased in DGCs contralateral, 
but not ipsilateral, to the injection. These changes were largely abrogated in tau-/- and htau 
mice. Synaptic hyperexcitability was reduced, but not entirely prevented, in both transgenic 
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strains. Evoked action potential frequency was not affected in DGCs from tau-/- and htau 
mice after IHK. 
The difference in functional changes after IHK in tau-/- and htau mice compared to 
C57BL/6J mice suggest the altered tau expression affected the process of epileptogenesis 
after IHK. DGCs contralateral to the injection in C57BL/6J mice exhibited increased 
intrinsic excitability. However, this effect was not observed ipsilateral to the injection. 
Kainate was injected into the dorsal CA1, whereas the DGCs studied were in the ventral 
dentate gyrus. The absence of changes in intrinsic excitability in DGCs ipsilateral to the 
injection suggests that seizures did not readily propagate along the septotemporal axis 
within the hippocampus. Changes in DGCs contralateral to the injection suggests 
involvement of the commissural inputs or secondary generalization of seizures in driving 
changes during epileptogenesis. This notion is supported by the increased synaptic 
excitability observed in DGCs from IHK-treated C57BL/6J mice. If synaptic 
hyperexcitability develops generally in IHK-treated mice, then epileptiform discharges 
could spread more easily, promoting widespread propagation of seizures. 
The assessment of excitability in DGCs from tau-/- and htau mice is consistent with 
and may explain, in part, the potentially reduced seizure prevalence/frequency previously 
discussed. Synaptic hyperexcitability was reduced, though not entirely abrogated, in DGCs 
from both transgenic strains, consistent with the reduction in seizure prevalence in tau-/- 
and seizure frequency in htau mice suggested here. If increased synaptic transmission could 
promote seizure propagation, then it stands to reason that preventing this hyperexcitability 
could inhibit seizure development. Furthermore, the incomplete prevention of 
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hyperexcitable changes observed is consistent with the modification, but not prevention, 
of epileptogenesis described previously. 
 Future directions 
The results of this study suggest tau contributes to IHK-induced changes in 
electrophysiological function. However, this study only investigated intrinsic and synaptic 
function in the DGCs. Although DGCs play a critical role in epileptogenesis, several 
additional cells, including hilar interneurons, are also involved in epileptogenesis. Further 
studies are needed to determine whether changes in tau expression modifies epileptogenic 
changes in other neuron populations. The current study also only investigated broad 
electrophysiological function in DGCs. More detailed investigation is needed to determine 
which specific processes involved in epileptogenesis might be influenced by tau. 
Furthermore, changes in excitability may occur throughout the trisynaptic circuit and 
should be investigated. 
5.5 Final conclusions 
This dissertation presented new insights regarding tau’s role in DGC function and 
IHK-induced epileptogenesis. The results presented here largely agreed with those of 
previous studies, but with a few important exceptions. Most notably, these results indicate 
that persistent expression of murine tau in most models of tauopathy may confound results 
by exacerbating pathology. The htau mice studied here did not display the same 
dysfunction described in other models. Although it is not entirely clear why these 
differences occurred, the potential for murine tau to interact with the various forms of 
human expressed in other animal tauopathy models should be considered and avoided 
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where feasible. The existing body of literature studying tau’s role in neuronal and synaptic 
excitability using specific electrophysiological techniques is sparse. More studies 
employing whole-cell recordings are needed to better understand the specific effects of tau 
deletion or hyperphosphorylation on neuronal function. While the current study was 
intended to address this paucity of information, it only measured broad 
electrophysiological function and should be considered a starting point for further research. 
Still, the insights gained here have identified several avenues for future research. 
Furthermore, studies of pathological tau have largely focused on hyperphosphorylation. 
Recent studies have identified key roles for other pathogenic tau modifications which 
should be further investigated.  
Numerous studies of tau’s role in several pathologic processes suggest tau’s 
involvement in disease may be even more significant than currently recognized. In addition 
to tauopathies, tau plays an increasingly recognized role in epilepsy. While the majority of 
the studies showing involvement of tau in epilepsy present correlative data, a growing body 
of evidence, including this dissertation, suggest the role may be more active. Tau deficient 
animal models exhibit improved survival in different models of epilepsy and induced 
seizures. However, improved survival in tau deficient animals is not unique to epilepsy. 
Tau deletion is also associated with reduced mortality associated with models of AD (Ittner 
et al., 2010; Roberson et al., 2011; Roberson et al., 2007), Huntington’s disease 
(Fernandez-Nogales et al., 2014), and amyotrophic lateral sclerosis (Roberson 2011). 
Improved survival associated with tau reduction is often dose dependent. Viewed broadly, 
this body of literature suggests tau may act as a mediator of neurological dysfunction not 
limited to primary tauopathies. Furthermore, tau reduction does not appear to be associated 
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with impaired survival (Li et al., 2014), although other adverse consequences have been 
identified. Although reduction of tau at the genome level is unlikely to be a viable option 
for novel therapeutics, ASO-mediated reduction of tau expression shows promise. 
Selectively modifying tau in the adult nervous system should avoid the negative effects on 
neuronal structure and development observed in tau-/- mice while still having disease-
modifying potential. Since tau’s toxic potential seems to be related to soluble oligomers, 
this approach may even be capable of reversing some neurological diseases. While 
development of such approaches is still at an early stage, research is underway. At the time 
of writing this, one phase 1 trial is recruiting patients to begin testing an ASO therapy 
directed at progressive supranacular palsy. This is unlikely to be last such trial and may 
open the door to development of disease-modifying therapies for other neurological 
diseases. 
With relevance to this dissertation, ASOs may represent an option to modify tau after 
the initiation of epileptogenesis. This approach is more realistic in terms of novel 
therapeutics than modifications at the genome level. While the limited data available 
suggest tau ASOs are effective at reducing tau expression in vivo, it remains to be 
determined whether this approach could interrupt or reverse epileptogenesis. Although the 
current study suggests such an approach may not be entirely preventative or curative, it 









APPENDIX 2 SOLUTIONS USED FOR ELECTROPHYSIOLOGY 
A2.1 Cutting/holding solution 
Compound Molecular weight (g) Concentration (mM) Grams for 1L (5X) 
NaCl 58.4 85 24.82 
Sucrose 342.3 75 128.36 
KCl 74.6 2.5 0.9325 
Glucose 180.2 25 22.525 
NaH2PO4·H2O 137.99 1.25 0.862 
MgCl2·6H2O 203.3 4 4/066 
CaCl2·2H2O 147 0.5 0.3675 
NaHCO3 84.01 24 10.081 
 
A2.2 Recording solution 
Compound Molecular weight (g) Concentration (mM) Grams for 1L 
NaCl 58.4 124 24.82 
NaHCO3 84.01 26 10.081 
NaH2PO4 119.98 1.4 22.525 
Glucose 180.2 11 22.525 
 
Solution Concentration (mM) Milliliters for 1L 
1M KCl 3 3 
2M MgCl2 1.3 2.6 






A2.3 Electrode internal solution 
Compound Molecular weight (g) Concentration (mM) Grams for 25mL 
K-gluconate 234.2 126 737.7 
KCl 74.6 4 7.5 
HEPES 238.3 10 59.6 
MgATP 507.2 4 50.7 
NaATP 523.2 0.3 3.9 
PO-Creatine 255.1 10 63.8 
• Adjust to pH7.2 by adding 1N KOH 
• Adjust osmolality to 290-295 by adding small amounts of MilliQ water 
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